https://trial.medpath.com/news/ca84508a76684421/cd40-targeted-therapies-advance-toward-first-approval-by-2027-with-over-35-candidates-in-clinical-development 2025-10-14T21:15:04+00:00 hourly 0.9 https://trial.medpath.com/news/63d6ac59274d1075/china-approves-world-s-first-functional-cure-drug-for-hepatitis-b 2025-10-14T17:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/c27f940792395fa0/krystal-biotech-receives-fda-platform-technology-designation-for-hsv-1-gene-therapy-vector 2025-10-14T17:31:11+00:00 hourly 0.9 https://trial.medpath.com/news/a3b38656dbbc60dd/cabaletta-bio-appoints-steve-gavel-as-chief-commercial-officer-to-lead-car-t-therapy-launch 2025-10-14T17:30:39+00:00 hourly 0.9 https://trial.medpath.com/news/96369da0635b218d/johnson-johnson-to-spin-off-9-2-billion-orthopedics-business-as-depuy-synthes 2025-10-14T17:28:56+00:00 hourly 0.9 https://trial.medpath.com/news/fc3097211f516435/lunit-s-ai-platform-demonstrates-predictive-power-for-immunotherapy-response-across-multiple-cancer-types-at-esmo-2025 2025-10-14T17:25:20+00:00 hourly 0.9 https://trial.medpath.com/news/999de85728d08e27/pilatus-biosciences-secures-global-patent-protection-for-cd36-targeted-immunotherapy-platform 2025-10-14T17:25:15+00:00 hourly 0.9 https://trial.medpath.com/news/e76013629299a30b/abalos-therapeutics-publishes-preclinical-data-for-novel-arenavirus-based-cancer-immunotherapy-abx-001 2025-10-14T17:25:12+00:00 hourly 0.9 https://trial.medpath.com/news/f76b2e81cb9135d7/rivus-pharmaceuticals-to-present-phase-2a-mash-trial-data-for-novel-metabolic-accelerator-hu6-at-aasld-2025 2025-10-14T17:24:24+00:00 hourly 0.9 https://trial.medpath.com/news/fc7047099e57eef0/frontier-medicines-unveils-fmc-242-novel-pi3ka-ras-inhibitor-targeting-cancer-s-most-common-genetic-drivers 2025-10-14T17:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/8a4363100e0a4676/tr1x-receives-fda-clearance-for-trx319-car-tr1-cell-therapy-in-progressive-multiple-sclerosis 2025-10-14T17:23:43+00:00 hourly 0.9 https://trial.medpath.com/news/c54b238f6502b848/swedish-researchers-launch-clinical-trial-testing-250-year-old-heart-drug-digitoxin-for-pancreatic-cancer-treatment 2025-10-14T17:23:24+00:00 hourly 0.9 https://trial.medpath.com/news/82eddde44b647d65/biocryst-acquires-astria-therapeutics-for-700-million-to-expand-hereditary-angioedema-treatment-portfolio 2025-10-14T17:23:16+00:00 hourly 0.9 https://trial.medpath.com/news/767aa5d44c48f142/abk-biomedical-secures-35m-series-d-to-advance-eye90-microspheres-for-liver-cancer-treatment 2025-10-14T17:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/5ed0c895abea1266/major-uk-study-reveals-risperidone-increases-stroke-risk-across-all-dementia-patient-groups 2025-10-14T17:23:08+00:00 hourly 0.9 https://trial.medpath.com/news/e719e11c5e575baa/lb-pharmaceuticals-strengthens-regulatory-leadership-with-james-rawls-appointment-ahead-of-lb-102-phase-3-trial 2025-10-14T17:22:48+00:00 hourly 0.9 https://trial.medpath.com/news/55acc8e82399dcae/genprex-s-reqorsa-gene-therapy-shows-79-tumor-reduction-in-alk-positive-lung-cancer-preclinical-study 2025-10-14T17:22:26+00:00 hourly 0.9 https://trial.medpath.com/news/030ada96721b6ca7/brogidirsen-shows-sustained-motor-function-benefits-in-3-5-year-duchenne-muscular-dystrophy-trial 2025-10-14T17:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/dba75f7819e02fac/candel-therapeutics-reports-breakthrough-data-for-can-3110-in-recurrent-glioblastoma-with-complete-pathological-response 2025-10-14T17:22:08+00:00 hourly 0.9 https://trial.medpath.com/news/a5ba27cd75df05e6/candel-therapeutics-secures-130-million-term-loan-to-advance-phase-3-nsclc-trial-and-prostate-cancer-commercialization 2025-10-14T17:22:05+00:00 hourly 0.9 https://trial.medpath.com/news/432152dfb62d85a0/caris-life-sciences-presents-six-multiomics-studies-at-esmo-2025-spanning-nine-cancer-types 2025-10-14T17:19:50+00:00 hourly 0.9 https://trial.medpath.com/news/83f54ee90d102ede/bvi-s-finevision-hp-trifocal-iol-receives-fda-approval-for-us-market-after-15-years-of-global-use 2025-10-14T17:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/513c944e77124927/calcimedica-partners-with-telperian-to-deploy-ai-analytics-for-auxora-clinical-trial-optimization 2025-10-14T17:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/107f6578bbeeac12/cambridge-scientists-create-lab-grown-embryo-models-that-generate-human-blood-stem-cells 2025-10-14T17:17:50+00:00 hourly 0.9 https://trial.medpath.com/news/ddfb9a09c2f007cf/cincinnati-children-s-develops-human-liver-organoid-platform-to-predict-immune-mediated-drug-toxicity 2025-10-14T17:17:47+00:00 hourly 0.9 https://trial.medpath.com/news/3b2e69c154c92a9d/neogenomics-showcases-radar-st-molecular-residual-disease-assay-at-esmo-congress-2025 2025-10-14T17:17:44+00:00 hourly 0.9 https://trial.medpath.com/news/4000845c445dd3b3/tonix-pharmaceuticals-advances-tnx-1500-anti-cd40l-antibody-for-transplant-rejection-prevention 2025-10-14T17:17:41+00:00 hourly 0.9 https://trial.medpath.com/news/448584f9094b8f6f/pfizer-s-tukysa-shows-positive-results-in-phase-iii-maintenance-trial-for-her2-positive-breast-cancer 2025-10-14T17:16:51+00:00 hourly 0.9 https://trial.medpath.com/news/24903717ed2df8b5/quotient-sciences-and-biorasi-form-strategic-partnership-to-streamline-early-phase-clinical-trials 2025-10-14T17:16:28+00:00 hourly 0.9 https://trial.medpath.com/news/09ccf4fb1d37786a/researchers-develop-gene-signature-to-predict-immunotherapy-response-in-triple-negative-breast-cancer 2025-10-14T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0b209bb1387abea1/dupilumab-reduces-severe-copd-exacerbations-regardless-of-cardiovascular-and-metabolic-comorbidities 2025-10-14T13:37:22+00:00 hourly 0.9 https://trial.medpath.com/news/12ac3f1e7c0d4486/takeda-expands-ai-drug-discovery-partnership-with-nabla-bio-in-1b-deal 2025-10-14T13:35:32+00:00 hourly 0.9 https://trial.medpath.com/news/0da82c8cbedc026e/kailera-therapeutics-secures-600m-series-b-to-advance-obesity-drug-kai-9531-to-phase-3-trials 2025-10-14T13:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/de03cbbed1f52c46/biontech-secures-german-regulatory-approval-for-1-25-billion-curevac-acquisition 2025-10-14T13:32:26+00:00 hourly 0.9 https://trial.medpath.com/news/4e2608715800fb57/activist-investor-shah-capital-calls-for-novavax-sale-amid-covid-vaccine-market-share-struggles 2025-10-14T13:32:20+00:00 hourly 0.9 https://trial.medpath.com/news/4aad6d8faa1cb203/aanastra-unveils-breakthrough-preclinical-data-for-in-vivo-car-t-and-p53-restoration-therapies 2025-10-14T13:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/fa84b072b327a57a/cancervax-universal-cancer-platform-demonstrates-liver-sparing-properties-in-preclinical-studies 2025-10-14T13:31:25+00:00 hourly 0.9 https://trial.medpath.com/news/8a018ec9382caf85/clover-biopharmaceuticals-reports-positive-phase-i-data-for-first-in-class-rsv-hmpv-piv3-combination-vaccines 2025-10-14T13:30:56+00:00 hourly 0.9 https://trial.medpath.com/news/e2547971afd86463/actithera-licenses-breakthrough-covalent-chemistry-technologies-from-weizmann-institute-for-next-generation-radiopharmaceuticals 2025-10-14T13:30:53+00:00 hourly 0.9 https://trial.medpath.com/news/36d2f9f64a69821b/first-in-class-autotaxin-inhibitor-cambritaxestat-shows-promise-in-metastatic-pancreatic-cancer-phase-ib-trial 2025-10-14T13:29:55+00:00 hourly 0.9 https://trial.medpath.com/news/4e9ec60fd058f2b7/quantro-therapeutics-extends-boehringer-ingelheim-partnership-for-transcription-factor-cancer-drug-discovery 2025-10-14T13:29:48+00:00 hourly 0.9 https://trial.medpath.com/news/7cd3e74c0da042ea/phase-i-study-demonstrates-favorable-pharmacokinetics-and-safety-profile-of-capivasertib-in-chinese-patients-with-advanced-solid-tumors 2025-10-14T13:29:45+00:00 hourly 0.9 https://trial.medpath.com/news/4ae02c3078179fbc/ona-therapeutics-appoints-adc-development-veteran-dr-antoine-yver-as-board-chair-to-advance-breast-cancer-pipeline 2025-10-14T13:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/714c1c605f01adde/apyx-medical-submits-fda-510-k-application-to-expand-ayon-body-contouring-system-for-power-liposuction 2025-10-14T13:28:46+00:00 hourly 0.9 https://trial.medpath.com/news/3be154d047420b4f/spago-nanomedical-s-177lu-sn201-shows-promising-tumor-uptake-in-phase-i-iia-trial 2025-10-14T13:28:39+00:00 hourly 0.9 https://trial.medpath.com/news/129dd274940847ea/innate-pharma-advances-lacutamab-toward-accelerated-approval-for-rare-t-cell-lymphomas 2025-10-14T09:34:26+00:00 hourly 0.9 https://trial.medpath.com/news/e7e8af09f1c7762e/adc-therapeutics-secures-60-million-to-advance-zynlonta-commercialization-and-prepare-for-2027-relaunch 2025-10-14T09:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/0d77194ae1b78052/first-patient-enrolled-in-global-phase-3-trial-testing-novel-immune-modulatory-therapy-for-relapsed-follicular-lymphoma 2025-10-14T09:31:00+00:00 hourly 0.9 https://trial.medpath.com/news/05ce87f8efbcb690/biosynth-experts-highlight-advanced-bioconjugation-strategies-for-enhanced-drug-development 2025-10-14T03:17:13+00:00 hourly 0.9 https://trial.medpath.com/news/29bd37b4d6afac51/eilean-therapeutics-unveils-ze77-0273-novel-pan-egfr-inhibitor-for-drug-resistant-nsclc 2025-10-14T01:22:02+00:00 hourly 0.9 https://trial.medpath.com/news/36f5526bfeac0eb3/pyxis-oncology-unveils-translational-data-supporting-novel-adc-micvo-s-triple-action-mechanism-against-solid-tumors 2025-10-14T01:20:45+00:00 hourly 0.9 https://trial.medpath.com/news/56dabb9f130e830d/oticara-s-intranasal-steroid-cream-shows-significant-symptom-improvement-in-post-surgical-chronic-rhinosinusitis-phase-2-trial 2025-10-14T01:19:14+00:00 hourly 0.9 https://trial.medpath.com/news/ae8d39da93d2e260/zentalis-pharmaceuticals-presents-four-azenosertib-studies-at-aacr-nci-eortc-conference 2025-10-14T01:19:11+00:00 hourly 0.9 https://trial.medpath.com/news/00e8fcb710670ea2/imdx-appoints-marketing-vp-to-spearhead-commercial-launch-of-transplant-rejection-diagnostic 2025-10-14T01:16:43+00:00 hourly 0.9 https://trial.medpath.com/news/9872566ad6d9b3ed/repare-therapeutics-to-present-first-clinical-data-for-novel-plk4-inhibitor-rp-1664-at-aacr-conference 2025-10-13T21:28:52+00:00 hourly 0.9 https://trial.medpath.com/news/8aeb87d3b6168596/merus-petosemtamab-phase-2-data-selected-for-plenary-presentation-at-aacr-nci-eortc-conference 2025-10-13T21:28:06+00:00 hourly 0.9 https://trial.medpath.com/news/6852d6ab05ade306/remix-therapeutics-to-present-phase-1-data-of-first-in-class-myb-rna-degrader-rem-422-for-adenoid-cystic-carcinoma-at-aacr-conference 2025-10-13T21:23:13+00:00 hourly 0.9 https://trial.medpath.com/news/a45f7499ca17bead/merck-faces-patent-challenge-over-keytruda-qlex-as-ptab-institutes-seven-post-grant-reviews 2025-10-13T21:22:38+00:00 hourly 0.9 https://trial.medpath.com/news/4dfd1cf5492762b6/lupin-invests-250-million-in-florida-manufacturing-facility-to-strengthen-us-respiratory-drug-supply 2025-10-13T21:22:35+00:00 hourly 0.9 https://trial.medpath.com/news/e7440adf603b75f0/mrna-therapy-restores-sperm-production-in-mouse-model-of-male-infertility 2025-10-13T21:22:26+00:00 hourly 0.9 https://trial.medpath.com/news/8b9dde8f504775dc/rectal-spacers-reduce-prostate-cancer-treatment-failure-by-50-in-real-world-analysis 2025-10-13T21:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/50076fb6b8a45d96/rna-nanotherapeutics-develops-novel-approach-to-combat-tamoxifen-resistance-in-breast-cancer 2025-10-13T21:21:12+00:00 hourly 0.9 https://trial.medpath.com/news/6e9a0751a31c8fe5/zai-lab-s-dll3-targeted-adc-zocilurtatug-pelitecan-shows-promise-in-phase-1-small-cell-lung-cancer-trial 2025-10-13T21:20:26+00:00 hourly 0.9 https://trial.medpath.com/news/d89a3ec0d16d052d/accugenomics-and-1cell-ai-partner-to-enhance-liquid-biopsy-testing-accuracy-across-asia-with-u-s-expansion-plans 2025-10-13T21:19:24+00:00 hourly 0.9 https://trial.medpath.com/news/b466c09219f35533/fda-grants-fast-track-designation-to-epion-s-epismart-cross-linking-system-for-keratoconus-treatment 2025-10-13T21:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/e4c6693261bb40b5/naya-therapeutics-partners-with-alpha-nuclide-to-advance-astatine-211-therapy-for-hepatocellular-carcinoma-in-china 2025-10-13T21:18:17+00:00 hourly 0.9 https://trial.medpath.com/news/c098517dbe00464f/neutrolis-to-present-early-human-proof-of-concept-data-for-novel-net-targeting-therapy-at-acr-2025 2025-10-13T19:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/5191b31cc04632e9/quanta-therapeutics-to-present-first-clinical-data-for-novel-kras-g12d-inhibitor-qtx3034-at-major-cancer-conference 2025-10-13T17:29:53+00:00 hourly 0.9 https://trial.medpath.com/news/d826aa1240c84dc3/cstone-pharmaceuticals-presents-first-in-class-pd-1-vegf-ctla-4-trispecific-antibody-data-at-esmo-2025 2025-10-13T17:26:35+00:00 hourly 0.9 https://trial.medpath.com/news/8b7fdcb6d283db87/vasa-therapeutics-receives-fda-ind-clearance-for-vs-041-in-heart-failure-with-preserved-ejection-fraction 2025-10-13T17:25:41+00:00 hourly 0.9 https://trial.medpath.com/news/490b579aadaf9de4/boehringer-ingelheim-to-begin-local-production-of-diabetes-drug-trajenta-in-shanghai-by-2028 2025-10-13T17:25:32+00:00 hourly 0.9 https://trial.medpath.com/news/b794dc6aa5e88903/general-oncology-to-present-phase-1-sharon-trial-results-for-brca-palb2-mutated-cancers-at-esmo-2025 2025-10-13T17:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/39b17a37bb2b4fe9/clearpoint-neuro-s-mr-guided-laser-therapy-shows-promise-for-brain-cancer-treatment-in-phase-i-ii-study 2025-10-13T17:22:43+00:00 hourly 0.9 https://trial.medpath.com/news/186ddc7fdb55cf4d/pantherx-rare-partners-with-chiesi-as-exclusive-distributor-for-oral-acromegaly-treatment-mycapssa 2025-10-13T17:21:57+00:00 hourly 0.9 https://trial.medpath.com/news/0a442207acb55d3c/abeona-therapeutics-abo-503-gene-therapy-selected-for-fda-s-rare-disease-endpoint-advancement-pilot-program 2025-10-13T17:20:30+00:00 hourly 0.9 https://trial.medpath.com/news/b18c96d1bb8d629d/4dmt-secures-11-million-cf-foundation-investment-to-advance-gene-therapy-4d-710-into-phase-2-for-cystic-fibrosis 2025-10-13T17:19:29+00:00 hourly 0.9 https://trial.medpath.com/news/0fe68046a3be5a52/yd-bio-partner-eg-biomed-secures-cap-accreditation-for-u-s-laboratory-strengthening-cancer-diagnostics-capabilities 2025-10-13T17:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/eb20eace9b62def8/blacksmith-medicines-receives-fda-fast-track-and-qidp-designation-for-novel-antibiotic-fg-2101-targeting-gram-negative-superbugs 2025-10-13T17:19:10+00:00 hourly 0.9 https://trial.medpath.com/news/24cdf7731a9f088b/nextbiomedical-initiates-u-s-pivotal-trial-for-nexsphere-f-microsphere-device-in-knee-osteoarthritis 2025-10-13T17:18:26+00:00 hourly 0.9 https://trial.medpath.com/news/7eda402a33dcd6d4/infant-bacterial-therapeutics-advances-regulatory-submissions-for-ibp-9414-first-live-biotherapeutic-for-premature-infants 2025-10-13T17:17:29+00:00 hourly 0.9 https://trial.medpath.com/news/1967afa4c7cf09bd/astrazeneca-strikes-most-favoured-nation-drug-pricing-deal-with-trump-administration 2025-10-13T17:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/0aaae036cac072a3/artivion-s-amds-device-shows-strong-malperfusion-resolution-rates-in-acute-aortic-dissection-trials 2025-10-13T17:17:04+00:00 hourly 0.9 https://trial.medpath.com/news/44259d9bd2200f30/excellergy-raises-70m-series-a-to-advance-novel-trifunctional-allergy-treatment-platform 2025-10-13T17:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/2143aac46cee4c78/fda-approves-expanded-rinvoq-label-for-ibd-treatment-allowing-earlier-use-when-tnf-blockers-inadvisable 2025-10-13T17:15:49+00:00 hourly 0.9 https://trial.medpath.com/news/c3de84ba0d772af7/mettl14-emerges-as-key-regulator-of-tumor-immunity-and-immunotherapy-response 2025-10-13T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fa6633ba201ac5b3/sellas-life-sciences-reports-promising-preclinical-and-phase-2-data-for-cdk9-inhibitor-sls009-across-multiple-hematologic-malignancies 2025-10-13T13:29:46+00:00 hourly 0.9 https://trial.medpath.com/news/4704eb4c2c7c95b9/artios-reports-first-clinical-data-for-dna-polymerase-theta-inhibitor-art6043-at-esmo-2025 2025-10-13T13:27:41+00:00 hourly 0.9 https://trial.medpath.com/news/e1b00f8099008357/eib-and-european-commission-partner-with-biontech-for-africa-s-first-mrna-vaccine-manufacturing-facility-in-rwanda 2025-10-13T13:26:19+00:00 hourly 0.9 https://trial.medpath.com/news/6387ff019a308274/lupin-to-present-phase-1a-data-on-sting-agonist-lnp3693-at-esmo-2025 2025-10-13T13:22:50+00:00 hourly 0.9 https://trial.medpath.com/news/a82f0f6ef29bcbdb/bristol-myers-squibb-and-lilly-showcase-major-oncology-data-at-esmo-2025 2025-10-13T13:21:13+00:00 hourly 0.9 https://trial.medpath.com/news/cb888809ef39f3f6/theolytics-advances-novel-oncolytic-immunotherapy-theo-260-in-phase-i-iia-ovarian-cancer-trial 2025-10-13T13:20:58+00:00 hourly 0.9 https://trial.medpath.com/news/8b3d40ac4ed6cd05/new-report-analyzes-1775-clinical-stage-pharma-partnerships-from-2020-2025 2025-10-13T13:20:52+00:00 hourly 0.9 https://trial.medpath.com/news/be71d71bb3a61285/fda-approves-rayner-s-rayone-emv-toric-iol-for-astigmatism-correction 2025-10-13T13:19:56+00:00 hourly 0.9 https://trial.medpath.com/news/9779d89f839567e4/abbvie-s-adc-portfolio-shows-promising-results-across-multiple-solid-tumors-at-esmo-2025 2025-10-13T13:18:46+00:00 hourly 0.9 https://trial.medpath.com/news/1259bc791c9388ef/fda-approves-lasix-onyu-first-at-home-subcutaneous-furosemide-infusion-device-for-heart-failure 2025-10-13T13:18:34+00:00 hourly 0.9 https://trial.medpath.com/news/b806247de5734d14/revir-therapeutics-secures-fda-orphan-drug-designation-for-rtx-117-in-charcot-marie-tooth-disease 2025-10-13T13:18:12+00:00 hourly 0.9 https://trial.medpath.com/news/63f71431ec4d92aa/lts-acquires-renaissance-lakewood-to-expand-cdmo-capabilities-in-nasal-drug-delivery 2025-10-13T13:18:05+00:00 hourly 0.9 https://trial.medpath.com/news/d6528ac4d93d25d4/gc-biopharma-partners-with-curevo-vaccine-to-manufacture-next-generation-shingles-vaccine-with-improved-tolerability 2025-10-13T09:20:10+00:00 hourly 0.9 https://trial.medpath.com/news/284a23633f6fa86d/takeda-completes-370-million-global-manufacturing-expansion-for-rare-disease-therapies 2025-10-13T09:19:40+00:00 hourly 0.9 https://trial.medpath.com/news/bae7376ee121aad0/annji-s-aj201-shows-clinical-promise-for-kennedy-s-disease-in-phase-2a-trial 2025-10-13T09:17:59+00:00 hourly 0.9 https://trial.medpath.com/news/89417fce8aa0d57c/avacta-develops-first-dual-payload-peptide-drug-conjugate-platform-for-cancer-combination-therapy 2025-10-13T09:17:31+00:00 hourly 0.9 https://trial.medpath.com/news/5ec8817081ac5353/cspc-pharmaceutical-s-syh2070-sirna-injection-receives-dual-fda-and-nmpa-approval-for-lipid-disorder-trials 2025-10-13T09:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/524f6fc2283c0d6b/ucb-s-pyrimidine-nucleoside-therapy-shows-95-reduction-in-death-risk-for-ultra-rare-tk2-deficiency 2025-10-13T09:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/ad834efa2be94cc5/dublin-biotech-meta-flux-raises-eur1-8m-to-enhance-drug-development-accuracy-with-ai-platform 2025-10-13T09:16:44+00:00 hourly 0.9 https://trial.medpath.com/news/852113d9e1d4aab7/ascendis-pharma-s-weekly-cnp-therapy-challenges-biomarin-s-daily-voxzogo-in-achondroplasia-market 2025-10-13T05:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/9e9e318bdcf70fc9/context-therapeutics-advances-two-bispecific-t-cell-engagers-with-promising-early-clinical-and-preclinical-data-at-sitc-2025 2025-10-13T05:16:48+00:00 hourly 0.9 https://trial.medpath.com/news/e401d93adb68de12/two-decade-analysis-reveals-high-discontinuation-rates-in-chinese-pediatric-drug-trials 2025-10-13T05:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/8905d6d817ad6ea7/proteomic-analysis-reveals-molecular-changes-following-anti-vegf-therapy-in-age-related-macular-degeneration 2025-10-13T01:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/a4aeaedd417047e6/nouscom-s-nous-209-shows-promise-in-anti-pd-1-resistant-msi-h-colorectal-cancer 2025-10-13T01:16:43+00:00 hourly 0.9 https://trial.medpath.com/news/1fba5979bb88e6fb/natera-s-signatera-mrd-test-shows-promise-in-guiding-bladder-cancer-treatment-at-esmo-2025 2025-10-13T01:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/ad21f19a695566c1/advancell-reports-first-clinical-data-for-lead-212-based-psma-therapy-in-prostate-cancer-at-esmo-2025 2025-10-13T01:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/bc237d46ae218d7a/punjab-health-department-suspends-eight-iv-fluids-and-antibiotics-following-adverse-drug-reactions 2025-10-12T21:20:38+00:00 hourly 0.9 https://trial.medpath.com/news/e4ece29600ca6e42/nafdac-partners-with-nigeria-natural-medicine-agency-to-advance-herbal-drug-clinical-trials 2025-10-12T21:19:38+00:00 hourly 0.9 https://trial.medpath.com/news/153a5523ddd12849/marstacimab-demonstrates-superior-efficacy-in-phase-3-basis-trial-for-hemophilia-a-and-b-patients 2025-10-12T17:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/52585526511a2d80/cefiderocol-shows-non-inferiority-to-standard-therapy-in-gram-negative-bloodstream-infections 2025-10-12T17:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/813f2e04d132b393/regeneron-s-db-oto-gene-therapy-restores-hearing-in-11-of-12-children-with-genetic-hearing-loss 2025-10-12T17:15:02+00:00 hourly 0.9 https://trial.medpath.com/news/62e7c123569a823d/dual-immune-checkpoint-blockade-shows-promising-results-across-multiple-cancer-types 2025-10-12T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/537d0faf4bb9adb2/hybrid-deep-learning-framework-achieves-85-accuracy-in-skin-lesion-diagnosis-with-enhanced-explainability 2025-10-12T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ade897c84e046a64/precision-biosciences-arcus-gene-editing-platform-achieves-85-efficiency-in-t-cells-advances-hepatitis-b-and-dmd-programs 2025-10-12T13:18:53+00:00 hourly 0.9 https://trial.medpath.com/news/690ba3e3aad8b122/indian-regulatory-committee-requests-protocol-revisions-for-enzene-s-nivolumab-biosimilar-phase-iii-trial 2025-10-12T09:17:23+00:00 hourly 0.9 https://trial.medpath.com/news/a4d39d3b3dfc8239/hmc-partners-with-abbvie-to-launch-clinical-research-training-program-in-qatar 2025-10-12T05:17:38+00:00 hourly 0.9 https://trial.medpath.com/news/82f9bcf4b349adbe/ligand-pharmaceuticals-gains-fda-approval-for-lasix-onyu-heart-failure-device-driving-46-share-price-surge 2025-10-12T05:17:36+00:00 hourly 0.9 https://trial.medpath.com/news/b13472595288c540/fda-authorizes-altria-s-on-plus-nicotine-pouches-under-new-pilot-program 2025-10-12T05:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/4cbebe8a78fcd8e6/nasus-pharma-partners-with-aptar-to-accelerate-ns002-intranasal-epinephrine-development 2025-10-12T01:17:47+00:00 hourly 0.9 https://trial.medpath.com/news/50305144ed1dfb9d/multi-cancer-blood-test-shows-62-accuracy-in-major-us-trial-raising-hopes-for-early-detection-revolution 2025-10-11T21:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/1275229126ac8cf4/fda-orphan-drug-director-sandra-retzky-reassigned-amid-inflation-reduction-act-policy-changes 2025-10-11T21:22:55+00:00 hourly 0.9 https://trial.medpath.com/news/1dbf38cdbfe33045/sandstone-medical-launches-patent-protected-hexagonal-hub-pen-needles-in-turkey-for-enhanced-diabetes-care 2025-10-11T17:22:53+00:00 hourly 0.9 https://trial.medpath.com/news/e97b7d998f0826ec/vimkunya-chikungunya-vaccine-shows-consistent-safety-profile-in-early-real-world-use 2025-10-11T17:21:58+00:00 hourly 0.9 https://trial.medpath.com/news/e81774fcd2d59038/biokin-pharmaceutical-receives-nmpa-approval-for-first-in-class-radiopharmaceutical-177lu-bl-arc001 2025-10-11T17:21:52+00:00 hourly 0.9 https://trial.medpath.com/news/c288207b60109afb/apogee-therapeutics-raises-345-million-to-advance-inflammatory-disease-pipeline 2025-10-11T17:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/2189bf50a99a7f15/singapore-opens-new-clinical-trial-centre-for-precision-geromedicine-at-nus-medicine 2025-10-11T17:20:48+00:00 hourly 0.9 https://trial.medpath.com/news/ae97c8228f6f2c62/protagonist-therapeutics-stock-surges-32-following-positive-icotrokinra-phase-3-results-and-strategic-partnerships 2025-10-11T13:23:33+00:00 hourly 0.9 https://trial.medpath.com/news/450eaa9ea9e0147c/global-study-links-hair-loss-drug-finasteride-to-increased-suicide-risk-and-depression 2025-10-11T13:22:54+00:00 hourly 0.9 https://trial.medpath.com/news/48494e69acceb12b/fda-adds-boxed-warning-to-carvykti-for-fatal-gastrointestinal-complications 2025-10-11T05:28:30+00:00 hourly 0.9 https://trial.medpath.com/news/4c1bb964d84a696d/large-real-world-study-confirms-long-term-benefits-of-allergen-immunotherapy-in-pediatric-allergic-rhinitis 2025-10-11T01:18:30+00:00 hourly 0.9 https://trial.medpath.com/news/7be48b9ba9ece958/ai-technology-group-acquires-avm-biotechnology-to-advance-novel-cancer-immunotherapy-avm0703 2025-10-11T01:17:28+00:00 hourly 0.9 https://trial.medpath.com/news/0e0583789c0462bc/bluejay-diagnostics-raises-4-5-million-to-advance-fda-approval-for-rapid-sepsis-diagnostic-test 2025-10-11T01:16:59+00:00 hourly 0.9 https://trial.medpath.com/news/ab93b43de872fc87/bridgebio-s-ribitol-shows-promise-in-phase-3-trial-for-rare-limb-girdle-muscular-dystrophy 2025-10-11T01:15:52+00:00 hourly 0.9 https://trial.medpath.com/news/273768b7a040af5d/gates-foundation-and-paho-explore-strategies-to-expand-weight-loss-drug-access-in-lower-income-countries 2025-10-10T21:25:09+00:00 hourly 0.9 https://trial.medpath.com/news/3d9a42484486e3c2/johnson-johnson-in-acquisition-talks-with-protagonist-therapeutics-following-positive-ulcerative-colitis-trial-results 2025-10-10T21:22:04+00:00 hourly 0.9 https://trial.medpath.com/news/2e1dd37432d17780/novo-nordisk-exits-cell-therapy-terminates-type-1-diabetes-cure-program 2025-10-10T21:21:58+00:00 hourly 0.9 https://trial.medpath.com/news/70f29528e3eb11f6/triple-drug-combination-triggers-immune-activating-cell-death-to-eliminate-leukemia-in-preclinical-models 2025-10-10T21:20:29+00:00 hourly 0.9 https://trial.medpath.com/news/7c21504ceb823f61/sareum-halts-sdc-1801-toxicology-study-due-to-animal-welfare-concerns-phase-2-psoriasis-trial-delayed 2025-10-10T21:19:33+00:00 hourly 0.9 https://trial.medpath.com/news/e8ca784ebf5cb556/spanish-researchers-develop-peptide-nanotube-system-to-overcome-doxorubicin-resistance-in-cancer 2025-10-10T21:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/2892af44814599e3/johnson-johnson-in-advanced-acquisition-talks-with-protagonist-therapeutics-for-4-2-billion-deal 2025-10-10T17:27:07+00:00 hourly 0.9 https://trial.medpath.com/news/a2281382c3276f6e/eli-lilly-and-astrazeneca-emerge-as-leading-candidates-for-next-trump-administration-drug-pricing-deal 2025-10-10T17:23:55+00:00 hourly 0.9 https://trial.medpath.com/news/507effdba1b08dc6/chugai-licenses-roche-s-ct-388-dual-glp-1-gip-receptor-agonist-for-japan-market 2025-10-10T17:21:24+00:00 hourly 0.9 https://trial.medpath.com/news/8b843ade78c41334/amplifi-vascular-s-novel-vein-dilation-system-shows-promise-for-improving-hemodialysis-access-in-first-in-human-study 2025-10-10T17:20:57+00:00 hourly 0.9 https://trial.medpath.com/news/70be7e80daac4ee9/gene-therapy-shows-promise-for-syngap1-related-brain-disorders-in-preclinical-study 2025-10-10T17:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/1523355dc7879847/genflow-biosciences-reports-positive-safety-data-from-second-administration-of-sirt6-gene-therapy-in-elderly-dogs 2025-10-10T17:19:40+00:00 hourly 0.9 https://trial.medpath.com/news/b5cfdb151df7cf73/neprilysin-gene-transfer-shows-promise-in-reducing-alzheimer-s-amyloid-beta-levels-and-improving-cognition 2025-10-10T17:19:35+00:00 hourly 0.9 https://trial.medpath.com/news/ec238ea9f038e957/orion-corporation-s-odm-105-fails-phase-2-insomnia-trial-as-company-pivots-to-oncology-focus 2025-10-10T17:18:34+00:00 hourly 0.9 https://trial.medpath.com/news/b70627882928a207/askbio-reports-positive-interim-safety-data-for-ab-1003-gene-therapy-in-rare-muscular-dystrophy-trial 2025-10-10T17:18:22+00:00 hourly 0.9 https://trial.medpath.com/news/fa7e95066286878e/bristol-myers-squibb-acquires-orbital-therapeutics-for-1-5-billion-to-advance-in-vivo-car-t-cell-therapy 2025-10-10T17:18:10+00:00 hourly 0.9 https://trial.medpath.com/news/18ebb4e8d4d293cd/senate-passes-biosecure-act-to-restrict-u-s-pharmaceutical-partnerships-with-chinese-companies 2025-10-10T17:18:08+00:00 hourly 0.9 https://trial.medpath.com/news/90aba8c37443b565/evommune-files-for-100m-ipo-to-advance-novel-mrgprx2-targeting-drug-for-chronic-urticaria 2025-10-10T17:17:39+00:00 hourly 0.9 https://trial.medpath.com/news/d1fad727f7d3dcc6/cd276-emerges-as-promising-cancer-target-with-major-licensing-deals-and-fda-breakthrough-designations 2025-10-10T17:15:50+00:00 hourly 0.9 https://trial.medpath.com/news/f5d0ff28c06c783d/wu-yifang-appointed-chairman-of-everest-medicines-as-company-advances-mrna-cancer-vaccine-platform 2025-10-10T13:18:21+00:00 hourly 0.9 https://trial.medpath.com/news/7398b47681850a19/jubilant-hollisterstier-launches-132-million-sterile-injectable-manufacturing-line-in-washington 2025-10-10T13:15:53+00:00 hourly 0.9 https://trial.medpath.com/news/6c40af59b271b2e9/renalys-completes-primary-endpoint-data-collection-for-sparsentan-phase-iii-trial-in-japanese-iga-nephropathy-patients 2025-10-10T09:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/0f7c2f5bdec0ecf7/pv-10-shows-promise-as-novel-sting-pathway-vaccine-adjuvant-in-university-of-calgary-research 2025-10-10T01:23:03+00:00 hourly 0.9 https://trial.medpath.com/news/9786e27df5798198/parse-biosciences-wins-patent-invalidation-case-against-10x-genomics-in-single-cell-sequencing-dispute 2025-10-10T01:18:25+00:00 hourly 0.9 https://trial.medpath.com/news/d3f4ef4a39fada36/shuttle-pharmaceuticals-signs-10-million-letter-of-intent-to-acquire-ai-drug-discovery-platform-molecule-ai 2025-10-10T01:17:14+00:00 hourly 0.9 https://trial.medpath.com/news/b864ae73a976a1b8/long-term-survival-data-reinforce-parp-inhibitor-benefits-in-brca-mutated-ovarian-cancer 2025-10-10T01:17:08+00:00 hourly 0.9 https://trial.medpath.com/news/bd8db9c8d1e3ed44/arcadia-medicine-receives-fda-approval-for-clinical-trials-of-safer-mdma-formulation-am-1002 2025-10-10T01:15:53+00:00 hourly 0.9 https://trial.medpath.com/news/cd583d1f7bcc1754/nurix-therapeutics-advances-bexobrutideg-toward-pivotal-cll-trials-with-strong-phase-1-data 2025-10-09T21:23:41+00:00 hourly 0.9 https://trial.medpath.com/news/bf2a1859e4a60267/expedition-therapeutics-secures-165-million-series-a-to-advance-first-in-class-dpp1-inhibitor-for-copd 2025-10-09T21:22:28+00:00 hourly 0.9 https://trial.medpath.com/news/9ed75f136252069b/novel-tor-inhibitor-rapalink-1-extends-lifespan-through-gut-bacteria-enzyme-pathway 2025-10-09T21:21:47+00:00 hourly 0.9 https://trial.medpath.com/news/848d930a9b1ff843/acurx-pharmaceuticals-secures-australian-patent-for-novel-dna-polymerase-iiic-inhibitor-antibiotics 2025-10-09T21:21:03+00:00 hourly 0.9 https://trial.medpath.com/news/3fa8625720a73cda/cabaletta-bio-s-car-t-therapy-shows-promise-without-preconditioning-in-pemphigus-vulgaris-trial 2025-10-09T21:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/57f6a7b0528e26be/phase-2-trial-of-inhaled-il-15-immunotherapy-halted-after-worse-outcomes-in-canine-osteosarcoma 2025-10-09T21:16:34+00:00 hourly 0.9 https://trial.medpath.com/news/79b5f1d9a8bae0ef/novel-ras-pi3k-inhibitor-enters-clinical-trials-targeting-cancer-growth-without-metabolic-side-effects 2025-10-09T21:15:37+00:00 hourly 0.9 https://trial.medpath.com/news/921b1ebbaecbd1d5/sq-innovation-secures-series-b-funding-following-fda-approval-of-subcutaneous-furosemide-for-heart-failure 2025-10-09T17:26:57+00:00 hourly 0.9 https://trial.medpath.com/news/8e8fedcc1a2e8ebf/cdsco-initiates-review-of-india-s-new-drug-approval-framework-to-address-first-mover-disadvantage 2025-10-09T17:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/7600e6cc6585624e/apogee-therapeutics-surges-19-7-on-positive-apg333-phase-1-data-and-345-million-funding 2025-10-09T17:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/b5776da6701a21aa/lexaria-bioscience-expands-drug-delivery-platform-development-with-4m-funding-and-strategic-advisory-partnership 2025-10-09T17:25:36+00:00 hourly 0.9 https://trial.medpath.com/news/1a47b3e1ca4e8fde/orexa-s-ore-001-shows-significant-promise-in-preventing-post-operative-ileus-in-phase-2-trial 2025-10-09T17:23:24+00:00 hourly 0.9 https://trial.medpath.com/news/1d9bbe4ce46206e1/telomir-1-demonstrates-selective-killing-of-triple-negative-breast-cancer-cells-through-iron-dependent-mechanism 2025-10-09T17:22:36+00:00 hourly 0.9 https://trial.medpath.com/news/73b1dcf471baafcd/delhi-high-court-clears-path-for-generic-risdiplam-launch-enabling-97-price-reduction-for-rare-disease-treatment 2025-10-09T17:21:50+00:00 hourly 0.9 https://trial.medpath.com/news/95033ea6fe2c2c6c/milestone-pharmaceuticals-to-present-etripamil-psvt-data-at-aha-scientific-sessions-2025 2025-10-09T17:21:36+00:00 hourly 0.9 https://trial.medpath.com/news/b96b22af927cab93/cognivia-launches-ai-powered-dashboard-to-predict-clinical-trial-dropout-and-placebo-response-in-real-time 2025-10-09T17:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/8ee923379ebe781a/transcode-therapeutics-acquires-polynoma-in-25-million-deal-to-advance-phase-3-ready-melanoma-vaccine 2025-10-09T17:21:04+00:00 hourly 0.9 https://trial.medpath.com/news/59e06246cab83820/henlius-hansizhuang-achieves-breakthrough-in-gastric-cancer-trial-enabling-world-first-chemotherapy-free-adjuvant-approach 2025-10-09T17:18:13+00:00 hourly 0.9 https://trial.medpath.com/news/be8e08dc4e5fc2cf/novo-nordisk-acquires-akero-therapeutics-for-up-to-5-2-billion-to-expand-mash-treatment-portfolio 2025-10-09T17:18:00+00:00 hourly 0.9 https://trial.medpath.com/news/498d637b0baa5346/adial-pharmaceuticals-completes-validation-of-genetic-test-for-alcohol-use-disorder-treatment 2025-10-09T17:17:19+00:00 hourly 0.9 https://trial.medpath.com/news/b8e3f91cfbe56538/bd-launches-xtract-registry-to-evaluate-real-world-performance-of-rotarex-catheter-system-in-peripheral-artery-disease 2025-10-09T17:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/bca85db049e4c888/advances-in-cancer-immunotherapy-reveal-complex-interplay-between-tumor-microenvironment-and-neoantigen-targeting 2025-10-09T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/fe9fc0859d940206/novo-nordisk-acquires-akero-therapeutics-for-5-2-billion-to-expand-mash-treatment-portfolio 2025-10-09T13:27:17+00:00 hourly 0.9 https://trial.medpath.com/news/3a94a684ab3d68df/zelluna-receives-mhra-approval-for-first-in-human-trial-of-novel-tcr-nk-cell-therapy-zi-ma4-1 2025-10-09T13:26:25+00:00 hourly 0.9 https://trial.medpath.com/news/d53e3edbc053bf3a/samsung-biologics-expands-japan-presence-with-new-excellens-brand-secures-half-of-top-10-pharma-companies 2025-10-09T13:25:48+00:00 hourly 0.9 https://trial.medpath.com/news/5cec66d8dce443b3/chance-pharma-partners-with-huadong-medicine-for-cxg87-asthma-treatment-in-china 2025-10-09T13:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/f219f124c4cca423/fda-grants-fast-track-designation-to-adcendo-s-adce-d01-for-soft-tissue-sarcoma-treatment 2025-10-09T13:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/c4905deca3a66013/aviadobio-secures-413m-option-deal-for-ugx-202-optogenetics-gene-therapy-to-restore-vision-in-retinitis-pigmentosa 2025-10-09T13:22:40+00:00 hourly 0.9 https://trial.medpath.com/news/fd60943e4198b764/university-of-washington-develops-programmable-proteins-with-boolean-logic-for-precision-drug-delivery 2025-10-09T13:21:20+00:00 hourly 0.9 https://trial.medpath.com/news/28c839fa81e5032e/zymeworks-appoints-dr-adam-schayowitz-as-acting-chief-development-officer-to-advance-oncology-pipeline 2025-10-09T13:21:09+00:00 hourly 0.9 https://trial.medpath.com/news/21a3a8f32d30fecd/ono-pharmaceutical-reports-promising-phase-2-results-for-ono-2808-in-multiple-system-atrophy-treatment 2025-10-09T13:20:57+00:00 hourly 0.9 https://trial.medpath.com/news/b376fd233f845ebb/ono-4578-ep4-antagonist-combination-shows-significant-pfs-improvement-in-advanced-gastric-cancer 2025-10-09T13:19:42+00:00 hourly 0.9 https://trial.medpath.com/news/e6a1fa0861f6732d/ariceum-therapeutics-advances-225ac-sso110-for-extensive-stage-small-cell-lung-cancer-with-novel-radioligand-therapy-approach 2025-10-09T09:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/a9424186916ce2cf/cutaneous-squamous-cell-carcinoma-pipeline-shows-robust-activity-with-45-therapies-in-development 2025-10-09T09:16:54+00:00 hourly 0.9 https://trial.medpath.com/news/44bed2cc87ddc99e/fda-breakthrough-therapy-designation-shows-72-approval-success-rate-in-decade-long-analysis 2025-10-09T09:13:54+00:00 hourly 0.9 https://trial.medpath.com/news/b2c9e9faf418bed2/vaxart-advances-second-generation-norovirus-oral-vaccine-with-improved-immune-response-data 2025-10-09T05:15:25+00:00 hourly 0.9 https://trial.medpath.com/news/c4e9c94969315625/phase-3-amplitude-trial-shows-niraparib-abiraterone-combination-improves-outcomes-in-hrr-deficient-metastatic-prostate-cancer 2025-10-09T05:14:20+00:00 hourly 0.9 https://trial.medpath.com/news/a22b8c888ac28b42/mirxes-gastroclear-becomes-first-nmpa-approved-blood-test-for-gastric-cancer-screening-in-china 2025-10-09T05:13:32+00:00 hourly 0.9 https://trial.medpath.com/news/36dca4faca332323/fda-approves-lasix-onyu-first-at-home-subcutaneous-diuretic-for-heart-failure-patients 2025-10-09T05:13:26+00:00 hourly 0.9 https://trial.medpath.com/news/be791fd0a360938a/lisata-therapeutics-partners-with-catalent-for-novel-adc-development-using-certepetide-technology 2025-10-09T01:19:32+00:00 hourly 0.9 https://trial.medpath.com/news/ebc740dd7abcca78/memantine-shows-promise-for-autism-communication-in-children-with-elevated-brain-glutamate 2025-10-09T01:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/49d8fe23a912450e/glp-1-agonists-may-interfere-with-cancer-imaging-potentially-leading-to-misdiagnosis 2025-10-09T01:18:38+00:00 hourly 0.9 https://trial.medpath.com/news/609ce4c17ea3e6b7/covid-19-boosters-reduce-hospitalizations-and-deaths-by-up-to-64-in-large-veterans-study 2025-10-09T01:17:31+00:00 hourly 0.9 https://trial.medpath.com/news/9712a60537ade180/hope-medicine-reports-positive-phase-2-results-for-non-hormonal-endometriosis-treatment-hmi-115 2025-10-09T01:16:46+00:00 hourly 0.9 https://trial.medpath.com/news/3b8354b2a0a9b88b/arthrosi-raises-153m-to-advance-next-generation-gout-therapy-through-phase-iii-trials 2025-10-09T01:15:22+00:00 hourly 0.9 https://trial.medpath.com/news/1593be4507deae45/ascendis-pharma-submits-european-marketing-application-for-transcon-cnp-in-achondroplasia-treatment 2025-10-09T01:14:38+00:00 hourly 0.9 https://trial.medpath.com/news/aba5eb53e5e22869/serial-tumor-biopsies-reveal-hidden-immune-responses-in-glioblastoma-treatment 2025-10-08T21:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/20ab458086314f11/ucsf-researchers-develop-novel-immunotherapy-combination-to-target-colorectal-cancer-liver-metastases 2025-10-08T21:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/9f4bf814714da6e8/trivalent-salmonella-vaccine-shows-strong-immune-response-in-phase-1-trial 2025-10-08T21:18:04+00:00 hourly 0.9 https://trial.medpath.com/news/cd6bd7a2a7b384ab/aardvark-therapeutics-expands-phase-3-hero-trial-for-prader-willi-syndrome-treatment-to-include-younger-patients 2025-10-08T21:17:21+00:00 hourly 0.9 https://trial.medpath.com/news/8f4e8f67df04bfee/theranica-presents-real-world-evidence-supporting-drug-free-migraine-treatment-at-cns-2025 2025-10-08T21:15:55+00:00 hourly 0.9 https://trial.medpath.com/news/81be36fdf97e2bfa/zenas-biopharma-acquires-three-autoimmune-drugs-from-innocare-in-2-billion-deal 2025-10-08T21:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/ecb78890d2e5c759/fairjourney-biologics-appoints-former-evotec-ceo-werner-lanthaler-to-lead-antibody-discovery-platform 2025-10-08T17:28:11+00:00 hourly 0.9 https://trial.medpath.com/news/2a19db7b26ef46d3/coave-therapeutics-advances-novel-gene-therapy-for-retinal-vascular-diseases-with-superior-suprachoroidal-capsid 2025-10-08T17:26:30+00:00 hourly 0.9 https://trial.medpath.com/news/61dc5da9445bce38/kiel-laboratories-achieves-16th-fda-approval-with-novel-excipient-based-oral-suspension-for-rheumatic-diseases 2025-10-08T17:26:03+00:00 hourly 0.9 https://trial.medpath.com/news/8c25375450abf6be/lonza-expands-biologics-manufacturing-with-new-gmp-approved-filling-line-in-switzerland 2025-10-08T17:24:47+00:00 hourly 0.9 https://trial.medpath.com/news/6cd5c4159f008654/global-standard-for-dengue-treatment-trials-published-to-accelerate-drug-development 2025-10-08T17:24:42+00:00 hourly 0.9 https://trial.medpath.com/news/df158763e9f4292b/gold-nanoparticle-nasal-spray-delivers-targeted-lithium-therapy-to-brain-for-neuropsychiatric-disorders 2025-10-08T17:24:09+00:00 hourly 0.9 https://trial.medpath.com/news/4d994cc1fef426fc/ars-pharmaceuticals-secures-european-patent-protection-for-neffy-epinephrine-nasal-spray-through-2039 2025-10-08T17:23:48+00:00 hourly 0.9 https://trial.medpath.com/news/2c130ca5cf5ecdc5/nutriband-files-patent-application-to-strengthen-abuse-deterrent-technology-for-opioid-patches 2025-10-08T17:23:20+00:00 hourly 0.9 https://trial.medpath.com/news/89a719621d8e661e/tessera-therapeutics-secures-41-3-million-arpa-h-award-to-develop-revolutionary-in-vivo-car-t-therapy 2025-10-08T17:23:15+00:00 hourly 0.9 https://trial.medpath.com/news/463459e8736cb573/itm-s-phase-3-compete-trial-dosimetry-data-shows-targeted-tumor-uptake-for-177lu-edotreotide-in-neuroendocrine-tumors 2025-10-08T17:22:21+00:00 hourly 0.9 https://trial.medpath.com/news/4b95e3334afc288f/rigel-pharmaceuticals-advances-r289-phase-1b-trial-for-lower-risk-mds-with-first-dose-expansion-patient 2025-10-08T17:22:02+00:00 hourly 0.9 https://trial.medpath.com/news/e3a766a25affdf18/boehringer-ingelheim-acquires-first-in-class-oncology-asset-from-accent-therapeutics-targeting-high-isg-expression-tumors 2025-10-08T17:21:33+00:00 hourly 0.9 https://trial.medpath.com/news/3d64e2d393026eed/alpha-fusion-establishes-world-s-first-commercial-at-211-drug-supply-chain-for-thyroid-cancer-trial 2025-10-08T17:21:22+00:00 hourly 0.9 https://trial.medpath.com/news/08b0b0d0fcaddc3d/fda-authorizes-expanded-access-program-for-first-in-class-tourette-syndrome-drug-ecopipam 2025-10-08T17:21:11+00:00 hourly 0.9 https://trial.medpath.com/news/22fa12ac9cd8d99d/ascend-advanced-therapies-successfully-defends-european-patent-for-epyq-aav-plasmid-technology 2025-10-08T17:20:57+00:00 hourly 0.9 https://trial.medpath.com/news/76aca51ddbc81267/bd-and-opentrons-partner-to-automate-single-cell-multiomics-research-for-drug-development 2025-10-08T17:20:43+00:00 hourly 0.9 https://trial.medpath.com/news/1f9087f09d803ea8/sanofi-s-alphamedix-radioligand-therapy-meets-all-primary-endpoints-in-phase-2-gep-net-trial 2025-10-08T17:20:01+00:00 hourly 0.9 https://trial.medpath.com/news/f293b7ea5611ba6b/spruce-biosciences-secures-50m-to-advance-sanfilippo-syndrome-type-b-therapy-toward-bla-submission 2025-10-08T17:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/7dac267a1769a8dd/lumen-bioscience-strengthens-leadership-following-30m-series-c-extension-to-advance-oral-biologics-platform 2025-10-08T17:18:48+00:00 hourly 0.9 https://trial.medpath.com/news/c75a7e4807309693/sandoz-and-formycon-secure-aflibercept-biosimilar-settlement-agreements-with-regeneron 2025-10-08T17:17:00+00:00 hourly 0.9 https://trial.medpath.com/news/1758248db901a916/zimmer-biomet-and-paragon-28-launch-advanced-foot-and-ankle-trauma-systems-for-complex-fracture-management 2025-10-08T17:16:14+00:00 hourly 0.9 https://trial.medpath.com/news/3562a7f724cf33b2/four-biotech-companies-report-promising-clinical-trial-milestones-across-cancer-hearing-loss-and-rare-disease-treatments 2025-10-08T17:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/3fa7f5cdf8300947/science-37-achieves-third-consecutive-fda-nai-inspection-rating-for-direct-to-patient-clinical-trial-platform 2025-10-08T17:14:37+00:00 hourly 0.9 https://trial.medpath.com/news/17c1422f69c77858/ireland-launches-phase-2-of-precision-oncology-ireland-program-with-expanded-investment-and-clinical-focus 2025-10-08T17:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/30fafbf057350363/fda-clears-celon-pharma-s-novel-pde10a-inhibitor-cpl-936-for-phase-3-schizophrenia-trials 2025-10-08T13:17:57+00:00 hourly 0.9 https://trial.medpath.com/news/b46e1dcc6252dd68/zenas-biopharma-secures-global-rights-to-orelabrutinib-btk-inhibitor-for-multiple-sclerosis-in-2-billion-deal 2025-10-08T13:17:54+00:00 hourly 0.9 https://trial.medpath.com/news/15d9cd0a70500e03/phase-1-trial-establishes-bireociclib-as-promising-cdk4-6-inhibitor-for-advanced-breast-cancer-treatment 2025-10-08T13:16:11+00:00 hourly 0.9 https://trial.medpath.com/news/f18e54a0af769c6b/breakthrough-blood-test-achieves-96-accuracy-in-diagnosing-chronic-fatigue-syndrome 2025-10-08T13:15:45+00:00 hourly 0.9 https://trial.medpath.com/news/c3a99e5d23f8265f/three-cdmos-form-integrated-cmc-partnership-to-accelerate-drug-development-from-discovery-to-clinic 2025-10-08T13:15:43+00:00 hourly 0.9 https://trial.medpath.com/news/2d67f3ece78c145e/phase-3-trial-launches-for-novel-triple-drug-malaria-treatment-to-combat-artemisinin-resistance 2025-10-08T13:15:20+00:00 hourly 0.9 https://trial.medpath.com/news/02429483bb1dc6e0/nilo-therapeutics-emerges-from-stealth-with-101-million-to-develop-neural-circuit-based-immunomodulation-therapies 2025-10-08T13:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/1047e1568d0c12be/bbg-advanced-therapies-and-cellforcure-form-transatlantic-partnership-to-expand-atmp-manufacturing-capacity 2025-10-08T09:16:30+00:00 hourly 0.9 https://trial.medpath.com/news/a6da508f2d8e7fed/bioinvent-initiates-phase-2a-trial-of-bi-1206-plus-pembrolizumab-for-advanced-nsclc-and-uveal-melanoma 2025-10-08T09:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/8b4b16316e93f484/dimerix-s-dmx-200-advances-in-phase-3-fsgs-trial-with-strong-safety-profile-and-fda-aligned-endpoint-data 2025-10-08T09:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/1b11708574937c78/angle-plc-rebrands-as-cellbxhealth-appoints-new-executive-chairman-to-drive-ctc-intelligence-strategy 2025-10-08T09:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/4db9a4a40dbf46b6/transmedics-group-stock-surges-102-following-fda-approval-for-new-organ-care-system 2025-10-08T09:14:34+00:00 hourly 0.9 https://trial.medpath.com/news/62f2ed567386b0dc/alphamedix-achieves-all-primary-endpoints-in-phase-2-trial-for-gastroenteropancreatic-neuroendocrine-tumors 2025-10-08T09:14:08+00:00 hourly 0.9 https://trial.medpath.com/news/7359ec30e728a9b9/celaid-therapeutics-secures-7-2-million-series-b-funding-to-advance-pediatric-stem-cell-therapy-cld-001 2025-10-08T05:16:07+00:00 hourly 0.9 https://trial.medpath.com/news/fa28a56d28060965/fda-issues-complete-response-letter-for-xspray-pharma-s-dasynoc-citing-manufacturing-issues 2025-10-08T05:14:42+00:00 hourly 0.9 https://trial.medpath.com/news/4ba4f0625ec05194/carsgen-s-gprc5d-car-t-therapy-ct071-achieves-100-response-rate-in-heavily-pretreated-multiple-myeloma-patients 2025-10-08T05:14:34+00:00 hourly 0.9 https://trial.medpath.com/news/8490a102aef9d3c5/painchek-receives-historic-fda-de-novo-approval-for-first-regulated-pain-assessment-device-in-us-market 2025-10-08T05:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/29bcccb79dee37e5/eli-lilly-s-omvoh-demonstrates-sustained-four-year-efficacy-in-ulcerative-colitis-extension-trial 2025-10-08T03:14:33+00:00 hourly 0.9 https://trial.medpath.com/news/e470495a34d86b09/major-study-questions-tramadol-s-effectiveness-for-chronic-pain-reveals-increased-cardiac-risk 2025-10-08T01:18:34+00:00 hourly 0.9 https://trial.medpath.com/news/6ef8bff549053ebe/glaukos-corporation-breaks-ground-on-82m-ophthalmic-r-d-facility-in-alabama 2025-10-08T01:17:19+00:00 hourly 0.9 https://trial.medpath.com/news/d64dad2e667ed5c9/cyteph-completes-enrollment-for-first-in-human-cyt-101-trial-in-recurrent-glioblastoma 2025-10-08T01:16:08+00:00 hourly 0.9 https://trial.medpath.com/news/b688909216c62b99/immuron-submits-ind-application-to-fda-for-novel-c-difficile-therapy-imm-529 2025-10-08T01:15:58+00:00 hourly 0.9 https://trial.medpath.com/news/2294fd15de545e83/humacyte-secures-60-million-in-oversubscribed-offering-to-advance-bioengineered-tissue-platform 2025-10-08T01:15:43+00:00 hourly 0.9 https://trial.medpath.com/news/57bf92fb287f72c1/celonic-and-carbogen-amcis-form-strategic-alliance-for-integrated-adc-development-and-manufacturing 2025-10-08T01:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/c7094f18f3cd2ce8/zimmer-biomet-completes-177-million-acquisition-of-monogram-technologies-to-pioneer-autonomous-orthopedic-robotics 2025-10-08T01:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/8effeebc68f3b28c/hengrui-advances-kras-g12d-inhibitor-hrs-4642-to-phase-3-trial-in-pancreatic-cancer 2025-10-08T01:15:22+00:00 hourly 0.9 https://trial.medpath.com/news/8f3ea3f0ee15c767/verrica-to-present-vp-315-immune-activation-data-from-phase-2-basal-cell-carcinoma-trial-at-sitc-2025 2025-10-08T01:15:12+00:00 hourly 0.9 https://trial.medpath.com/news/f362971420960439/trudiagnostic-receives-nih-grant-to-develop-revolutionary-epigenetic-disease-prediction-platform 2025-10-08T01:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/18c628e03145c6eb/former-fda-vaccine-chief-peter-marks-joins-eli-lilly-to-lead-infectious-disease-and-molecule-discovery 2025-10-08T01:14:34+00:00 hourly 0.9 https://trial.medpath.com/news/ef5e6fb1488bc58e/fda-approves-johnson-johnson-s-simponi-for-pediatric-ulcerative-colitis-treatment 2025-10-08T01:14:14+00:00 hourly 0.9 https://trial.medpath.com/news/d643326a38973a20/nexalin-s-neurostimulation-device-shows-significant-cognitive-improvements-in-alzheimer-s-disease-trial 2025-10-08T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/6a274fd66feab53e/uk-pharma-industry-pushes-for-67-increase-in-nice-cost-effectiveness-threshold-amid-investment-exodus 2025-10-07T21:23:15+00:00 hourly 0.9 https://trial.medpath.com/news/9b8b86fc7fa71df7/patent-board-rules-against-johns-hopkins-in-pembrolizumab-patent-dispute-with-merck 2025-10-07T21:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/ddc701f7a1d766f5/kernal-bio-secures-48-million-arpa-h-grant-to-develop-revolutionary-in-vivo-car-t-cell-therapies 2025-10-07T21:19:08+00:00 hourly 0.9 https://trial.medpath.com/news/c10996fe055580f1/jcr-pharmaceuticals-just-aav-platform-achieves-52-fold-improvement-in-muscle-gene-delivery-while-reducing-liver-exposure 2025-10-07T21:18:15+00:00 hourly 0.9 https://trial.medpath.com/news/23c3cbab044286ed/predicta-biosciences-raises-23-4m-series-a-to-advance-non-invasive-diagnostics-for-multiple-myeloma-and-blood-cancers 2025-10-07T21:17:44+00:00 hourly 0.9 https://trial.medpath.com/news/a824c5350180d501/cnd-life-sciences-receives-fda-breakthrough-device-designation-and-3m-nih-grant-for-parkinson-s-disease-diagnostic-test 2025-10-07T21:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/0ecf6f806b34602a/neurona-therapeutics-receives-ema-prime-designation-for-nrtx-1001-cell-therapy-in-drug-resistant-focal-epilepsy 2025-10-07T20:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/d3a71ba7191c101f/alloy-therapeutics-partners-with-university-of-british-columbia-to-accelerate-pandemic-preparedness-through-cryo-em-antibody-discovery 2025-10-07T17:28:16+00:00 hourly 0.9 https://trial.medpath.com/news/ce284b40b719d065/zoliflodacin-shows-high-cure-rates-against-resistant-gonorrhea-in-phase-3-trial-subset-analysis 2025-10-07T17:24:02+00:00 hourly 0.9 https://trial.medpath.com/news/94201fa2262c948c/novel-inhalable-crizotinib-nanoparticles-show-promise-for-targeted-lung-cancer-treatment 2025-10-07T17:22:27+00:00 hourly 0.9 https://trial.medpath.com/news/f5764b503a4c90af/affinia-therapeutics-raises-40m-series-c-to-advance-first-in-class-gene-therapy-for-bag3-dilated-cardiomyopathy 2025-10-07T17:21:00+00:00 hourly 0.9 https://trial.medpath.com/news/5123a5a35d68eafb/eyedura-partners-with-singapore-eye-research-institute-for-insulin-based-neurotrophic-keratitis-treatment 2025-10-07T17:19:45+00:00 hourly 0.9 https://trial.medpath.com/news/b7f4d20da3327824/subcutaneous-nivolumab-demonstrates-noninferiority-to-iv-formulation-in-checkmate-67t-trial 2025-10-07T17:19:23+00:00 hourly 0.9 https://trial.medpath.com/news/e64cc8512d6ef477/kazia-therapeutics-secures-first-in-class-pd-l1-protein-degrader-through-qimr-berghofer-partnership 2025-10-07T17:19:15+00:00 hourly 0.9 https://trial.medpath.com/news/5aab01d531ba1597/oragenics-partners-with-receptor-ai-to-accelerate-ai-driven-neurological-drug-discovery 2025-10-07T17:18:38+00:00 hourly 0.9 https://trial.medpath.com/news/25b5098ea04e8939/igc-pharma-s-igc-1c-targets-novel-tau-protein-pathway-in-alzheimer-s-disease 2025-10-07T17:18:36+00:00 hourly 0.9 https://trial.medpath.com/news/a17188fc41dbdbbf/university-of-houston-receives-3-9m-nih-grant-to-develop-first-treatment-for-deadly-cryptosporidium-infections 2025-10-07T17:18:31+00:00 hourly 0.9 https://trial.medpath.com/news/af87233b51905061/veris-health-and-ohio-state-university-cancer-center-launch-commercial-digital-cancer-care-platform 2025-10-07T17:17:56+00:00 hourly 0.9 https://trial.medpath.com/news/4c9051b48927b8df/fda-approves-15-new-antidepressants-as-novel-mechanisms-challenge-traditional-depression-treatment 2025-10-07T17:17:47+00:00 hourly 0.9 https://trial.medpath.com/news/e5751130b3147338/johnson-johnson-s-icotrokinra-demonstrates-strong-efficacy-in-phase-2b-ulcerative-colitis-trial 2025-10-07T17:17:20+00:00 hourly 0.9 https://trial.medpath.com/news/3ed20d1643d7dc13/immusoft-achieves-first-ever-safe-re-dosing-of-gene-therapy-patient-with-isp-001-for-mps-i 2025-10-07T17:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/47451141bc4925ec/vir-biotechnology-to-present-48-week-solstice-trial-results-for-hepatitis-delta-combination-therapy-at-aasld-2025 2025-10-07T17:16:56+00:00 hourly 0.9 https://trial.medpath.com/news/c7e29bfa3d5f59d6/gld-partners-launches-altagenics-to-target-muscle-wasting-diseases-using-advanced-functional-genomics-platform 2025-10-07T17:16:41+00:00 hourly 0.9 https://trial.medpath.com/news/40de867f28dea5c2/cellectar-biosciences-raises-5-8-million-through-warrant-exercise-to-advance-cancer-drug-pipeline 2025-10-07T17:15:35+00:00 hourly 0.9 https://trial.medpath.com/news/c81ecde4f7e6c568/fda-approves-restart-of-noblestitch-clinical-trial-for-device-free-pfo-closure 2025-10-07T17:15:28+00:00 hourly 0.9 https://trial.medpath.com/news/ed568a2f3eafdf54/bavarian-nordic-s-mpox-vaccine-shows-superior-immune-response-in-children-aged-2-11-years 2025-10-07T17:15:19+00:00 hourly 0.9 https://trial.medpath.com/news/867c9d17d385592c/ontario-launches-first-in-canada-fast-program-to-accelerate-cancer-drug-access 2025-10-07T17:14:38+00:00 hourly 0.9 https://trial.medpath.com/news/e113cb06651202ae/peer-ai-secures-12-1m-to-transform-drug-approval-process-with-specialized-ai-platform 2025-10-07T17:14:36+00:00 hourly 0.9 https://trial.medpath.com/news/f025b59baf46b975/ryght-ai-forms-scientific-advisory-board-to-advance-ai-powered-clinical-trial-technology 2025-10-07T17:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/f0a21af82837bada/cellectis-advances-non-viral-gene-therapy-with-circular-dna-templates-and-tale-base-editor-safety-data 2025-10-07T13:22:39+00:00 hourly 0.9 https://trial.medpath.com/news/b1be0f7e775a9275/who-launches-global-clinical-trials-forum-with-indian-research-institutions-as-key-members 2025-10-07T13:22:03+00:00 hourly 0.9 https://trial.medpath.com/news/0dc2b456d418ed14/medicare-s-first-negotiated-drug-prices-launch-january-2026-delivering-1-5-billion-in-patient-savings 2025-10-07T13:18:41+00:00 hourly 0.9 https://trial.medpath.com/news/b0171b5b5bd1b2b0/jade-biosciences-unveils-jade201-half-life-extended-anti-baff-receptor-antibody-for-autoimmune-diseases 2025-10-07T13:18:22+00:00 hourly 0.9 https://trial.medpath.com/news/45bb4f84eea13287/nanophoria-secures-98m-series-a-to-advance-novel-heart-failure-treatment 2025-10-07T13:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/c3f6b851b2932407/oxford-biomedica-expands-us-gene-therapy-manufacturing-with-4-5m-north-carolina-facility-acquisition 2025-10-07T13:16:48+00:00 hourly 0.9 https://trial.medpath.com/news/61081b9f43cd05f4/torl-biotherapeutics-raises-96m-series-c-to-advance-claudin-6-targeted-adc-for-platinum-resistant-ovarian-cancer 2025-10-07T13:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/38f4e4af51af66b5/bioxodes-appoints-industry-veteran-philippe-monteyne-as-chairman-to-advance-breakthrough-stroke-therapy-biox-101 2025-10-07T13:15:34+00:00 hourly 0.9 https://trial.medpath.com/news/45bcac4b42ad6898/kauvery-hospital-achieves-world-s-first-transcatheter-mitral-valve-replacement-with-novel-technique-for-high-risk-patient 2025-10-07T09:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/d453858e65f17726/salipro-biotech-secures-two-japanese-patents-for-membrane-protein-technology-platform 2025-10-07T09:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/5ec5cfaf3adfe27c/maat-pharma-s-maat033-microbiome-therapy-passes-second-safety-review-in-pivotal-phase-2b-trial-for-blood-cancer-patients 2025-10-07T09:14:18+00:00 hourly 0.9 https://trial.medpath.com/news/25bc89312ab53865/beactica-receives-regulatory-support-for-bea-17-development-in-first-swedish-medical-products-agency-advisory-meeting 2025-10-07T09:14:16+00:00 hourly 0.9 https://trial.medpath.com/news/0373aadb67d2bc64/cms-finalizes-ipay-2028-drug-price-negotiation-guidance-expands-program-to-part-b-drugs 2025-10-07T09:14:14+00:00 hourly 0.9 https://trial.medpath.com/news/f9fed90638b015c5/molcure-partners-with-boehringer-ingelheim-in-multi-year-ai-driven-antibody-discovery-collaboration 2025-10-07T09:14:11+00:00 hourly 0.9 https://trial.medpath.com/news/5191d35bd02fb296/ribomic-s-umedaptanib-pegol-shows-promising-growth-rate-improvements-in-phase-2-achondroplasia-trial 2025-10-07T09:14:09+00:00 hourly 0.9 https://trial.medpath.com/news/a2418e4d538c833c/biocon-pharma-receives-fda-approval-for-tofacitinib-extended-release-tablets 2025-10-07T09:13:07+00:00 hourly 0.9 https://trial.medpath.com/news/a1fe593ac503412f/theriva-biologics-to-present-expanded-vcn-01-data-and-next-generation-vcn-12-oncolytic-adenovirus-at-major-medical-conferences 2025-10-07T05:15:50+00:00 hourly 0.9 https://trial.medpath.com/news/ce6a65df794087ef/rovi-rebrands-as-rois-expands-u-s-operations-with-100m-phoenix-manufacturing-facility-acquisition 2025-10-07T01:25:33+00:00 hourly 0.9 https://trial.medpath.com/news/44e52331ca551b85/fda-grants-first-conditional-approval-for-new-world-screwworm-treatment-in-cattle 2025-10-07T01:24:58+00:00 hourly 0.9 https://trial.medpath.com/news/33945c6efb3a0e4c/biorestorative-therapies-secures-1-085-million-funding-to-advance-stem-cell-therapies-for-disc-disease-and-metabolic-disorders 2025-10-07T01:23:57+00:00 hourly 0.9 https://trial.medpath.com/news/174a3cb3f966cb10/arcadia-medicine-receives-fda-clearance-for-novel-non-racemic-mdma-compound-am-1002 2025-10-07T01:23:24+00:00 hourly 0.9 https://trial.medpath.com/news/9dd07f8b514e8b11/clario-partners-with-oxford-to-advance-parkinson-s-disease-research-using-opal-wearable-sensors 2025-10-07T01:22:38+00:00 hourly 0.9 https://trial.medpath.com/news/e73092b3e5c42cac/valneva-secures-500m-debt-facility-to-support-lyme-disease-vaccine-development 2025-10-07T01:21:44+00:00 hourly 0.9 https://trial.medpath.com/news/2c412ea370fabc65/octave-bioscience-receives-grant-to-develop-world-s-first-blood-test-for-multiple-sclerosis-progression 2025-10-07T01:21:41+00:00 hourly 0.9 https://trial.medpath.com/news/7fd28bcce8a77cca/vicore-pharma-s-buloxibutid-shows-promise-in-ipf-trial-using-innovative-synthetic-control-arms 2025-10-07T01:21:35+00:00 hourly 0.9 https://trial.medpath.com/news/5b8b994ac3cc8ea0/biomea-fusion-s-icovamenib-shows-sustained-blood-sugar-control-in-type-2-diabetes-patients-unresponsive-to-glp-1-therapies 2025-10-07T01:20:44+00:00 hourly 0.9 https://trial.medpath.com/news/85874fc224600f6c/cellares-to-build-asia-s-first-automated-car-t-cell-therapy-manufacturing-facility-in-japan 2025-10-07T01:18:32+00:00 hourly 0.9 https://trial.medpath.com/news/258f9e549d340b9e/cell-based-influenza-vaccines-show-19-8-superior-effectiveness-over-egg-based-vaccines-in-real-world-study 2025-10-07T01:18:26+00:00 hourly 0.9 https://trial.medpath.com/news/3a303c0674cb5cf9/form-bio-and-cure-rare-disease-partner-to-accelerate-gene-therapy-development-for-duchenne-muscular-dystrophy 2025-10-07T01:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/f69ff21082cfe9af/biomea-fusion-s-icovamenib-shows-sustained-diabetes-benefits-nine-months-after-treatment-ends 2025-10-07T01:14:21+00:00 hourly 0.9 https://trial.medpath.com/news/c099c67a31d38237/dyne-therapeutics-reports-sustained-one-year-functional-improvements-with-zeleciment-basivarsen-in-myotonic-dystrophy-type-1 2025-10-07T01:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/bb140ac63455f7c1/moffitt-cancer-center-receives-22-4m-grant-to-pioneer-clinical-trials-for-leptomeningeal-disease 2025-10-06T21:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/2b5ec58688336beb/algen-biotechnologies-partners-with-astrazeneca-in-555m-ai-driven-drug-discovery-deal-for-immunology-targets 2025-10-06T17:17:34+00:00 hourly 0.9 https://trial.medpath.com/news/d7ab3d1a7bcfe452/placental-stem-cell-hydrogel-shows-promise-in-phase-ii-trial-for-radiation-induced-skin-injuries 2025-10-06T17:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/c58b4fe1cc2b2ac4/prilenia-and-ferrer-announce-pivotal-phase-3-trial-for-pridopidine-in-als-following-encouraging-phase-2-results 2025-10-06T17:17:18+00:00 hourly 0.9 https://trial.medpath.com/news/1f39f8352de9a807/eccogene-receives-fda-clearance-for-phase-2a-mosaic-trial-testing-dual-target-mash-therapy 2025-10-06T17:17:11+00:00 hourly 0.9 https://trial.medpath.com/news/90b4d71f107dbdd2/revbio-secures-2-2-million-nih-grant-to-advance-tetranite-bone-adhesive-for-vertebral-fracture-treatment 2025-10-06T17:16:34+00:00 hourly 0.9 https://trial.medpath.com/news/63e5213654d4b278/topical-bimiralisib-achieves-92-clearance-rate-in-phase-2-actinic-keratosis-trial 2025-10-06T17:16:08+00:00 hourly 0.9 https://trial.medpath.com/news/7ebdd2bd9350560e/spruce-biosciences-ta-ert-receives-fda-breakthrough-therapy-designation-for-ultra-rare-sanfilippo-syndrome-type-b 2025-10-06T17:15:10+00:00 hourly 0.9 https://trial.medpath.com/news/a16586715a425c63/fda-approves-ucla-s-heart-regeneration-drug-ad-np1-for-clinical-trials 2025-10-06T17:14:34+00:00 hourly 0.9 https://trial.medpath.com/news/865a3d973458bc76/abbvie-s-botox-shows-promise-for-essential-tremor-in-phase-2-elate-trial 2025-10-06T17:13:39+00:00 hourly 0.9 https://trial.medpath.com/news/220e2220a63686dc/marker-therapeutics-initiates-first-off-the-shelf-t-cell-therapy-trial-with-promising-early-safety-data 2025-10-06T17:13:37+00:00 hourly 0.9 https://trial.medpath.com/news/0234af2a5401c6be/historic-malaria-trial-enrolls-first-pregnant-woman-in-mali-addressing-critical-treatment-gap 2025-10-06T17:13:34+00:00 hourly 0.9 https://trial.medpath.com/news/b7983f87d23e3f0a/skye-bioscience-s-cb1-inhibitor-nimacimab-fails-monotherapy-trial-but-shows-promise-in-combination-with-semaglutide 2025-10-06T17:13:21+00:00 hourly 0.9 https://trial.medpath.com/news/dd67affe85b061a6/amgen-launches-direct-to-patient-program-for-cholesterol-drug-repatha-at-60-discount 2025-10-06T17:13:19+00:00 hourly 0.9 https://trial.medpath.com/news/052ad06afdb6c9d0/systematic-review-reveals-emicizumab-cost-effectiveness-varies-by-patient-population-and-comparator-in-hemophilia-a-treatment 2025-10-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/665a08121c904353/precision-cardiovascular-medicine-emerges-as-new-paradigm-to-address-disease-heterogeneity-and-drug-development-challenges 2025-10-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/52890d97f0fdcba9/novel-body-composition-model-predicts-gastric-cancer-response-to-pd-1-immunotherapy 2025-10-06T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/c6ce97527921d541/hikma-and-celltrion-expand-biosimilar-access-across-mena-through-exclusive-partnership 2025-10-06T13:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/1a826032035d014e/irish-court-invalidates-bayer-s-rivaroxaban-dosing-patent-in-eur3-5-billion-xarelto-challenge 2025-10-06T13:19:03+00:00 hourly 0.9 https://trial.medpath.com/news/7c89f662c871778c/merck-expands-tulisokibart-clinical-program-with-three-new-phase-2b-trials-across-immune-mediated-inflammatory-diseases 2025-10-06T13:17:27+00:00 hourly 0.9 https://trial.medpath.com/news/917101e558d2c517/stoke-therapeutics-appoints-ian-smith-as-ceo-as-phase-3-trial-for-dravet-syndrome-treatment-advances 2025-10-06T13:16:22+00:00 hourly 0.9 https://trial.medpath.com/news/6673143494917b54/owlstone-medical-secures-49-1m-arpa-h-award-to-develop-revolutionary-at-home-multi-cancer-detection-tests 2025-10-06T13:15:45+00:00 hourly 0.9 https://trial.medpath.com/news/65ddb646cff05535/pentixapharm-s-cxcr4-targeted-radiopharmaceuticals-show-promise-in-primary-aldosteronism-and-bladder-cancer 2025-10-06T13:15:35+00:00 hourly 0.9 https://trial.medpath.com/news/76108bde4f784bb0/fda-approves-first-generic-mifepristone-as-takeda-discontinues-cell-therapy-research-programs 2025-10-06T13:14:08+00:00 hourly 0.9 https://trial.medpath.com/news/568cdc2379c52d96/csl-behring-secures-canadian-reimbursement-agreement-for-first-gene-therapy-for-hemophilia-b 2025-10-06T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/5d7e1df09fc530ef/trogenix-secures-95-million-series-a-to-advance-revolutionary-cancer-platform-targeting-glioblastoma 2025-10-06T09:16:38+00:00 hourly 0.9 https://trial.medpath.com/news/e49d36e30efa0b7b/harness-therapeutics-launches-misba-duo-platform-for-dual-target-neurodegenerative-disease-treatment 2025-10-06T09:16:30+00:00 hourly 0.9 https://trial.medpath.com/news/98af4d5b83bc044e/nigerian-government-backs-homegrown-brain-cancer-treatment-research-with-multi-institute-support 2025-10-06T09:15:55+00:00 hourly 0.9 https://trial.medpath.com/news/0998721b8a3dcc87/roche-receives-ce-mark-for-first-ai-based-kidney-risk-assessment-tool 2025-10-06T09:14:07+00:00 hourly 0.9 https://trial.medpath.com/news/583cabdc9d452ddc/ignota-labs-acquires-kronos-bio-s-failed-clinical-pipeline-to-revive-shelved-cancer-and-autoimmune-drugs 2025-10-06T09:13:41+00:00 hourly 0.9 https://trial.medpath.com/news/f48d96ec18c9cf71/lupin-launches-generic-liraglutide-injection-in-us-market-despite-fda-manufacturing-compliance-issues 2025-10-06T09:13:13+00:00 hourly 0.9 https://trial.medpath.com/news/4046f3923605387e/d-c-circuit-court-upholds-skinny-label-practice-for-generic-drug-manufacturers 2025-10-06T05:20:18+00:00 hourly 0.9 https://trial.medpath.com/news/4136fa160161c082/carsgen-therapeutics-to-present-ct0596-allogeneic-car-t-data-at-ash-2025 2025-10-06T05:20:15+00:00 hourly 0.9 https://trial.medpath.com/news/e1953103553189ac/risvodetinib-shows-first-ever-reduction-in-alpha-synuclein-pathology-in-phase-2-parkinson-s-disease-trial 2025-10-06T05:19:20+00:00 hourly 0.9 https://trial.medpath.com/news/db8267c767307ee5/indian-immunologicals-receives-regulatory-approval-for-phase-i-trial-of-kyasanur-forest-disease-vaccine 2025-10-06T05:18:10+00:00 hourly 0.9 https://trial.medpath.com/news/c3367e47b51e61ee/iksuda-therapeutics-to-present-phase-1-data-for-her2-targeting-adc-iks014-at-esmo-congress 2025-10-05T22:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4d2d2ef5fa8231db/long-term-clinical-data-show-vatiquinone-and-omaveloxolone-slow-friedreich-s-ataxia-progression 2025-10-05T21:16:25+00:00 hourly 0.9 https://trial.medpath.com/news/45ed36963194af73/guard-therapeutics-rmc-035-fails-phase-2b-pointer-trial-despite-earlier-positive-results 2025-10-05T17:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/cbd65d8aed5879f8/qlife-holding-extends-letter-of-intent-with-hipro-biotechnology-for-reverse-takeover-through-december-2025 2025-10-05T17:15:14+00:00 hourly 0.9 https://trial.medpath.com/news/06f01a6a4de8a4d9/alberta-advances-70m-turkish-drug-contract-with-health-canada-review-of-generic-acetaminophen 2025-10-05T17:14:49+00:00 hourly 0.9 https://trial.medpath.com/news/98f04293657ad9fc/needle-free-vaccine-delivery-through-skin-stretching-shows-superior-immune-response-in-preclinical-study 2025-10-05T09:13:47+00:00 hourly 0.9 https://trial.medpath.com/news/9323738b28c7da79/novocure-reports-positive-phase-3-metis-trial-results-for-brain-metastases-from-lung-cancer 2025-10-05T01:38:21+00:00 hourly 0.9 https://trial.medpath.com/news/fbb81c7a0b7ee883/fda-initiates-pdufa-viii-negotiations-with-industry-leaders-emphasizing-america-first-approach 2025-10-05T01:37:37+00:00 hourly 0.9 https://trial.medpath.com/news/a9b06fea4dc84bac/fdc-limited-receives-fda-approval-for-generic-pilocarpine-hcl-ophthalmic-solution 2025-10-05T01:37:26+00:00 hourly 0.9 https://trial.medpath.com/news/985dd6aee878daec/european-medicines-agency-accelerates-pfizer-biontech-covid-19-vaccine-review-following-pressure-from-eu-member-states 2025-10-05T01:37:17+00:00 hourly 0.9 https://trial.medpath.com/news/90bb51cafac13d71/kyowa-kirin-stock-shows-mixed-valuation-signals-following-recent-fda-approval-and-market-recovery 2025-10-05T01:37:12+00:00 hourly 0.9 https://trial.medpath.com/news/321f3f972b63bcd7/esperion-therapeutics-stock-surges-13-1-following-patent-settlement-victory-with-dr-reddy-s 2025-10-04T21:40:16+00:00 hourly 0.9 https://trial.medpath.com/news/b4f688215ebcaa3e/vasopressin-shows-promise-as-alternative-to-epinephrine-in-neonatal-resuscitation-study 2025-10-04T21:39:51+00:00 hourly 0.9 https://trial.medpath.com/news/5838fdea3e3d38bf/study-reveals-major-gaps-in-phase-iii-cancer-trial-design-and-patient-centered-outcomes 2025-10-04T21:39:29+00:00 hourly 0.9 https://trial.medpath.com/news/e0b4fad66bc93c1d/bridgebio-s-acoramidis-demonstrates-sustained-cardiovascular-benefits-in-phase-3-attr-cm-trial 2025-10-04T17:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/344436708f8b2714/ovid-therapeutics-reports-positive-phase-1-results-for-ov329-in-drug-resistant-epilepsy 2025-10-04T17:14:44+00:00 hourly 0.9 https://trial.medpath.com/news/1f3d5a07cc75cdac/cdsco-launches-multi-state-drug-manufacturing-inspections-following-fatal-cough-syrup-contamination 2025-10-04T17:12:46+00:00 hourly 0.9 https://trial.medpath.com/news/83345e1b54764ef8/ocular-therapeutix-advances-otx-tki-phase-3-trials-for-wet-amd-with-novel-9-month-sustained-release-platform 2025-10-04T17:12:43+00:00 hourly 0.9 https://trial.medpath.com/news/20e9cd1a3c9c0f9f/colorado-sets-first-in-nation-price-ceiling-on-amgen-s-enbrel-limiting-annual-costs-to-31200 2025-10-04T13:14:48+00:00 hourly 0.9 https://trial.medpath.com/news/31dea953506d094a/real-world-evidence-becomes-mandatory-component-of-drug-development-and-post-market-surveillance 2025-10-04T13:14:45+00:00 hourly 0.9 https://trial.medpath.com/news/dff47e032c6a4c28/bajaj-healthcare-receives-cdsco-approval-for-phase-iii-suvorexant-trials-in-india 2025-10-04T13:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/d9b967c3f3128050/barinthus-bio-and-clywedog-therapeutics-announce-merger-to-advance-diabetes-and-celiac-disease-therapies 2025-10-04T01:15:30+00:00 hourly 0.9 https://trial.medpath.com/news/f56a8f0feb23b944/novithera-initiates-preclinical-studies-for-novel-monoclonal-antibody-targeting-psoriasis 2025-10-04T01:14:37+00:00 hourly 0.9 https://trial.medpath.com/news/585894b84c225421/ctmc-partners-with-einstein-hospital-to-launch-global-cell-therapy-network-alliance 2025-10-04T01:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/dc578ea455758aa6/fda-launches-fast-track-review-program-for-u-s-made-generic-drugs-to-strengthen-supply-chain-resilience 2025-10-04T01:12:40+00:00 hourly 0.9 https://trial.medpath.com/news/be20d0e759dba3cd/titan-pharmaceuticals-completes-merger-with-black-titan-corporation-creating-new-nasdaq-listed-entity 2025-10-03T22:26:00+00:00 hourly 0.9 https://trial.medpath.com/news/27e61328e86393ab/aulos-bioscience-to-present-updated-phase-2-data-for-ai-designed-imneskibart-in-checkpoint-inhibitor-refractory-cancers-at-sitc-2025 2025-10-03T21:20:35+00:00 hourly 0.9 https://trial.medpath.com/news/482f750ac46c1a1d/coherus-oncology-to-present-chs-114-anti-ccr8-antibody-data-showing-selective-treg-depletion-at-sitc-2025 2025-10-03T21:16:28+00:00 hourly 0.9 https://trial.medpath.com/news/2515a9a6d8d5664d/ansa-biotechnologies-raises-54-4-million-series-b-to-revolutionize-dna-synthesis-with-enzymatic-platform 2025-10-03T21:16:05+00:00 hourly 0.9 https://trial.medpath.com/news/dcca3f683de0bf78/brazilian-regulators-face-mounting-pressure-to-crack-down-on-compounded-glp-1-weight-loss-drugs 2025-10-03T21:15:21+00:00 hourly 0.9 https://trial.medpath.com/news/ead2e4f78a808f2c/frontier-medicines-unveils-dcaf2-as-novel-e3-ligase-for-targeted-protein-degradation-in-cancer-treatment 2025-10-03T21:13:44+00:00 hourly 0.9 https://trial.medpath.com/news/c9bc8637b8e03500/senator-gallego-demands-transparency-on-pfizer-trump-administration-drug-pricing-agreement 2025-10-03T21:12:25+00:00 hourly 0.9 https://trial.medpath.com/news/5d682de6d32e1fb1/takeda-pharmaceutical-exits-cell-therapy-to-focus-on-near-term-commercial-programs 2025-10-03T17:26:34+00:00 hourly 0.9 https://trial.medpath.com/news/cc1d3fe9501c947c/enara-bio-unveils-darkfox-dark-antigen-for-solid-tumor-immunotherapy-at-sitc-2025 2025-10-03T17:26:26+00:00 hourly 0.9 https://trial.medpath.com/news/59abed6b8636ab7b/curonix-freedom-pns-system-demonstrates-69-response-rate-in-first-fda-approved-randomized-trial-for-chronic-craniofacial-pain 2025-10-03T17:25:59+00:00 hourly 0.9 https://trial.medpath.com/news/bc245200e9a924c0/kihealth-secures-5m-to-commercialize-first-of-its-kind-beta-cell-apoptosis-diagnostic-for-early-diabetes-detection 2025-10-03T17:25:36+00:00 hourly 0.9 https://trial.medpath.com/news/a4e596a84796a1bf/revvity-partners-with-sanofi-to-develop-population-scale-type-1-diabetes-screening-test 2025-10-03T17:25:34+00:00 hourly 0.9 https://trial.medpath.com/news/1cd6b5b731343163/scientists-successfully-transplant-first-universal-donor-kidney-after-blood-type-conversion 2025-10-03T17:24:55+00:00 hourly 0.9 https://trial.medpath.com/news/623037f907e863fc/kernal-bio-joins-lilly-gateway-labs-to-advance-ai-driven-in-vivo-cell-therapies 2025-10-03T17:23:29+00:00 hourly 0.9 https://trial.medpath.com/news/9fc162446dcc083f/radiant-biotherapeutics-to-present-novel-multabody-technology-for-cancer-immunotherapy-at-sitc-2025 2025-10-03T17:22:56+00:00 hourly 0.9 https://trial.medpath.com/news/7a1f1c0b15496d08/bioinvent-to-present-phase-1-data-for-bi-1910-tnfr2-agonist-at-sitc-despite-pausing-development 2025-10-03T17:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/53a38bf00f4d0d26/ovid-therapeutics-secures-175m-pipe-financing-to-advance-cns-drug-pipeline-through-2028 2025-10-03T17:21:45+00:00 hourly 0.9 https://trial.medpath.com/news/9af4ab58584855fa/mitsubishi-tanabe-pharma-to-present-phase-3-data-on-continuous-levodopa-infusion-nd0612-for-parkinson-s-disease 2025-10-03T17:21:29+00:00 hourly 0.9 https://trial.medpath.com/news/6a93b07fa5b75d60/sarepta-advances-srp-1003-sirna-therapy-for-myotonic-dystrophy-type-1-with-positive-safety-review 2025-10-03T17:16:06+00:00 hourly 0.9 https://trial.medpath.com/news/8f9ac18df8374356/alto-neuroscience-receives-fda-fast-track-designation-for-alto-101-schizophrenia-cognitive-impairment-treatment 2025-10-03T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/2578e6e86fcd9041/experimental-peptide-drug-nvg-291-shows-promise-in-phase-2-trial-for-spinal-cord-injury-recovery 2025-10-03T17:14:49+00:00 hourly 0.9 https://trial.medpath.com/news/4cd624c15d025c56/rocket-pharmaceuticals-withdraws-fda-application-for-fanconi-anemia-gene-therapy-rp-l102 2025-10-03T13:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/f4fee077bc0d2e54/ai-guided-discovery-of-enterololin-offers-new-hope-for-ibd-treatment 2025-10-03T13:16:25+00:00 hourly 0.9 https://trial.medpath.com/news/ac946b002dea51c7/amgen-s-repatha-demonstrates-long-term-cardiovascular-benefits-in-phase-iii-vesalius-cv-trial 2025-10-03T13:16:12+00:00 hourly 0.9 https://trial.medpath.com/news/9a7ea8239010f940/fda-unveils-eight-science-priorities-for-2026-generic-drug-program-emphasizing-ai-integration-and-complex-product-development 2025-10-03T13:16:03+00:00 hourly 0.9 https://trial.medpath.com/news/ea8b36ed1d5c1fc5/ovid-therapeutics-ov329-shows-53-gaba-inhibition-in-phase-1-trial-for-drug-resistant-epilepsy 2025-10-03T13:13:39+00:00 hourly 0.9 https://trial.medpath.com/news/8192b4e4d84fb4b2/medhub-ai-secures-national-reimbursement-approval-in-japan-for-ai-powered-coronary-assessment-system 2025-10-03T13:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/45f06dbcbcdd1600/world-s-first-elephant-herpesvirus-vaccine-shows-promise-in-breakthrough-safety-trial 2025-10-03T13:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/143b4b3bb868a0d0/heriot-watt-university-secures-ps475000-for-revolutionary-vibroacoustic-sensor-to-transform-eczema-diagnosis-and-treatment 2025-10-03T09:15:20+00:00 hourly 0.9 https://trial.medpath.com/news/3ecbe6481b22d5c6/aberdeen-royal-infirmary-launches-car-t-cell-therapy-program-first-patient-achieves-remission 2025-10-03T09:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/e278d7d7cf7f2827/india-launches-rs-4200-crore-prip-scheme-to-boost-pharmaceutical-and-medtech-r-d-innovation 2025-10-03T09:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/6a227b11bf74fdff/fda-outlines-2026-medical-device-regulatory-guidance-priorities-emphasizes-real-world-evidence-and-ai-software-oversight 2025-10-03T05:17:28+00:00 hourly 0.9 https://trial.medpath.com/news/2150ce0e1d9990d5/ss-innovations-pivots-to-510-k-pathway-for-ssi-mantra-surgical-robot-fda-approval 2025-10-03T05:17:25+00:00 hourly 0.9 https://trial.medpath.com/news/1d1bfeb0dc868cba/monash-university-establishes-boston-hub-to-accelerate-global-drug-discovery-partnerships 2025-10-03T05:16:45+00:00 hourly 0.9 https://trial.medpath.com/news/84579eca5d6ed8e0/defence-therapeutics-strengthens-leadership-with-quality-operations-expert-to-advance-adc-platform 2025-10-03T05:16:42+00:00 hourly 0.9 https://trial.medpath.com/news/b7a2eeab52596766/health-canada-approves-agamree-as-first-treatment-for-duchenne-muscular-dystrophy-in-canada 2025-10-03T01:22:57+00:00 hourly 0.9 https://trial.medpath.com/news/a4bd3f7c6b4f4543/quanthealth-secures-strategic-investment-from-sanofi-ventures-to-advance-ai-driven-clinical-trial-simulation 2025-10-03T01:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/f6e6ed22e4462f65/askbio-to-present-aav-gene-therapy-advances-at-esgct-2025-meeting 2025-10-03T01:16:58+00:00 hourly 0.9 https://trial.medpath.com/news/52052289975efd16/rockcliffe-labs-secures-75-million-financing-for-late-stage-sepsis-biomarker-program 2025-10-03T01:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/0d0ae728678ba5e1/vivex-biologics-initiates-pivotal-trial-for-via-disc-np-in-degenerative-disc-disease 2025-10-03T01:13:39+00:00 hourly 0.9 https://trial.medpath.com/news/ad0299ab60a7f6e0/fda-approves-generic-mifepristone-from-evita-solutions-drawing-congressional-criticism 2025-10-03T01:13:24+00:00 hourly 0.9 https://trial.medpath.com/news/f8fcc42e7cc421b2/fda-approves-genentech-s-tecentriq-plus-lurbinectedin-as-first-line-maintenance-therapy-for-extensive-stage-small-cell-lung-cancer 2025-10-03T01:12:54+00:00 hourly 0.9 https://trial.medpath.com/news/4789bd810d4d61cb/thermo-fisher-scientific-partners-with-astrazeneca-bioventurehub-for-collaborative-r-d-innovation 2025-10-02T21:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/843eb7857a89e010/fda-approves-second-generic-mifepristone-despite-trump-administration-safety-review 2025-10-02T21:12:59+00:00 hourly 0.9 https://trial.medpath.com/news/a7cbabd58d8b8570/medsir-and-ataraxis-ai-launch-strategic-collaboration-to-integrate-ai-platform-in-breast-cancer-clinical-trials 2025-10-02T21:12:48+00:00 hourly 0.9 https://trial.medpath.com/news/dd6868c407e40091/roche-s-obinutuzumab-awaits-fda-decision-as-lupus-market-analysis-reveals-launch-success-factors 2025-10-02T17:31:34+00:00 hourly 0.9 https://trial.medpath.com/news/60bdd363a83eb8cc/neuraptive-therapeutics-initiates-phase-3-trial-for-ntx-001-in-traumatic-peripheral-nerve-injuries 2025-10-02T17:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/c41272b1cfdc3678/hologic-receives-fda-clearance-for-automated-gi-bacterial-pathogen-detection-assays 2025-10-02T17:29:44+00:00 hourly 0.9 https://trial.medpath.com/news/de6d7020801d4fe3/igyxos-biotherapeutics-secures-eur5-7-million-french-government-grant-to-advance-first-in-class-infertility-treatment 2025-10-02T17:29:31+00:00 hourly 0.9 https://trial.medpath.com/news/c3ed2d6b137f663f/sotio-biotech-appoints-amy-jensen-smith-as-cso-and-ulrich-moebius-as-cdo-to-advance-adc-pipeline 2025-10-02T17:28:02+00:00 hourly 0.9 https://trial.medpath.com/news/64064dec98bc062e/cirrus-therapeutics-secures-11m-to-advance-gene-therapy-targeting-age-related-cause-of-dry-amd 2025-10-02T17:25:52+00:00 hourly 0.9 https://trial.medpath.com/news/ca42ddb1b1f8ba59/incendia-s-prth-101-shows-promise-in-rare-thymic-cancers-with-7-9-month-median-pfs 2025-10-02T17:25:44+00:00 hourly 0.9 https://trial.medpath.com/news/096af83085ab22dd/restart-trial-launches-to-test-novel-hiv-treatment-targeting-toxic-viral-protein-gp120 2025-10-02T17:24:48+00:00 hourly 0.9 https://trial.medpath.com/news/d2ce36c6b36e0c72/cytomed-therapeutics-publishes-promising-preclinical-data-on-donor-derived-gd-t-cell-therapy-for-acute-myeloid-leukemia 2025-10-02T17:24:00+00:00 hourly 0.9 https://trial.medpath.com/news/eebb98e679f01568/anavex-reports-positive-phase-2-results-for-anavex-r-3-71-in-schizophrenia-and-successful-once-daily-formulation-development 2025-10-02T17:23:35+00:00 hourly 0.9 https://trial.medpath.com/news/07fe252cf1a81026/london-health-sciences-centre-launches-phase-ii-trial-of-internal-radiation-therapy-for-kidney-cancer 2025-10-02T17:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/5c48f872f52a868d/bial-s-bia-28-6156-reaches-key-milestone-in-phase-2-trial-for-gba-associated-parkinson-s-disease 2025-10-02T17:22:12+00:00 hourly 0.9 https://trial.medpath.com/news/c1dfd5b87354fa3a/draig-therapeutics-receives-fda-clearance-for-phase-2-trial-of-novel-ampa-receptor-modulator-dt-101-in-major-depressive-disorder 2025-10-02T17:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/e24bac57a2097e62/eisai-presents-5-year-survival-data-for-lenvatinib-plus-pembrolizumab-in-endometrial-cancer-at-esmo-2025 2025-10-02T17:21:31+00:00 hourly 0.9 https://trial.medpath.com/news/88578325c99b66e8/sitryx-receives-fda-clearance-for-first-in-class-pkm2-modulator-syx-5219-in-atopic-dermatitis 2025-10-02T17:20:33+00:00 hourly 0.9 https://trial.medpath.com/news/58de9e0ad4dbca75/wisconsin-biotech-secures-1-8m-nih-grant-to-advance-ipsc-based-diabetes-cure 2025-10-02T17:20:30+00:00 hourly 0.9 https://trial.medpath.com/news/868a6a6820d05427/start-and-minerva-imaging-expand-partnership-to-create-integrated-radiopharmaceutical-development-platform 2025-10-02T17:18:23+00:00 hourly 0.9 https://trial.medpath.com/news/da5a39cbf242847c/am-pharma-completes-phase-2-enrollment-for-ilofotase-alfa-in-cardiac-surgery-associated-kidney-injury-prevention 2025-10-02T17:17:26+00:00 hourly 0.9 https://trial.medpath.com/news/9ff5ae3fa9177caa/fda-grants-breakthrough-therapy-designation-to-nacuity-s-npi-001-for-retinitis-pigmentosa-treatment 2025-10-02T17:17:19+00:00 hourly 0.9 https://trial.medpath.com/news/f402d800fc92faab/calico-s-abbv-cls-628-receives-fda-fast-track-designation-for-autosomal-dominant-polycystic-kidney-disease 2025-10-02T17:16:41+00:00 hourly 0.9 https://trial.medpath.com/news/a0fc033f386d4f17/amgen-s-repatha-becomes-first-pcsk9-inhibitor-to-demonstrate-primary-prevention-of-cardiovascular-events-in-landmark-12000-patient-trial 2025-10-02T17:16:25+00:00 hourly 0.9 https://trial.medpath.com/news/ce9746092a6119f0/eg-427-s-hsv-gene-therapy-shows-88-reduction-in-urinary-incontinence-episodes-in-phase-ib-iia-trial 2025-10-02T17:16:04+00:00 hourly 0.9 https://trial.medpath.com/news/e2036d110da4362e/vanqua-bio-s-vq-101-achieves-over-70-gcase-activation-in-phase-1b-trial-for-gba-parkinson-s-disease 2025-10-02T13:19:35+00:00 hourly 0.9 https://trial.medpath.com/news/9bf4ea0e9cd66f37/cartography-biosciences-raises-67m-series-b-to-advance-novel-t-cell-engager-for-colorectal-cancer 2025-10-02T13:18:49+00:00 hourly 0.9 https://trial.medpath.com/news/bdbf6c52fa518217/oncoc4-secures-50-million-series-b-funding-to-advance-immuno-oncology-pipeline 2025-10-02T13:16:01+00:00 hourly 0.9 https://trial.medpath.com/news/a1a439b30656b598/asabys-partners-integrates-aliath-bioventures-in-eur468m-strategic-consolidation-to-build-eur1b-life-sciences-platform 2025-10-02T13:15:58+00:00 hourly 0.9 https://trial.medpath.com/news/28664ed99017c8fc/edinburgh-researchers-develop-anti-cancer-drug-potentially-500-times-more-effective-than-current-treatments 2025-10-02T13:15:55+00:00 hourly 0.9 https://trial.medpath.com/news/0ed1d65764703916/who-reports-alarming-decline-in-antibacterial-pipeline-as-drug-resistance-crisis-deepens 2025-10-02T13:15:34+00:00 hourly 0.9 https://trial.medpath.com/news/710304b16b2d5413/india-approves-1500-crore-biomedical-research-career-programme-phase-iii-to-train-2000-scientists-by-2031 2025-10-02T13:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/ff78539aaecfb8d8/msn-labs-receives-regulatory-approval-for-phase-iii-trial-of-vibegron-75-mg-in-overactive-bladder 2025-10-02T13:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/44444e990a9015e4/lundbeck-advances-innovative-phase-3-trial-design-for-amlenetug-in-multiple-system-atrophy 2025-10-02T09:13:15+00:00 hourly 0.9 https://trial.medpath.com/news/e11f8203b7e27769/race-oncology-discovers-novel-mechanism-for-cancer-drug-targeting-previously-undruggable-myc-pathway 2025-10-02T09:13:00+00:00 hourly 0.9 https://trial.medpath.com/news/56f1aee8a4517f00/arovella-s-cldn18-2-car-inkt-therapy-shows-potent-activity-against-pancreatic-cancer-cells 2025-10-02T05:12:41+00:00 hourly 0.9 https://trial.medpath.com/news/bd909009014937cc/nuclidium-secures-us-patent-protection-for-copper-based-fap-targeting-radiotheranostics-platform 2025-10-02T02:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/96ba7b267b54ae75/northern-ireland-children-with-duchenne-muscular-dystrophy-gain-access-to-givinostat-through-early-access-programme 2025-10-02T01:15:17+00:00 hourly 0.9 https://trial.medpath.com/news/6bc49ec78241aa04/pop-biotechnologies-secures-2-46m-nih-grant-for-novel-dual-target-alzheimer-s-immunotherapy 2025-10-02T01:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/ff5733953c035182/uc-davis-scientists-develop-precision-gene-therapy-for-kaposi-s-sarcoma-using-viral-trojan-horse-strategy 2025-10-02T01:14:08+00:00 hourly 0.9 https://trial.medpath.com/news/c3cb6d7d4db5c5ed/novo-nordisk-s-semaglutide-fails-in-alzheimer-s-trials-boosting-biogen-s-leqembi-prospects 2025-10-02T01:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/e69e34ece8427ada/fda-issues-complete-response-letter-for-fortress-biotech-s-menkes-disease-treatment-due-to-manufacturing-deficiencies 2025-10-02T01:13:33+00:00 hourly 0.9 https://trial.medpath.com/news/b6966d665b16c4b4/hypha-labs-and-tryptomics-advance-biotechnology-partnership-for-pharmaceutical-grade-mushroom-production 2025-10-02T01:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/deb6b934bb9507af/single-dose-mm120-lsd-demonstrates-sustained-anxiety-relief-in-phase-2b-gad-trial 2025-10-01T21:18:24+00:00 hourly 0.9 https://trial.medpath.com/news/cf1b6ceffe236bcd/pace-c-trial-reveals-higher-urinary-toxicity-with-sbrt-compared-to-conventional-radiotherapy-in-prostate-cancer 2025-10-01T21:16:45+00:00 hourly 0.9 https://trial.medpath.com/news/53857570b7077324/rheumagen-unveils-universal-hla-gene-editing-approach-for-autoimmune-disease-treatment 2025-10-01T21:16:33+00:00 hourly 0.9 https://trial.medpath.com/news/3a97c843ae54b450/fda-issues-draft-guidance-integrating-real-world-data-and-ai-for-enhanced-cell-and-gene-therapy-postmarket-surveillance 2025-10-01T21:16:30+00:00 hourly 0.9 https://trial.medpath.com/news/263547478a91c5f5/takeda-exits-cell-therapy-research-takes-395-million-impairment-loss 2025-10-01T21:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/169180f18314b3ab/alivegen-s-alg-801-demonstrates-superior-efficacy-over-standard-pah-therapies-in-preclinical-studies 2025-10-01T17:27:26+00:00 hourly 0.9 https://trial.medpath.com/news/fd7e75efa73141fe/keyron-s-forepass-device-shows-8x-greater-weight-control-than-semaglutide-in-head-to-head-study 2025-10-01T17:26:48+00:00 hourly 0.9 https://trial.medpath.com/news/83e3487d59a12759/neonc-technologies-strengthens-scientific-advisory-board-with-two-leading-duke-neuro-oncologists 2025-10-01T17:24:42+00:00 hourly 0.9 https://trial.medpath.com/news/476d5e814d9eb759/folia-health-raises-10-5m-series-a-to-advance-patient-driven-real-world-evidence-platform 2025-10-01T17:24:08+00:00 hourly 0.9 https://trial.medpath.com/news/3451b3ec9b102fa1/17-year-study-demonstrates-hpv-vaccine-s-real-world-effectiveness-and-herd-immunity-protection 2025-10-01T17:24:05+00:00 hourly 0.9 https://trial.medpath.com/news/baafad36330e21d4/cellphire-s-frozen-platelet-therapy-clph-511-meets-primary-endpoint-in-phase-2-3-cryptics-trial 2025-10-01T17:18:51+00:00 hourly 0.9 https://trial.medpath.com/news/10ff542ee5342c73/camp4-therapeutics-advances-syngap1-gene-therapy-toward-clinical-testing-with-glp-toxicology-studies 2025-10-01T17:18:43+00:00 hourly 0.9 https://trial.medpath.com/news/364548bfb8fdf8a0/empatica-acquires-pkg-health-to-advance-digital-parkinson-s-disease-monitoring 2025-10-01T17:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/7401b54e66f19c6b/spur-therapeutics-to-present-long-term-durability-data-for-phase-3-ready-gaucher-disease-gene-therapy 2025-10-01T17:17:02+00:00 hourly 0.9 https://trial.medpath.com/news/1cd168d84da6788f/aerska-raises-21m-to-develop-rna-therapies-for-brain-diseases-using-novel-delivery-platform 2025-10-01T17:16:57+00:00 hourly 0.9 https://trial.medpath.com/news/1bb6cf85c90d5185/omniabio-partners-with-brainchild-bio-to-manufacture-car-t-therapy-for-fatal-pediatric-brain-cancer 2025-10-01T17:16:12+00:00 hourly 0.9 https://trial.medpath.com/news/334685e684fca5d3/fda-issues-complete-response-letter-for-cutx-101-menkes-disease-treatment-due-to-manufacturing-deficiencies 2025-10-01T17:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/038e67431f127b53/aspire-biopharma-targets-h2-2025-fda-submission-for-sublingual-aspirin-following-positive-clinical-results 2025-10-01T17:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/7abf677e750c2a84/halozyme-acquires-elektrofi-for-750m-to-expand-ultra-high-concentration-drug-delivery-technology 2025-10-01T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/29b89ad8c71a44ac/cd47-inhibitor-pipeline-expands-to-over-80-drugs-as-market-anticipates-first-approval-by-2028 2025-10-01T17:14:08+00:00 hourly 0.9 https://trial.medpath.com/news/a8d47ce1d1e0b02b/japan-emerges-as-second-choice-market-for-orphan-drug-launches-new-analysis-reveals 2025-10-01T17:13:47+00:00 hourly 0.9 https://trial.medpath.com/news/2577c97db662db87/wearable-heart-rate-variability-patch-reduces-substance-use-by-64-in-recovery-patients 2025-10-01T17:13:44+00:00 hourly 0.9 https://trial.medpath.com/news/c835f5e6bd08fd43/reflexion-s-scintix-platform-achieves-100-local-control-in-lung-and-bone-metastases-trial 2025-10-01T15:54:00+00:00 hourly 0.9 https://trial.medpath.com/news/ecb60b6b72c95780/biopharma-m-a-activity-surges-in-q3-2025-with-55-7-billion-in-acquisitions 2025-10-01T13:17:46+00:00 hourly 0.9 https://trial.medpath.com/news/b1ae994807a60a16/bristol-myers-squibb-s-anti-tau-antibody-bms-986446-receives-fda-fast-track-designation-for-alzheimer-s-disease 2025-10-01T13:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/4d2ce07702a2525c/appili-therapeutics-secures-40-million-niaid-contract-to-develop-first-in-class-fungal-vaccine-vxv-01 2025-10-01T13:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/fa8e68061a2c8ade/merck-and-daiichi-s-raludotatug-deruxtecan-shows-51-response-rate-in-platinum-resistant-ovarian-cancer 2025-10-01T13:16:59+00:00 hourly 0.9 https://trial.medpath.com/news/ed1c3aee823d96a3/chugai-launches-piasky-as-taiwan-s-first-subcutaneous-treatment-for-paroxysmal-nocturnal-hemoglobinuria 2025-10-01T13:15:42+00:00 hourly 0.9 https://trial.medpath.com/news/6dfb8a6457a3713a/major-pharma-companies-form-ai-consortium-to-accelerate-drug-discovery-through-federated-data-sharing 2025-10-01T13:15:34+00:00 hourly 0.9 https://trial.medpath.com/news/73bc3f04461ec6dd/wockhardt-submits-first-indian-developed-antibiotic-to-us-fda-for-multidrug-resistant-uti-treatment 2025-10-01T13:15:22+00:00 hourly 0.9 https://trial.medpath.com/news/077222b1b6b334aa/taho-pharma-submits-world-s-first-apixaban-oral-dissolving-film-to-fda-for-stroke-survivors-with-swallowing-difficulties 2025-10-01T09:25:00+00:00 hourly 0.9 https://trial.medpath.com/news/3d8491cda3f819ee/dutch-court-blocks-glenmark-s-early-generic-eltrombopag-launch-reinforces-spc-protection 2025-10-01T09:24:32+00:00 hourly 0.9 https://trial.medpath.com/news/fe5adbb4a86b246a/university-of-arizona-researchers-develop-long-acting-opioid-overdose-reversal-agent 2025-10-01T09:24:18+00:00 hourly 0.9 https://trial.medpath.com/news/403a42bbca854004/fda-grants-priority-review-for-leniolisib-in-children-with-rare-immunodeficiency-apds 2025-10-01T09:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/5e3574d4c399491a/predictmedix-ai-launches-clinical-trial-ai-platform-to-optimize-pharmaceutical-development 2025-10-01T09:12:14+00:00 hourly 0.9 https://trial.medpath.com/news/57fc408600080af7/enanta-pharmaceuticals-raises-65-million-in-upsized-public-offering-to-advance-rsv-and-immunology-pipeline 2025-10-01T05:15:17+00:00 hourly 0.9 https://trial.medpath.com/news/ec174e8da83089e2/ultragenyx-appoints-eric-olson-as-chief-business-officer-to-lead-rare-disease-pipeline-expansion 2025-10-01T05:12:53+00:00 hourly 0.9 https://trial.medpath.com/news/4eee3c057f9ea3ef/first-in-human-trial-shows-engineered-exosomes-safely-target-kras-g12d-in-pancreatic-cancer 2025-10-01T05:12:47+00:00 hourly 0.9 https://trial.medpath.com/news/b2b447d3c45f0d9f/emagene-life-partners-with-institute-for-functional-medicine-to-launch-ai-driven-healthcare-platform-in-asia 2025-10-01T05:12:33+00:00 hourly 0.9 https://trial.medpath.com/news/c0a085739e4eaa8e/pharmaceutical-industry-warns-against-forced-onshoring-as-tariffs-threaten-generic-and-biosimilar-efficiency 2025-10-01T03:22:58+00:00 hourly 0.9 https://trial.medpath.com/news/71c6c126f5df2909/ohsu-scientists-create-functional-human-eggs-from-skin-cells-using-novel-mitomeiosis-technique 2025-10-01T02:27:19+00:00 hourly 0.9 https://trial.medpath.com/news/50a98f0dfda45ee7/medera-strengthens-leadership-team-with-three-key-executive-appointments-to-advance-cardiac-gene-therapy-pipeline 2025-10-01T01:27:04+00:00 hourly 0.9 https://trial.medpath.com/news/c151b709a5dd724e/debiopharm-advances-bispecific-adc-development-with-sunrock-biopharma-s-anti-her2-her3-antibody-license 2025-10-01T01:26:42+00:00 hourly 0.9 https://trial.medpath.com/news/3d3a6612207d0d7e/pricing-negotiations-for-car-t-therapy-carvykti-collapse-in-canada-leaving-multiple-myeloma-patients-without-access 2025-10-01T01:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/b30f9f66abbd95e6/vidac-pharma-secures-broad-u-s-patent-protection-for-novel-mitochondria-targeted-cancer-therapy 2025-10-01T01:22:44+00:00 hourly 0.9 https://trial.medpath.com/news/57599237df0f7ae2/moffitt-cancer-center-reports-promising-results-for-avelumab-radiation-combination-in-leptomeningeal-disease 2025-10-01T01:22:34+00:00 hourly 0.9 https://trial.medpath.com/news/40accbfc22d97e1a/parse-biosciences-expands-global-single-cell-sequencing-access-through-strategic-service-provider-partnerships 2025-10-01T01:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/172fda6670dbcdae/proton-therapy-shows-survival-benefit-in-glioblastoma-trial-advances-to-phase-iii 2025-10-01T01:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/f16b9b64d472f60c/first-fda-approved-neuropixels-study-targets-executive-function-deficits-in-parkinson-s-disease 2025-10-01T01:18:40+00:00 hourly 0.9 https://trial.medpath.com/news/271f0644c80af48c/indivior-halts-marketing-of-controversial-overdose-drug-opvee-following-new-york-settlement 2025-10-01T01:17:20+00:00 hourly 0.9 https://trial.medpath.com/news/b0a5f1d687cf9efc/fda-approves-remibrutinib-as-first-oral-btk-inhibitor-for-chronic-spontaneous-urticaria 2025-10-01T01:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/d3f081994a4fb56e/adagio-medical-s-ultra-low-temperature-cryoablation-shows-97-acute-success-rate-in-pivotal-ventricular-tachycardia-trial 2025-10-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/7d093eda43d4c625/prima-retinal-implant-restores-central-vision-in-geographic-atrophy-patients-achieving-81-response-rate 2025-10-01T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/36ad493d4e944e9c/hinge-bio-partners-with-kyorin-for-105m-hb2198-autoimmune-deal-in-japan 2025-09-30T23:36:00+00:00 hourly 0.9 https://trial.medpath.com/news/8ba55ceadc5e286d/fda-halts-new-drug-application-acceptance-as-government-shutdown-begins 2025-09-30T21:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/25e77cd01feb56e1/novavax-and-sanofi-expand-partnership-to-include-matrix-m-adjuvant-in-pandemic-influenza-vaccine-development 2025-09-30T21:18:09+00:00 hourly 0.9 https://trial.medpath.com/news/577cb4c345541cf2/real-world-safety-analysis-reveals-key-adverse-event-patterns-for-lutetium-177-psma-617-in-advanced-prostate-cancer 2025-09-30T21:16:28+00:00 hourly 0.9 https://trial.medpath.com/news/1c09677c4e6e33cf/roche-s-sixth-generation-troponin-t-test-demonstrates-high-precision-in-heart-attack-diagnosis 2025-09-30T21:16:05+00:00 hourly 0.9 https://trial.medpath.com/news/c1e72f1cfbe8c1c3/pila-pharma-partners-with-gubra-for-preclinical-obesity-trials-of-trpv1-inhibitor-xen-d0501 2025-09-30T21:15:26+00:00 hourly 0.9 https://trial.medpath.com/news/388e0019e092eb51/kaia-health-and-medimprove-launch-digital-copd-rehabilitation-pilot-at-ers-2025 2025-09-30T21:15:19+00:00 hourly 0.9 https://trial.medpath.com/news/7256ae93ada20da1/henlius-pd-l1-adc-hlx43-receives-fda-orphan-drug-designation-for-thymic-epithelial-tumors 2025-09-30T21:15:11+00:00 hourly 0.9 https://trial.medpath.com/news/eea93ed76a0d27a0/affluent-medical-advances-three-medical-device-programs-with-pivotal-trial-launch-and-fda-regulatory-progress 2025-09-30T21:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/fa53784f7d41fbf5/labcorp-partners-with-roche-to-deploy-digital-pathology-technology-amid-growing-pathologist-shortage 2025-09-30T17:39:36+00:00 hourly 0.9 https://trial.medpath.com/news/d5fcc832d8d0c86c/lunai-bioworks-completes-corporate-rebranding-with-focus-on-ai-powered-drug-discovery-and-parkinson-s-research 2025-09-30T17:38:41+00:00 hourly 0.9 https://trial.medpath.com/news/fff063e26ba111e2/ai-powered-gene-signature-tests-transform-infection-diagnosis-and-critical-care-treatment 2025-09-30T17:37:50+00:00 hourly 0.9 https://trial.medpath.com/news/eafb549bde3f8269/biolegacy-files-patent-for-revolutionary-air-driven-intranasal-drug-delivery-platform 2025-09-30T17:31:17+00:00 hourly 0.9 https://trial.medpath.com/news/67f8772beff894ad/landmark-radcomp-trial-shows-proton-and-photon-radiation-therapies-deliver-equivalent-quality-of-life-for-breast-cancer-patients 2025-09-30T17:30:40+00:00 hourly 0.9 https://trial.medpath.com/news/12ea09bad1190864/addf-releases-speechdx-dataset-to-advance-ai-powered-alzheimer-s-detection-through-speech-biomarkers 2025-09-30T17:30:07+00:00 hourly 0.9 https://trial.medpath.com/news/01e4bedad8780d8f/fda-reverses-position-on-nmn-declares-supplement-ingredient-lawful-after-industry-legal-challenge 2025-09-30T17:29:26+00:00 hourly 0.9 https://trial.medpath.com/news/2167bf9c5d582273/fda-authorizes-expanded-access-programs-for-jaguar-health-s-crofelemer-in-rare-pediatric-intestinal-disease 2025-09-30T17:27:54+00:00 hourly 0.9 https://trial.medpath.com/news/328b5dac42cb2c1a/insufficient-source-material-prevents-comprehensive-oncology-pipeline-analysis 2025-09-30T17:27:50+00:00 hourly 0.9 https://trial.medpath.com/news/089f8dc6a9e234d5/fda-grants-fast-track-designation-to-ub-vv111-first-in-vivo-car-t-therapy-for-relapsed-b-cell-malignancies 2025-09-30T17:27:44+00:00 hourly 0.9 https://trial.medpath.com/news/7eb8e4618c747885/merakris-therapeutics-secures-fda-type-c-meeting-to-advance-mtx-001-wound-healing-therapy 2025-09-30T17:26:15+00:00 hourly 0.9 https://trial.medpath.com/news/58d6dfb22208592a/sellas-life-sciences-announces-r-d-day-to-showcase-phase-3-aml-trial-results-and-cdk9-inhibitor-program 2025-09-30T17:25:27+00:00 hourly 0.9 https://trial.medpath.com/news/68c65ee38d1dfd5d/benchsci-partners-with-thermo-fisher-scientific-to-deploy-ai-powered-drug-discovery-tools 2025-09-30T17:25:08+00:00 hourly 0.9 https://trial.medpath.com/news/fd823b1687b7a371/nanoviricides-advances-broad-spectrum-antiviral-nv-387-to-phase-ii-trials-for-mpox-and-respiratory-infections 2025-09-30T17:24:13+00:00 hourly 0.9 https://trial.medpath.com/news/1c0827eead1febcc/kynexis-initiates-phase-2-trial-of-first-in-class-kat-ii-inhibitor-for-schizophrenia-associated-cognitive-impairment 2025-09-30T17:23:36+00:00 hourly 0.9 https://trial.medpath.com/news/93e945fa1821dc42/inflammatix-publishes-breakthrough-sepsis-research-in-nature-medicine-validates-ai-powered-triverity-test 2025-09-30T17:22:15+00:00 hourly 0.9 https://trial.medpath.com/news/4da327d0307e0f5d/abbvie-submits-fda-application-for-pivekimab-sunirine-to-treat-rare-blood-cancer-bpdcn 2025-09-30T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/ba5b53700cbfb55d/chosa-s-platinum-drug-predictor-shows-promise-across-multiple-cancer-types-in-clinical-validation-studies 2025-09-30T17:20:55+00:00 hourly 0.9 https://trial.medpath.com/news/26db6ee0929f6d5b/aidoc-receives-fda-breakthrough-device-designation-for-multi-condition-ai-triage-system 2025-09-30T17:20:15+00:00 hourly 0.9 https://trial.medpath.com/news/fe0eb88586a7e80b/zenflow-receives-fda-510-k-clearance-for-first-single-use-cystoscope-with-largest-working-channel 2025-09-30T17:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/f8a18b5a615b6626/coya-therapeutics-completes-patient-enrollment-for-frontotemporal-dementia-combination-therapy-study 2025-09-30T17:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/70c0e2b13a65b5ed/zoll-zenix-monitor-defibrillator-receives-fda-approval-for-advanced-emergency-care 2025-09-30T17:19:33+00:00 hourly 0.9 https://trial.medpath.com/news/3275bd8e13549d59/real-world-evidence-bridges-clinical-trial-gaps-in-colorectal-cancer-treatment-selection 2025-09-30T17:19:30+00:00 hourly 0.9 https://trial.medpath.com/news/43b0692e5d386b48/crystalys-therapeutics-emerges-with-205m-series-a-to-advance-gout-treatment-dotinurad 2025-09-30T17:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/202bb17efd2bf02c/applied-therapeutics-faces-regulatory-setback-as-fda-meeting-fails-to-establish-govorestat-approval-pathway 2025-09-30T13:19:29+00:00 hourly 0.9 https://trial.medpath.com/news/1f096f83ed942d4b/eyepoint-pharmaceuticals-raises-150-million-to-advance-duravyu-phase-3-trials-for-retinal-diseases 2025-09-30T13:18:44+00:00 hourly 0.9 https://trial.medpath.com/news/6a2cdeb647972462/star-therapeutics-secures-125-million-series-d-to-advance-vga039-phase-3-trial-for-von-willebrand-disease 2025-09-30T13:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/5cd35ac28d66ee20/star-therapeutics-secures-125m-series-d-to-advance-von-willebrand-disease-drug-vga039-through-phase-3-testing 2025-09-30T13:14:42+00:00 hourly 0.9 https://trial.medpath.com/news/bc24c03e9adf6114/io-biotech-cuts-workforce-by-50-following-fda-rejection-of-cancer-drug-application 2025-09-30T13:14:40+00:00 hourly 0.9 https://trial.medpath.com/news/6fd49ad95583261c/china-approves-first-ren-based-migraine-wearable-device-opening-new-treatment-pathway-for-130-million-patients 2025-09-30T13:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/b346b3be3dae1d66/acurx-receives-ema-approval-for-pediatric-investigation-plan-for-ibezapolstat-in-c-difficile-infection 2025-09-30T13:13:36+00:00 hourly 0.9 https://trial.medpath.com/news/a82cea375ae02c85/fda-grants-fast-track-designation-to-cs-1103-for-methamphetamine-overdose-treatment 2025-09-30T13:13:33+00:00 hourly 0.9 https://trial.medpath.com/news/85cab87b92d959b6/ono-pharmaceutical-submits-cenobamate-application-in-japan-following-successful-phase-3-trial 2025-09-30T13:13:27+00:00 hourly 0.9 https://trial.medpath.com/news/49ae3594714764b5/orion-discontinues-odm-105-development-after-phase-2-insomnia-trial-fails-to-meet-primary-endpoints 2025-09-30T12:06:00+00:00 hourly 0.9 https://trial.medpath.com/news/9f9aba840d11be90/tumor-specific-mhc-ii-expression-emerges-as-predictive-biomarker-for-immunotherapy-response-in-triple-negative-breast-cancer 2025-09-30T09:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/d90c99455173d828/vicore-pharma-s-buloxibutid-receives-orphan-drug-designation-in-japan-for-idiopathic-pulmonary-fibrosis-treatment 2025-09-30T09:14:05+00:00 hourly 0.9 https://trial.medpath.com/news/e3c197a21d077c12/wockhardt-s-nafithromycin-faces-nppa-pricing-exemption-hurdle-over-patent-validity-questions 2025-09-30T09:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/40f39d8a0315c0df/phase-iii-bart-trial-shows-adjuvant-radiation-therapy-significantly-reduces-pelvic-recurrence-in-high-risk-bladder-cancer 2025-09-30T05:15:56+00:00 hourly 0.9 https://trial.medpath.com/news/8a65426925cf35f7/sugemalimab-plus-chemotherapy-shows-clinical-promise-but-lacks-cost-effectiveness-in-advanced-gastric-cancer 2025-09-30T05:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/3030458c04bf299e/novel-alzheimer-s-drug-thn391-targets-fibrin-protein-in-first-in-human-trial 2025-09-30T05:14:33+00:00 hourly 0.9 https://trial.medpath.com/news/9a3e842dc390e57e/full-life-technologies-secures-77-million-series-c-to-advance-radiopharmaceutical-pipeline-and-manufacturing 2025-09-30T05:14:28+00:00 hourly 0.9 https://trial.medpath.com/news/703d272082c6b448/humacyte-secures-patent-protection-for-bioengineered-esophagus-through-2041 2025-09-30T05:13:59+00:00 hourly 0.9 https://trial.medpath.com/news/1f18726edf130bbb/dimerix-s-dmx-200-receives-orphan-drug-designation-in-japan-for-rare-kidney-disease-treatment 2025-09-30T05:13:57+00:00 hourly 0.9 https://trial.medpath.com/news/360127e9aae9aa3b/novocure-s-ttfields-therapy-significantly-delays-brain-metastasis-progression-in-nsclc-patients-following-stereotactic-radiosurgery 2025-09-30T05:13:51+00:00 hourly 0.9 https://trial.medpath.com/news/1dcece80b2681fb5/remote-monitoring-reduces-pediatric-asthma-hospitalizations-by-58-in-dutch-multicentre-study 2025-09-30T01:20:43+00:00 hourly 0.9 https://trial.medpath.com/news/c45b8bccda898689/anaptysbio-plans-corporate-split-to-separate-royalty-assets-from-drug-development-operations 2025-09-30T01:18:41+00:00 hourly 0.9 https://trial.medpath.com/news/bffdb7ae464b645c/danicamtiv-shows-promise-in-phase-2a-trial-for-genetic-dilated-cardiomyopathy 2025-09-30T01:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/6a3036b5137db63b/sutro-biopharma-cuts-33-of-workforce-to-extend-cash-runway-through-adc-development-milestones 2025-09-30T01:15:45+00:00 hourly 0.9 https://trial.medpath.com/news/a265a334ff70a6e2/biodegradable-brain-implants-show-promise-in-preventing-glioblastoma-recurrence-through-immune-system-reprogramming 2025-09-30T01:14:50+00:00 hourly 0.9 https://trial.medpath.com/news/5bb10ec9599c8b32/led-based-photobiomodulation-device-shows-70-reduction-in-severe-oral-mucositis-for-head-and-neck-cancer-patients 2025-09-30T01:14:47+00:00 hourly 0.9 https://trial.medpath.com/news/8814edbef47e22f2/phase-iii-trial-shows-five-treatment-radiation-regimen-improves-quality-of-life-for-prostate-cancer-patients 2025-09-30T01:14:45+00:00 hourly 0.9 https://trial.medpath.com/news/b8ed2751a5b00791/ars-pharmaceuticals-secures-250-million-loan-facility-to-accelerate-neffy-commercialization 2025-09-30T01:14:27+00:00 hourly 0.9 https://trial.medpath.com/news/53d65292e06c243f/septerna-appoints-keith-gottesdiener-as-board-director-and-r-d-committee-chair 2025-09-30T01:13:07+00:00 hourly 0.9 https://trial.medpath.com/news/015e6eb473b57cf6/locus-cell-secures-first-international-phase-iii-cdmo-partnership-with-cambium-bio-for-dry-eye-therapy 2025-09-30T01:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/52f7dd4cd559f912/outlook-surgical-receives-fda-510-k-clearance-for-revolutionary-hybrid-endoscope-system 2025-09-30T01:12:51+00:00 hourly 0.9 https://trial.medpath.com/news/d6b4ce1b5f983f0f/fda-issues-new-rmat-guidance-to-accelerate-regenerative-medicine-development 2025-09-30T01:12:48+00:00 hourly 0.9 https://trial.medpath.com/news/8eb3a2a4318bd648/gammacore-non-invasive-vagus-nerve-stimulation-shows-promise-for-persistent-post-concussion-symptoms-in-102-patient-study 2025-09-30T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/063e980cc20cc79f/fda-director-criticizes-lupus-nephritis-drug-lupkynis-questions-surrogate-endpoint-approvals 2025-09-29T21:16:47+00:00 hourly 0.9 https://trial.medpath.com/news/b2f30015cbaa8c38/conflicting-results-emerge-from-two-major-trials-comparing-proton-beam-therapy-to-imrt-for-head-and-neck-cancer 2025-09-29T21:15:31+00:00 hourly 0.9 https://trial.medpath.com/news/2e0ba059d5e17018/real-world-study-confirms-adebrelimab-efficacy-in-extensive-stage-small-cell-lung-cancer 2025-09-29T21:15:01+00:00 hourly 0.9 https://trial.medpath.com/news/517de4b832801b0c/chlorate-antibiotic-combination-shows-10000-fold-increase-in-efficacy-against-chronic-wound-infections 2025-09-29T21:14:24+00:00 hourly 0.9 https://trial.medpath.com/news/abbe7c8ff242704d/jr-446-receives-japanese-orphan-drug-designation-for-rare-sanfilippo-syndrome-type-b 2025-09-29T21:13:45+00:00 hourly 0.9 https://trial.medpath.com/news/489c507c68ddf45e/tae-life-sciences-demonstrates-enhanced-tumor-control-with-novel-bnct-immunotherapy-combination-in-preclinical-studies 2025-09-29T21:13:43+00:00 hourly 0.9 https://trial.medpath.com/news/2fd95062accc6b16/phase-ii-trial-shows-promise-for-probiotic-bl21-in-preventing-radiation-induced-enteritis 2025-09-29T21:12:35+00:00 hourly 0.9 https://trial.medpath.com/news/996de3293e9f9bfe/accendatech-initiates-phase-3-trial-of-act001-for-small-cell-lung-cancer-with-brain-metastasis 2025-09-29T21:12:19+00:00 hourly 0.9 https://trial.medpath.com/news/9897f8dff848ef28/angiosafe-s-santreva-atk-receives-fda-clearance-for-peripheral-artery-disease-treatment 2025-09-29T21:11:51+00:00 hourly 0.9 https://trial.medpath.com/news/11c8d1404f4976e4/cannabis-based-drug-shows-significant-pain-relief-in-large-clinical-trial-for-chronic-lower-back-pain 2025-09-29T21:11:38+00:00 hourly 0.9 https://trial.medpath.com/news/423fa4a18372a8b3/affluent-medical-s-artus-robotic-urinary-sphincter-shows-87-improvement-in-pilot-trial-results 2025-09-29T21:10:55+00:00 hourly 0.9 https://trial.medpath.com/news/c368174b659ec27b/moonlake-s-sonelokimab-shows-promise-in-teen-hs-patients-despite-adult-trial-setbacks 2025-09-29T21:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/8783028b29733ba4/lisata-therapeutics-reports-promising-results-for-certepetide-in-pancreatic-cancer-trial 2025-09-29T17:29:01+00:00 hourly 0.9 https://trial.medpath.com/news/9e27ad8f70d79029/aarvik-therapeutics-secures-series-seed-2-funding-to-advance-next-generation-adc-platform 2025-09-29T17:27:43+00:00 hourly 0.9 https://trial.medpath.com/news/ee60db29490a77c7/gilead-sciences-secures-exclusive-global-rights-to-first-in-class-p-glycoprotein-inhibitor-encequidar 2025-09-29T17:27:34+00:00 hourly 0.9 https://trial.medpath.com/news/664ec096a841e0a9/gi-innovation-receives-fda-fast-track-designation-for-gi-102-melanoma-therapy 2025-09-29T17:23:41+00:00 hourly 0.9 https://trial.medpath.com/news/80c949eb12253f20/iqure-pharma-secures-us-patent-for-first-in-class-cns-drug-iq-007-targeting-glutamate-excitotoxicity 2025-09-29T17:22:27+00:00 hourly 0.9 https://trial.medpath.com/news/f2fa1e611b4b4023/phase-iii-trilynx-trial-shows-xevinapant-worsens-outcomes-in-head-and-neck-cancer-patients 2025-09-29T17:21:38+00:00 hourly 0.9 https://trial.medpath.com/news/386ee85e3808b473/vascarta-completes-phase-1-trial-of-topical-curcumin-gel-vas-101-for-knee-osteoarthritis 2025-09-29T17:21:30+00:00 hourly 0.9 https://trial.medpath.com/news/a138be068d085dce/revolution-medicines-appoints-alan-sandler-as-chief-development-officer-to-advance-ras-targeted-cancer-pipeline 2025-09-29T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/471465f88cc18a85/rigel-pharmaceuticals-reports-strong-growth-across-oncology-portfolio-with-44-revenue-increase 2025-09-29T17:21:12+00:00 hourly 0.9 https://trial.medpath.com/news/d62150396c20f5bb/predictive-oncology-secures-343-5-million-to-launch-world-s-first-strategic-compute-reserve-for-ai-drug-discovery 2025-09-29T17:20:59+00:00 hourly 0.9 https://trial.medpath.com/news/1b9e5c3ac7ec3030/provectus-biopharmaceuticals-launches-preclinical-study-of-oral-pv-10-for-bladder-cancer-treatment 2025-09-29T17:20:00+00:00 hourly 0.9 https://trial.medpath.com/news/c01eb4c7dd761f5b/cue-biopharma-appoints-dr-usman-azam-as-ceo-pivots-to-autoimmune-disease-focus-with-cue-401 2025-09-29T17:19:03+00:00 hourly 0.9 https://trial.medpath.com/news/4580401f569c8ca4/xenopax-demonstrates-superior-efficacy-in-steroid-refractory-acute-gvhd-treatment 2025-09-29T17:17:21+00:00 hourly 0.9 https://trial.medpath.com/news/9b1ca79f9ca18881/rome-trial-demonstrates-precision-oncology-benefits-in-advanced-solid-tumors 2025-09-29T17:17:05+00:00 hourly 0.9 https://trial.medpath.com/news/35c926c8eec24eba/phase-3-trial-shows-cannabis-extract-ver-01-delivers-significant-pain-relief-for-chronic-low-back-pain 2025-09-29T17:16:59+00:00 hourly 0.9 https://trial.medpath.com/news/96adf35aad5ee847/cormedix-completes-phase-iii-enrollment-for-rezzayo-antifungal-prophylaxis-in-bone-marrow-transplant-patients 2025-09-29T17:16:24+00:00 hourly 0.9 https://trial.medpath.com/news/5e442e50fd887426/quotient-therapeutics-appoints-andrew-bayliffe-as-chief-development-officer-to-advance-somatic-genomics-platform 2025-09-29T17:14:34+00:00 hourly 0.9 https://trial.medpath.com/news/d02c3b97b3ba0e4e/tabuk-launches-vibativ-antibiotic-in-saudi-arabia-to-combat-multidrug-resistant-infections 2025-09-29T17:13:27+00:00 hourly 0.9 https://trial.medpath.com/news/bcb2cc14b570e081/zurnai-auto-injector-shows-superior-performance-over-intranasal-naloxone-in-fentanyl-overdose-reversal-study 2025-09-29T17:13:21+00:00 hourly 0.9 https://trial.medpath.com/news/97f5cb7ad1734e7c/rezon-bio-launches-as-european-cdmo-for-biologics-with-dual-facility-operations-in-poland 2025-09-29T17:13:13+00:00 hourly 0.9 https://trial.medpath.com/news/ed154049aed1fc08/novartis-launches-direct-to-patient-platform-for-cosentyx-with-55-discount-in-us 2025-09-29T17:12:25+00:00 hourly 0.9 https://trial.medpath.com/news/08cba5b13b946426/novo-nordisk-resubmits-fda-application-for-first-once-weekly-insulin-for-type-2-diabetes 2025-09-29T17:11:36+00:00 hourly 0.9 https://trial.medpath.com/news/4c302b36813bf782/abbvie-to-launch-ovarian-cancer-drug-elahere-in-uk-at-us-list-price 2025-09-29T17:11:11+00:00 hourly 0.9 https://trial.medpath.com/news/8f2d76b81ce06208/climb-bio-s-clym116-shows-superior-performance-in-iga-nephropathy-preclinical-study 2025-09-29T13:20:05+00:00 hourly 0.9 https://trial.medpath.com/news/43c2ba38b1b669bd/low-dose-radiation-therapy-shows-promise-for-knee-osteoarthritis-pain-relief-in-clinical-trial 2025-09-29T13:19:34+00:00 hourly 0.9 https://trial.medpath.com/news/ba9aaa9bcd339af3/recode-therapeutics-secures-29m-financing-to-advance-inhaled-mrna-therapy-for-cystic-fibrosis 2025-09-29T13:17:32+00:00 hourly 0.9 https://trial.medpath.com/news/3a2d1e054df83e3f/moonlake-s-sonelokimab-falls-short-in-hidradenitis-suppurativa-trials-shares-plummet-80 2025-09-29T13:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/a8195a409a4bc6ee/dogwood-therapeutics-secures-exclusive-license-for-sp16-cancer-pain-treatment-with-nci-funded-phase-1b-trial 2025-09-29T13:15:57+00:00 hourly 0.9 https://trial.medpath.com/news/74d60a9d8a048df3/redx-pharma-s-zelasudil-shows-promise-in-phase-2a-ipf-trial-with-47-reduction-in-lung-function-decline 2025-09-29T13:15:52+00:00 hourly 0.9 https://trial.medpath.com/news/2cc4d8ee35ee0948/tonix-pharmaceuticals-advances-tnx-2900-to-phase-2-trial-for-prader-willi-syndrome-following-fda-clearance 2025-09-29T13:15:44+00:00 hourly 0.9 https://trial.medpath.com/news/122658164d4169f6/oxccu-raises-28m-series-b-to-scale-sustainable-aviation-fuel-technology-from-waste-carbon 2025-09-29T13:15:23+00:00 hourly 0.9 https://trial.medpath.com/news/79dab2b8192e1dff/mannkind-appoints-dr-ajay-ahuja-as-chief-medical-officer-to-advance-inhaled-therapeutics-pipeline 2025-09-29T13:14:49+00:00 hourly 0.9 https://trial.medpath.com/news/b5d094ca9fcc8abd/rapt-therapeutics-receives-fda-clearance-to-advance-rpt904-phase-2b-trial-for-food-allergy-treatment 2025-09-29T13:12:27+00:00 hourly 0.9 https://trial.medpath.com/news/74eadbc60a000f78/kedrion-biopharma-secures-fda-approval-for-qivigy-first-proprietary-ivig-therapy-for-primary-immunodeficiency 2025-09-29T13:12:16+00:00 hourly 0.9 https://trial.medpath.com/news/827c38b106dd02f3/lupin-acquires-visufarma-for-eur190-million-to-expand-european-ophthalmology-portfolio 2025-09-29T09:22:53+00:00 hourly 0.9 https://trial.medpath.com/news/bf830021f289318d/virometix-completes-enrollment-in-phase-i-trial-of-v-212-synthetic-pneumococcal-vaccine 2025-09-29T09:20:10+00:00 hourly 0.9 https://trial.medpath.com/news/88a2ee16afd1d5e5/dinamiqs-opens-switzerland-s-first-cgmp-viral-vector-manufacturing-facility-partners-with-seal-therapeutics-for-muscular-dystrophy-gene-therapy 2025-09-29T09:19:06+00:00 hourly 0.9 https://trial.medpath.com/news/db6d7ec5c115dc5b/gsk-ceo-emma-walmsley-to-step-down-luke-miels-named-successor 2025-09-29T09:18:59+00:00 hourly 0.9 https://trial.medpath.com/news/631cf44222c43ca2/clinuvel-advances-novel-sustained-release-peptide-formulations-to-preclinical-testing 2025-09-29T09:13:33+00:00 hourly 0.9 https://trial.medpath.com/news/e68a0112fe4a1bff/hong-kong-accepts-nda-for-dorzagliatin-world-s-first-glucokinase-activator-for-type-2-diabetes 2025-09-29T09:13:16+00:00 hourly 0.9 https://trial.medpath.com/news/a1699c9a65d38c7f/agentic-ai-poised-to-transform-pharmaceutical-r-d-through-autonomous-multi-agent-systems 2025-09-29T08:52:06+00:00 hourly 0.9 https://trial.medpath.com/news/cc8c3ad760714739/united-therapeutics-reports-phase-3-teton-2-trial-results-in-conference-call 2025-09-29T01:11:55+00:00 hourly 0.9 https://trial.medpath.com/news/42470d78cfadb1b0/pam50-biomarker-predicts-hormone-therapy-benefit-in-recurrent-prostate-cancer-balance-trial-shows 2025-09-29T01:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/fde1981c7c2728a2/genmab-announces-5-2-billion-acquisition-of-merus-to-expand-late-stage-oncology-pipeline 2025-09-29T01:10:54+00:00 hourly 0.9 https://trial.medpath.com/news/d190c927bb25a3e0/first-predictive-biomarker-for-hormone-therapy-in-recurrent-prostate-cancer-validated-in-phase-ii-balance-trial 2025-09-29T01:10:32+00:00 hourly 0.9 https://trial.medpath.com/news/4f767017f51001b8/beta-technologies-files-for-825-million-ipo-to-fund-electric-aircraft-development 2025-09-29T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a02a2fdc860a3fa6/leo-cancer-care-unveils-gracetm-first-upright-photon-therapy-system-at-astro-2025 2025-09-28T21:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/4ecd7d7677a95e77/vision-preserving-uveal-melanoma-treatment-shows-unexpected-survival-benefits-in-ucla-study 2025-09-28T21:13:20+00:00 hourly 0.9 https://trial.medpath.com/news/726a192d8793edbb/moonlake-s-sonelokimab-shows-mixed-results-in-phase-3-hidradenitis-suppurativa-trials 2025-09-28T17:14:51+00:00 hourly 0.9 https://trial.medpath.com/news/850ac4b99cb4b369/altesa-biosciences-vapendavir-shows-promise-in-copd-rhinovirus-challenge-study 2025-09-28T17:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/721dd1fd54c6767f/recursion-pharmaceuticals-advances-ai-powered-cancer-drug-rec-617-to-phase-2-trial-despite-high-risk-profile 2025-09-28T17:09:49+00:00 hourly 0.9 https://trial.medpath.com/news/91088e41427d0afd/uniqure-s-huntington-s-disease-gene-therapy-shows-75-reduction-in-disease-progression-pressures-ptc-therapeutics 2025-09-28T13:10:34+00:00 hourly 0.9 https://trial.medpath.com/news/849c7623f1182b32/combination-inhaler-reduces-asthma-attacks-in-children-by-45-in-landmark-trial 2025-09-28T09:12:44+00:00 hourly 0.9 https://trial.medpath.com/news/5560bfca07570e6f/illumina-launches-bioinsight-ai-unit-and-expands-kras-companion-diagnostic-partnerships 2025-09-28T09:11:55+00:00 hourly 0.9 https://trial.medpath.com/news/b31f54c8e69a3177/ruxolitinib-cream-achieves-positive-phase-3-results-for-atopic-dermatitis-in-china 2025-09-28T09:11:25+00:00 hourly 0.9 https://trial.medpath.com/news/135949543221d059/gossamer-bio-secures-option-to-acquire-first-in-class-on-demand-pulmonary-hypertension-therapy-rt234 2025-09-28T01:13:04+00:00 hourly 0.9 https://trial.medpath.com/news/76d2136f6e131976/bio-techne-expands-oxford-nanopore-partnership-through-2032-for-advanced-genetic-diagnostics 2025-09-28T01:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/b44eb48319edfd0d/carnegie-mellon-develops-living-microbots-from-human-lung-cells-for-targeted-drug-delivery 2025-09-28T01:11:49+00:00 hourly 0.9 https://trial.medpath.com/news/8f7ee8187b3402e1/ionis-pharmaceuticals-stock-surges-85-following-strong-performance-in-gene-targeted-therapies 2025-09-28T01:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/aad70008f92b08ae/clearpoint-neuro-appoints-dr-paul-larson-as-chief-medical-officer-and-unveils-robotic-neuro-navigation-system 2025-09-27T21:11:15+00:00 hourly 0.9 https://trial.medpath.com/news/533fde0db6775317/genomic-tool-enables-personalized-radiation-dosing-for-hpv-positive-throat-cancer 2025-09-27T21:10:44+00:00 hourly 0.9 https://trial.medpath.com/news/fa39238d9e43c383/vidofludimus-calcium-shows-promise-for-progressive-ms-despite-missing-primary-endpoint-in-phase-2-trial 2025-09-27T17:12:10+00:00 hourly 0.9 https://trial.medpath.com/news/4228e45c005dc0c4/stream-program-delivers-actionable-genomic-insights-for-59-of-pediatric-cancer-patients-in-asia-s-first-nationwide-wgs-initiative 2025-09-27T17:11:52+00:00 hourly 0.9 https://trial.medpath.com/news/24ea0797b687ce79/pepgen-raises-115-million-to-advance-oligonucleotide-therapies-for-neuromuscular-diseases 2025-09-27T17:11:06+00:00 hourly 0.9 https://trial.medpath.com/news/7a305911248d0378/dmt-shows-neuroprotective-effects-in-stroke-through-blood-brain-barrier-stabilization-and-anti-inflammatory-action 2025-09-27T13:12:33+00:00 hourly 0.9 https://trial.medpath.com/news/49463a23813edb14/shape-therapeutics-to-present-novel-aav5-capsid-and-alpha-synuclein-targeting-therapy-for-parkinson-s-disease-at-esgct-congress 2025-09-27T09:12:29+00:00 hourly 0.9 https://trial.medpath.com/news/4d4f1f16da19f3c0/amalee-trial-shows-400mg-ribociclib-dose-fails-to-match-600mg-efficacy-in-advanced-breast-cancer 2025-09-27T09:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/01937fbd1dde907a/newcastle-university-researchers-develop-first-targeted-therapy-for-rare-kidney-disease-c3g 2025-09-27T09:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/fc2ca4268e01da2d/soligenix-raises-7-5-million-in-public-offering-to-advance-rare-disease-pipeline 2025-09-27T05:11:39+00:00 hourly 0.9 https://trial.medpath.com/news/49896c7e6d205c31/sanofi-expands-35-monthly-insulin-program-to-all-americans-regardless-of-insurance-status 2025-09-27T01:22:08+00:00 hourly 0.9 https://trial.medpath.com/news/301fa974afdbece5/factor-bioscience-sues-astrazeneca-and-cellectis-over-gene-editing-patent-infringement 2025-09-27T01:18:33+00:00 hourly 0.9 https://trial.medpath.com/news/76095fd4d1b8b6f7/mrna-lipid-nanoparticles-show-promise-for-non-surgical-cataract-treatment-in-rat-studies 2025-09-27T01:18:30+00:00 hourly 0.9 https://trial.medpath.com/news/54bcabd9b09556cc/astrazeneca-launches-direct-to-consumer-platform-offering-up-to-70-discounts-on-key-medications 2025-09-27T01:16:49+00:00 hourly 0.9 https://trial.medpath.com/news/6b2b01973cf1475b/apixaban-shows-superior-safety-profile-compared-to-rivaroxaban-in-cancer-associated-venous-thromboembolism 2025-09-27T01:15:52+00:00 hourly 0.9 https://trial.medpath.com/news/bed3bf18d08cf094/university-of-cincinnati-researchers-develop-novel-drug-targeting-hsp70-for-pancreatic-cancer-treatment 2025-09-27T01:15:14+00:00 hourly 0.9 https://trial.medpath.com/news/e8f6fa1bc5b45277/new-antibiotic-approval-pathways-balance-urgent-medical-need-with-limited-clinical-data 2025-09-27T01:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/c022fc4ece8d4030/pepgen-s-dm1-therapy-achieves-record-53-7-splicing-correction-in-phase-1-trial 2025-09-26T17:24:11+00:00 hourly 0.9 https://trial.medpath.com/news/3cb0d3f246caf58f/astrazeneca-launches-direct-to-consumer-platform-with-up-to-70-drug-discounts-following-trump-administration-pressure 2025-09-26T17:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/a8b9a8e34ab2a750/novel-t-cell-receptor-therapy-targets-ctnnb1-mutation-achieves-complete-tumor-clearance-in-preclinical-studies 2025-09-26T17:21:16+00:00 hourly 0.9 https://trial.medpath.com/news/00379acadb6a8b67/isth0036-shows-unexpected-anti-fibrotic-and-visual-benefits-in-phase-2a-retinal-disease-trial 2025-09-26T17:19:29+00:00 hourly 0.9 https://trial.medpath.com/news/be9715159873ec81/predict-rt-trial-completes-enrollment-testing-genomic-guided-treatment-strategies-for-high-risk-prostate-cancer 2025-09-26T17:18:01+00:00 hourly 0.9 https://trial.medpath.com/news/c919829c1deb764d/amneal-submits-bla-for-omalizumab-biosimilar-to-challenge-4-1-billion-xolair-market 2025-09-26T17:15:58+00:00 hourly 0.9 https://trial.medpath.com/news/3146d6698e9a3483/me-therapeutics-secures-u-s-patent-for-g-csf-antibody-cancer-therapy-and-advances-multi-platform-pipeline 2025-09-26T17:15:50+00:00 hourly 0.9 https://trial.medpath.com/news/b2c9da298159d65e/nigeria-partners-with-china-to-establish-africa-s-first-local-insulin-production-facility 2025-09-26T17:15:26+00:00 hourly 0.9 https://trial.medpath.com/news/8ce5fa48d46eeee5/kerry-inaugurates-leipzig-biotechnology-centre-to-advance-pharmaceutical-and-food-applications 2025-09-26T17:14:29+00:00 hourly 0.9 https://trial.medpath.com/news/6f2004ad27ffe636/harrow-acquires-melt-pharmaceuticals-to-advance-non-opioid-sedation-therapy-melt-300 2025-09-26T13:16:52+00:00 hourly 0.9 https://trial.medpath.com/news/796a102ee3d3fb00/cambridge-trial-shows-promise-for-ms-myelin-repair-using-diabetes-drug-antihistamine-combination 2025-09-26T13:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/24a7ce626122cefc/who-supported-study-reveals-covid-19-vaccine-effectiveness-among-egyptian-healthcare-workers-during-omicron-era 2025-09-26T13:15:33+00:00 hourly 0.9 https://trial.medpath.com/news/793a967fcc956aea/trump-s-100-tariffs-on-branded-pharmaceuticals-trigger-sharp-decline-in-indian-pharma-stocks 2025-09-26T13:15:27+00:00 hourly 0.9 https://trial.medpath.com/news/fc1ecd78add62b87/swissmedic-approves-two-orphan-drugs-for-rare-cancers-ayvakyt-for-gist-and-mastocytosis-vanflyta-for-flt3-itd-aml 2025-09-26T13:14:03+00:00 hourly 0.9 https://trial.medpath.com/news/dfcb07b7d6b24c94/deep-eigenmatics-receives-us-patent-for-ai-driven-protein-design-method-in-drug-discovery 2025-09-26T13:13:38+00:00 hourly 0.9 https://trial.medpath.com/news/4b8528b06cc2e60e/concept-life-sciences-establishes-one-of-uk-s-largest-drug-discovery-research-sites-with-major-facility-expansion 2025-09-26T13:13:35+00:00 hourly 0.9 https://trial.medpath.com/news/c7e13a554f50c00f/electra-battery-materials-secures-30-million-financing-for-north-america-s-first-cobalt-sulfate-refinery 2025-09-26T12:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/0f91862f60a5c9ad/lancet-study-confirms-rabishield-monoclonal-antibody-therapy-as-safe-effective-alternative-for-rabies-prevention 2025-09-26T09:23:46+00:00 hourly 0.9 https://trial.medpath.com/news/35e5b73da6427bca/first-successful-car-t-cell-therapy-for-multidrug-resistant-ulcerative-colitis-achieves-complete-remission 2025-09-26T09:23:07+00:00 hourly 0.9 https://trial.medpath.com/news/ff83909c6dd4a0c0/cayman-chemical-partners-with-akadeum-to-distribute-revolutionary-microbubble-cell-isolation-technology 2025-09-26T09:21:46+00:00 hourly 0.9 https://trial.medpath.com/news/288ea7cecb1a628c/zimmer-biomet-receives-world-s-first-pmda-approval-for-iodine-treated-hip-replacement-system 2025-09-26T09:20:31+00:00 hourly 0.9 https://trial.medpath.com/news/513b317bc6e27a1f/roche-presents-complete-tigit-failure-data-at-esmo-2025-revealing-costly-misstep-in-cancer-immunotherapy 2025-09-26T09:20:17+00:00 hourly 0.9 https://trial.medpath.com/news/c1faff699a3eed0b/cadence-launches-rocs-x-ai-platform-for-drug-discovery-enabling-trillion-molecule-virtual-screening 2025-09-26T09:20:14+00:00 hourly 0.9 https://trial.medpath.com/news/0d1b901fafd4014d/inoviq-secures-exclusive-global-rights-to-university-of-queensland-s-ovarian-cancer-biomarker-technology 2025-09-26T05:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/e5e697662c44d06c/bayer-canada-partners-with-mint-pharmaceuticals-for-adalat-xl-distribution-to-strengthen-canadian-market-access 2025-09-26T01:35:04+00:00 hourly 0.9 https://trial.medpath.com/news/1728c6fd7689a5ed/organogenesis-renu-fails-to-meet-primary-endpoint-in-second-phase-3-trial-for-knee-osteoarthritis 2025-09-26T01:28:59+00:00 hourly 0.9 https://trial.medpath.com/news/c508bbce1fc11403/uk-extends-vpag-2026-decision-deadline-to-november-14-amid-life-sciences-uncertainty 2025-09-26T01:28:35+00:00 hourly 0.9 https://trial.medpath.com/news/0c32f2ac05b1db7f/anebulo-pharmaceuticals-initiates-phase-i-trial-of-iv-selonabant-as-first-cannabis-toxicity-antidote 2025-09-26T01:26:13+00:00 hourly 0.9 https://trial.medpath.com/news/6cc637853083cc74/n2off-stockholders-approve-acquisition-of-mitocarex-bio-targeting-mitochondrial-slc25-proteins-for-cancer-therapy 2025-09-26T01:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/d09e53bbbddf160a/bullfrog-ai-and-sygnature-discovery-launch-commercial-sales-of-ai-powered-drug-discovery-platform 2025-09-26T01:24:56+00:00 hourly 0.9 https://trial.medpath.com/news/b9e2491887bd3cb3/onconetix-and-ocuvex-terminate-merger-agreement-as-ocuvex-prepares-omlonti-commercial-launch 2025-09-26T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a107282e5372aa37/tae-life-sciences-partners-with-university-of-wisconsin-madison-to-launch-first-us-accelerator-based-bnct-cancer-treatment-center 2025-09-25T22:24:58+00:00 hourly 0.9 https://trial.medpath.com/news/db5a2d6e0e385640/hitachi-high-tech-partners-with-elitech-to-develop-automated-pcr-platform-for-infectious-disease-testing 2025-09-25T22:19:00+00:00 hourly 0.9 https://trial.medpath.com/news/c8d56c8765374e63/uc-irvine-researchers-develop-pan-cancer-immunotherapy-using-velcro-like-glycan-targeting-technology 2025-09-25T22:18:37+00:00 hourly 0.9 https://trial.medpath.com/news/3b7773b8be386ce3/abu-dhabi-doctors-pioneer-car-t-cell-therapy-for-severe-lupus-in-regional-first 2025-09-25T22:16:36+00:00 hourly 0.9 https://trial.medpath.com/news/6f46bc5b7aa7ad08/mediwound-s-nexobrid-receives-marketing-authorization-in-australia-expanding-global-burn-treatment-access 2025-09-25T22:14:50+00:00 hourly 0.9 https://trial.medpath.com/news/747ffc4283dbb276/kardigan-secures-254-million-series-b-to-advance-three-late-stage-cardiovascular-programs 2025-09-25T22:14:28+00:00 hourly 0.9 https://trial.medpath.com/news/012cd1ec331349f8/hansa-biopharma-reports-positive-phase-iii-confides-trial-results-for-highly-sensitized-kidney-transplant-patients 2025-09-25T20:20:12+00:00 hourly 0.9 https://trial.medpath.com/news/183b7fdf3920db13/esmo-2025-showcases-promising-first-in-human-data-for-kras-g12c-and-fgfr3-inhibitors 2025-09-25T20:20:03+00:00 hourly 0.9 https://trial.medpath.com/news/a7246caaba0c2de0/fda-authorizes-first-spectacle-lens-to-slow-myopia-progression-in-children 2025-09-25T20:19:42+00:00 hourly 0.9 https://trial.medpath.com/news/81ea2dda6c3e06e5/fda-removes-rems-program-for-vandetanib-in-medullary-thyroid-cancer-after-decade-of-safe-use 2025-09-25T20:19:01+00:00 hourly 0.9 https://trial.medpath.com/news/6f97606e10ab73fa/clean-food-group-acquires-million-liter-fermentation-facility-to-scale-sustainable-oil-production 2025-09-25T20:18:55+00:00 hourly 0.9 https://trial.medpath.com/news/305b86cbddb59019/apiject-submits-first-of-kind-prefilled-plastic-injection-device-to-fda-for-approval 2025-09-25T20:18:38+00:00 hourly 0.9 https://trial.medpath.com/news/1c2361653925aa40/qurient-and-synaffix-partner-to-develop-first-in-class-cdk7-dual-payload-adc-for-refractory-cancers 2025-09-25T20:18:28+00:00 hourly 0.9 https://trial.medpath.com/news/db328008be013d7c/university-of-miami-enrolls-first-patients-in-pivotal-trial-testing-ai-powered-spine-pain-diagnostic-technology 2025-09-25T19:05:32+00:00 hourly 0.9 https://trial.medpath.com/news/f4866921ff8015f7/generate-biomedicines-advances-ai-engineered-asthma-antibody-gb-0895-to-phase-3-trials-with-six-month-dosing-interval 2025-09-25T19:02:19+00:00 hourly 0.9 https://trial.medpath.com/news/2156e1107e285dbe/aim-immunotech-secures-japanese-patent-for-ampligen-combination-therapy-in-oncology-through-2039 2025-09-25T19:01:07+00:00 hourly 0.9 https://trial.medpath.com/news/868be19da6a5d470/german-federal-patent-court-upholds-newron-s-xadago-patent-for-parkinson-s-disease-treatment 2025-09-25T19:01:01+00:00 hourly 0.9 https://trial.medpath.com/news/0ddb21b456cd13a2/verismo-therapeutics-partners-with-miltenyi-biotec-to-advance-kir-car-platform-for-solid-tumor-treatment 2025-09-25T19:00:18+00:00 hourly 0.9 https://trial.medpath.com/news/1b92aacf4c0a7aec/poolbeg-pharma-advances-polb-001-phase-2a-trial-to-prevent-cytokine-release-syndrome-in-multiple-myeloma 2025-09-25T19:00:02+00:00 hourly 0.9 https://trial.medpath.com/news/c6807bbeb628863e/ac-immune-s-tau-targeting-immunotherapy-achieves-94-100-response-rate-in-alzheimer-s-phase-1b-2a-trial 2025-09-25T18:59:56+00:00 hourly 0.9 https://trial.medpath.com/news/97fd53b4452407b4/aspen-neuroscience-advances-commercial-ready-parkinson-s-cell-therapy-in-phase-1-2a-trial 2025-09-25T18:59:36+00:00 hourly 0.9 https://trial.medpath.com/news/75e8d9ed5cc5ab4f/bambusa-therapeutics-advances-bbt001-bispecific-antibody-to-patient-testing-following-promising-healthy-volunteer-data 2025-09-25T18:59:30+00:00 hourly 0.9 https://trial.medpath.com/news/573bf4e046b24b6a/clearnote-health-receives-uk-regulatory-approval-for-multi-cancer-detection-tests 2025-09-25T18:59:21+00:00 hourly 0.9 https://trial.medpath.com/news/ece568356cb38ca5/phase-1-2-trial-shows-promise-for-gut-microbiome-therapy-combined-with-immunotherapy-in-advanced-cancers 2025-09-25T18:58:49+00:00 hourly 0.9 https://trial.medpath.com/news/de5ef9f6fbb648f3/nih-awards-15-6-million-to-advance-research-on-rare-bone-and-metabolic-disorders 2025-09-25T18:58:43+00:00 hourly 0.9 https://trial.medpath.com/news/98eb71c1d3d85445/evaxion-out-licenses-ai-discovered-vaccine-candidate-evx-b3-to-merck-for-7-5m-upfront-592m-in-milestones 2025-09-25T18:57:52+00:00 hourly 0.9 https://trial.medpath.com/news/7f20a28d8066db14/tiziana-life-sciences-advances-il-6-receptor-antibody-tzls-501-following-novartis-1-4b-tourmaline-acquisition 2025-09-25T18:57:13+00:00 hourly 0.9 https://trial.medpath.com/news/f3f596feccea3f52/lunai-bioworks-advances-ai-powered-parkinson-s-biomarker-discovery-program-for-strategic-pharma-partnerships 2025-09-25T18:56:24+00:00 hourly 0.9 https://trial.medpath.com/news/79048b040782f69a/recode-precision-medicine-protocol-shows-dual-benefits-for-cognitive-decline-and-depression 2025-09-25T18:55:50+00:00 hourly 0.9 https://trial.medpath.com/news/2d74d1c83a6fbe4f/quantoom-biosciences-partners-with-memorial-sloan-kettering-to-advance-personalized-rna-cancer-therapies 2025-09-25T18:55:36+00:00 hourly 0.9 https://trial.medpath.com/news/bf0b765716e37197/scisparc-launches-quantum-computing-initiative-to-revolutionize-3d-protein-modeling-for-drug-discovery 2025-09-25T18:55:18+00:00 hourly 0.9 https://trial.medpath.com/news/35f2a249484e2aa1/fda-grants-third-orphan-drug-designation-to-biostar-s-utidelone-for-pancreatic-cancer-treatment 2025-09-25T18:54:28+00:00 hourly 0.9 https://trial.medpath.com/news/46de2b869133c88e/axon-therapies-secures-32m-series-a-to-advance-novel-heart-failure-treatment-through-sympathetic-nervous-system-ablation 2025-09-25T18:05:00+00:00 hourly 0.9 https://trial.medpath.com/news/96a4424b401ee7a0/sparrow-pharmaceuticals-secures-95-million-series-b-to-advance-novel-diabetes-treatment-targeting-elevated-cortisol 2025-09-25T13:16:20+00:00 hourly 0.9 https://trial.medpath.com/news/787e84a9d3c2a002/leap-therapeutics-to-present-final-defiance-phase-2-results-for-sirexatamab-in-advanced-colorectal-cancer-at-esmo-2025 2025-09-25T13:15:43+00:00 hourly 0.9 https://trial.medpath.com/news/e30f09e718be3e3e/zydus-lifesciences-advances-two-drug-development-programs-with-cdsco-regulatory-approvals 2025-09-25T13:14:49+00:00 hourly 0.9 https://trial.medpath.com/news/d91de29d225c11ca/real-world-analysis-reveals-new-safety-signals-for-sonidegib-in-basal-cell-carcinoma-treatment 2025-09-25T13:14:39+00:00 hourly 0.9 https://trial.medpath.com/news/82d42b8945498ae6/pfizer-presents-breakthrough-cancer-data-at-esmo-2025-showcasing-unprecedented-survival-results 2025-09-25T13:14:30+00:00 hourly 0.9 https://trial.medpath.com/news/d35cc6d9138935a0/abbvie-s-qulipta-gains-public-reimbursement-in-quebec-for-migraine-prevention 2025-09-25T13:14:19+00:00 hourly 0.9 https://trial.medpath.com/news/3b5be643d18ec77d/levicept-s-levi-04-shows-dual-benefit-in-osteoarthritis-reduces-bone-marrow-lesions-while-alleviating-pain 2025-09-25T13:13:24+00:00 hourly 0.9 https://trial.medpath.com/news/79506e747b719d4c/pi-health-partners-with-gsk-to-accelerate-phase-2-oncology-trial-using-ai-powered-platform 2025-09-25T13:12:20+00:00 hourly 0.9 https://trial.medpath.com/news/3f4154cfd00b4c79/fda-issues-three-draft-guidances-to-accelerate-cell-and-gene-therapy-development-through-innovative-trial-designs 2025-09-25T13:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/f4a93637e9327cc7/marine-sponge-compounds-show-promise-as-novel-leishmaniasis-treatments 2025-09-25T09:18:22+00:00 hourly 0.9 https://trial.medpath.com/news/e6c9c1d5d24f6945/sequana-medical-advances-us-commercialization-of-alfapump-system-with-cms-reimbursement-approval 2025-09-25T09:16:55+00:00 hourly 0.9 https://trial.medpath.com/news/c3b5af33e464e861/penn-medicine-develops-novel-mrna-vaginal-gel-therapy-for-heavy-menstrual-bleeding 2025-09-25T09:16:34+00:00 hourly 0.9 https://trial.medpath.com/news/33f61fb2567f5774/huntington-s-disease-pipeline-shows-strong-growth-with-over-20-companies-developing-novel-therapies 2025-09-25T09:16:02+00:00 hourly 0.9 https://trial.medpath.com/news/97bb845a7c91bc3f/monash-university-researchers-develop-entelli-02-phage-cocktail-to-combat-antimicrobial-resistant-enterobacter-infections 2025-09-25T09:15:54+00:00 hourly 0.9 https://trial.medpath.com/news/6e6b0e8d411f4fa3/essa-pharma-amends-xenotherapeutics-agreement-reduces-shareholder-payout-to-0-12-per-share 2025-09-25T09:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/03cc36653d55d3ad/advocate-health-launches-nation-s-largest-clinical-trial-network-with-69-hospitals-and-six-million-patients 2025-09-25T09:13:43+00:00 hourly 0.9 https://trial.medpath.com/news/6a014493ebd4d8ff/global-medical-research-funders-unite-to-strengthen-clinical-trial-standards-worldwide 2025-09-25T09:12:35+00:00 hourly 0.9 https://trial.medpath.com/news/38480add5d94d255/cellectar-partners-with-evestia-clinical-for-phase-1b-trial-of-clr-125-radiopharmaceutical-in-triple-negative-breast-cancer 2025-09-25T07:47:00+00:00 hourly 0.9 https://trial.medpath.com/news/c860e11aa558333f/rapid-car-t-cell-expansion-linked-to-delayed-neurotoxicity-risk-in-multiple-myeloma-patients-receiving-cilta-cel 2025-09-25T05:17:17+00:00 hourly 0.9 https://trial.medpath.com/news/48a401a845e27fd6/st-louis-children-s-hospital-begins-administering-fda-approved-gene-therapy-lyfgenia-for-sickle-cell-disease 2025-09-25T05:16:52+00:00 hourly 0.9 https://trial.medpath.com/news/fc84141631267b36/manas-ai-secures-26-million-seed-extension-to-advance-ai-driven-drug-discovery-platform 2025-09-25T05:16:39+00:00 hourly 0.9 https://trial.medpath.com/news/fce508a7b47813cd/startnewera-phase-ii-trial-shows-promising-5-year-outcomes-for-stereotactic-radiotherapy-in-advanced-lung-cancer 2025-09-25T05:16:31+00:00 hourly 0.9 https://trial.medpath.com/news/6a8ff79a4c266f97/recce-pharmaceuticals-initiates-phase-3-trial-for-novel-diabetic-foot-infection-treatment-in-indonesia 2025-09-25T05:16:24+00:00 hourly 0.9 https://trial.medpath.com/news/7da242373ca1a02d/hetlioz-demonstrates-significant-sleep-improvement-in-primary-insomnia-trial-published-in-plos-one 2025-09-25T05:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/e985fb6728b1d52d/seven-year-study-reveals-hidden-pre-clinical-stage-of-rheumatoid-arthritis 2025-09-25T01:28:47+00:00 hourly 0.9 https://trial.medpath.com/news/3fc46144a0587a1f/lantheus-and-ge-healthcare-partner-to-bring-psma-pet-imaging-agent-pylarify-to-japan-s-prostate-cancer-market 2025-09-25T01:26:27+00:00 hourly 0.9 https://trial.medpath.com/news/ea88397202042d20/moderna-opens-first-uk-mrna-manufacturing-facility-in-oxfordshire-strengthening-pandemic-preparedness 2025-09-25T01:23:16+00:00 hourly 0.9 https://trial.medpath.com/news/1090c5d12ee40d44/kashiv-biosciences-and-jamp-pharma-launch-neutropenia-biosimilars-in-canada 2025-09-25T01:20:13+00:00 hourly 0.9 https://trial.medpath.com/news/5ee2615726ff5461/faeth-therapeutics-reports-positive-phase-2-results-for-sapanisertib-in-ovarian-cancer-treatment 2025-09-25T01:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/ecdde3311688ef2b/duke-researchers-identify-stk17b-kinase-as-key-target-for-overcoming-multiple-myeloma-drug-resistance 2025-09-25T01:15:45+00:00 hourly 0.9 https://trial.medpath.com/news/10f5141ec450d0a8/inhaled-heparin-reduces-covid-19-ventilation-risk-by-50-in-international-trial 2025-09-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/2ccde09483ac1d74/dr-park-cdmo-partners-with-thermo-fisher-to-expand-viral-vector-manufacturing-capacity-in-south-korea 2025-09-25T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/4095eb6acfbc8c8d/camkk2-enzyme-knockout-in-immune-cells-prevents-diet-induced-obesity-and-diabetes-in-mice 2025-09-24T17:21:50+00:00 hourly 0.9 https://trial.medpath.com/news/efd1991c98f97142/harmony-biosciences-zyn002-phase-3-trial-fails-to-meet-primary-endpoint-in-fragile-x-syndrome 2025-09-24T17:21:17+00:00 hourly 0.9 https://trial.medpath.com/news/abcc0e4cf6328a1e/quantumzyme-secures-uspto-patent-for-green-enzymatic-ibuprofen-manufacturing-process 2025-09-24T17:21:01+00:00 hourly 0.9 https://trial.medpath.com/news/18236cbe50b46759/replicate-bioscience-s-self-replicating-rna-rabies-vaccine-shows-superior-durability-in-phase-i-trial 2025-09-24T17:20:38+00:00 hourly 0.9 https://trial.medpath.com/news/3ec0e6b667d60b31/aera-therapeutics-nominates-aera-109-as-first-development-candidate-for-in-vivo-car-t-therapy 2025-09-24T17:20:25+00:00 hourly 0.9 https://trial.medpath.com/news/e682191962a06d99/immorta-bio-s-senovax-shows-strongest-senolytic-activity-in-preclinical-cte-model 2025-09-24T17:19:54+00:00 hourly 0.9 https://trial.medpath.com/news/fda6881e9f2197e2/aro-biotherapeutics-completes-enrollment-in-phase-1b-trial-of-novel-sirna-therapy-for-late-onset-pompe-disease 2025-09-24T17:19:49+00:00 hourly 0.9 https://trial.medpath.com/news/4943d2bd04dd57bd/sapu-nano-s-injectable-everolimus-formulation-sapu003-receives-approval-for-phase-1-breast-cancer-trial 2025-09-24T17:19:44+00:00 hourly 0.9 https://trial.medpath.com/news/e2693ad367089a62/veracyte-presents-first-prospective-validation-data-for-hormone-therapy-biomarker-in-recurrent-prostate-cancer-at-astro-2025 2025-09-24T17:19:32+00:00 hourly 0.9 https://trial.medpath.com/news/6c6c179ce7cce268/fyr-bio-secures-8-million-to-advance-blood-based-biomarkers-for-brain-cancer-and-neurodegeneration 2025-09-24T17:18:37+00:00 hourly 0.9 https://trial.medpath.com/news/ca90b155d412cc5e/resvita-bio-receives-fda-clearance-to-advance-novel-bacterial-therapy-for-rare-skin-disease 2025-09-24T17:16:23+00:00 hourly 0.9 https://trial.medpath.com/news/fee9da4b12e0a290/lupin-receives-tentative-fda-approval-for-generic-hiv-treatment-targeting-16-2-billion-market 2025-09-24T17:15:50+00:00 hourly 0.9 https://trial.medpath.com/news/0412cf6dec364e2d/ipca-laboratories-partners-with-biosimilar-sciences-for-us-manufacturing-of-cancer-and-autoimmune-biosimilars 2025-09-24T17:15:48+00:00 hourly 0.9 https://trial.medpath.com/news/cde6ab7d83a35f94/hovione-partners-with-microinnova-to-advance-modular-flow-chemistry-manufacturing-technology 2025-09-24T17:15:45+00:00 hourly 0.9 https://trial.medpath.com/news/2c3210e902f48355/cognision-and-somnomedics-partner-to-advance-sleep-biomarkers-in-cns-drug-development 2025-09-24T17:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/b02bd2a1672f7a76/jaguar-health-seeks-orphan-drug-designation-for-crofelemer-in-breast-cancer-brain-metastasis-patients 2025-09-24T17:14:26+00:00 hourly 0.9 https://trial.medpath.com/news/092128eacfdb8d91/gene-therapy-achieves-first-successful-treatment-of-huntington-s-disease-slowing-progression-by-75 2025-09-24T17:13:37+00:00 hourly 0.9 https://trial.medpath.com/news/4ed200354d8ce4f7/scitech-development-raises-5-5-million-for-nanotechnology-cancer-drug-following-100-disease-control-rate-in-t-cell-lymphoma-trials 2025-09-24T17:13:32+00:00 hourly 0.9 https://trial.medpath.com/news/49bdf223a641668b/inato-partners-with-realtime-to-enhance-clinical-trial-site-selection-and-patient-enrollment 2025-09-24T17:13:10+00:00 hourly 0.9 https://trial.medpath.com/news/a51c1f2c5a6156e6/rhode-island-hospital-launches-first-in-nation-trial-combining-focused-ultrasound-with-immunotherapy-for-brain-metastases 2025-09-24T17:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/a9aa3436bec3492c/cyclerion-therapeutics-pivots-to-neuropsychiatry-with-mit-licensed-treatment-resistant-depression-program 2025-09-24T14:26:37+00:00 hourly 0.9 https://trial.medpath.com/news/070b884a617bc112/uniqure-secures-175-million-loan-facility-to-support-amt-130-gene-therapy-launch-for-huntington-s-disease 2025-09-24T14:24:35+00:00 hourly 0.9 https://trial.medpath.com/news/9a929de8eca25644/ocrelizumab-demonstrates-superior-multiple-sclerosis-relapse-control-in-large-real-world-registry-analysis 2025-09-24T14:22:19+00:00 hourly 0.9 https://trial.medpath.com/news/51070f39f6cdb256/northstar-medical-radioisotopes-partners-with-university-of-wisconsin-to-accelerate-radiopharmaceutical-development 2025-09-24T14:22:10+00:00 hourly 0.9 https://trial.medpath.com/news/e8e225e87edf43c8/inoviq-s-car-nk-exosomes-demonstrate-61-5-tumor-reduction-in-triple-negative-breast-cancer-study 2025-09-24T14:21:21+00:00 hourly 0.9 https://trial.medpath.com/news/431193a466934469/fda-approves-enhertu-plus-pertuzumab-as-first-new-first-line-treatment-for-her2-positive-metastatic-breast-cancer-in-a-decade 2025-09-24T14:21:10+00:00 hourly 0.9 https://trial.medpath.com/news/66db7afe539e722b/genelux-reports-q3-2025-results-as-olvi-vec-advances-toward-key-clinical-milestones 2025-09-24T14:20:59+00:00 hourly 0.9 https://trial.medpath.com/news/41e0ed753f861734/bispecific-antibody-tobemstomig-shows-promise-in-neoadjuvant-melanoma-trial-despite-discontinued-development 2025-09-24T14:20:11+00:00 hourly 0.9 https://trial.medpath.com/news/c39028ca39c91a20/acadia-pharmaceuticals-phase-3-trial-of-intranasal-carbetocin-for-prader-willi-syndrome-fails-to-meet-primary-endpoint 2025-09-24T14:20:04+00:00 hourly 0.9 https://trial.medpath.com/news/8a38a814c7301e5a/sanofi-ventures-secures-625-million-to-accelerate-biotech-and-digital-health-investments 2025-09-24T14:18:41+00:00 hourly 0.9 https://trial.medpath.com/news/fd458c69545ace7a/sensory-cloud-s-sc0023-shows-34-cough-reduction-in-phase-ii-refractory-chronic-cough-trial 2025-09-24T14:17:04+00:00 hourly 0.9 https://trial.medpath.com/news/5127ede662597d37/gccl-and-frontage-laboratories-form-strategic-partnership-to-enhance-global-clinical-trial-capabilities 2025-09-24T14:15:31+00:00 hourly 0.9 https://trial.medpath.com/news/e173574d5eaaaeb6/ucla-launches-first-large-scale-u-s-trial-testing-ai-in-breast-cancer-screening 2025-09-24T14:15:03+00:00 hourly 0.9 https://trial.medpath.com/news/b23f639e67847939/japan-approves-oncoguide-oncoscreen-plus-cdx-system-for-breast-cancer-companion-diagnostics 2025-09-24T14:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/a527cc2dfceb0d79/xeltis-achieves-breakthrough-results-in-eu-phase-3-trial-for-revolutionary-hemodialysis-vascular-access-device 2025-09-24T14:14:58+00:00 hourly 0.9 https://trial.medpath.com/news/6c86b593a8523935/igc-pharma-s-tgr-63-shows-dual-target-activity-against-alzheimer-s-pathology-in-preclinical-studies 2025-09-24T14:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/41a42bb4bef49533/macumira-receives-first-health-canada-approval-for-non-invasive-dry-amd-treatment-device 2025-09-24T09:16:25+00:00 hourly 0.9 https://trial.medpath.com/news/84867de808cb7d33/synendos-therapeutics-advances-first-in-class-seri-compound-syt-510-to-phase-2-following-positive-phase-1-results 2025-09-24T09:14:27+00:00 hourly 0.9 https://trial.medpath.com/news/64ce21c59576ed69/five-year-intrepid-trial-confirms-long-term-benefits-of-subthalamic-deep-brain-stimulation-for-parkinson-s-disease 2025-09-24T06:04:00+00:00 hourly 0.9 https://trial.medpath.com/news/e96041705eb68401/ucla-researchers-present-breakthrough-177lutetium-psma-therapy-results-for-recurrent-prostate-cancer-at-astro-2025 2025-09-24T01:24:33+00:00 hourly 0.9 https://trial.medpath.com/news/0b94ac53d05dbabc/hemostemix-submits-fda-pre-ind-application-for-multi-indication-basket-trial-of-autologous-stem-cell-therapy-acp-01 2025-09-24T01:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/642f3f5cf854ffc5/fda-breaks-precedent-with-literature-based-approval-for-leucovorin-in-cerebral-folate-deficiency 2025-09-24T01:21:23+00:00 hourly 0.9 https://trial.medpath.com/news/ede03ff612d76e89/zimbabwe-selected-for-global-rollout-of-lenacapavir-breakthrough-twice-yearly-hiv-prevention-drug 2025-09-24T01:21:18+00:00 hourly 0.9 https://trial.medpath.com/news/85959036962c8e95/rion-partners-with-lonza-to-scale-commercial-production-of-platelet-derived-exosome-therapeutics 2025-09-23T21:34:58+00:00 hourly 0.9 https://trial.medpath.com/news/8e4bb985310a4f5a/australian-researchers-develop-nano-cubosome-eyedrops-to-replace-painful-eye-injections-for-retinal-diseases 2025-09-23T21:32:04+00:00 hourly 0.9 https://trial.medpath.com/news/90e834a25e362a25/celecor-s-zalunfiban-meets-primary-endpoints-in-phase-iii-stemi-trial 2025-09-23T21:31:28+00:00 hourly 0.9 https://trial.medpath.com/news/ca10ccf68c9cb40c/transpire-bio-achieves-fda-filing-acceptance-for-generic-breo-ellipta-positioning-for-market-exclusivity 2025-09-23T21:29:41+00:00 hourly 0.9 https://trial.medpath.com/news/4705e8565eb66fb4/university-of-alberta-develops-ai-powered-microbiome-test-for-personalized-ibd-treatment 2025-09-23T21:26:33+00:00 hourly 0.9 https://trial.medpath.com/news/5037b11ed5ab3b25/celecor-s-disaggpro-shows-positive-results-in-phase-3-trial-for-pre-hospital-stemi-treatment 2025-09-23T21:26:23+00:00 hourly 0.9 https://trial.medpath.com/news/df014dc313030961/ventoux-biosciences-secures-u-s-patent-for-novel-dupuytren-s-disease-treatment-approach 2025-09-23T21:24:25+00:00 hourly 0.9 https://trial.medpath.com/news/c0a6a34264258ebb/expert-commentary-questions-hsk21542-efficacy-claims-for-chronic-kidney-disease-associated-pruritus 2025-09-23T21:24:01+00:00 hourly 0.9 https://trial.medpath.com/news/18f439b6f2021c86/fda-finalizes-guidance-on-alternative-inspection-tools-for-drug-manufacturing-facilities 2025-09-23T21:23:58+00:00 hourly 0.9 https://trial.medpath.com/news/607508a80dc7a5c5/duke-engineers-develop-ai-powered-platform-to-optimize-nanoparticle-drug-delivery 2025-09-23T21:23:55+00:00 hourly 0.9 https://trial.medpath.com/news/47346ab50b246ce8/medic-life-sciences-acquires-clinical-stage-oncology-program-using-sls-biomarker-platform-for-precision-medicine 2025-09-23T21:22:41+00:00 hourly 0.9 https://trial.medpath.com/news/9d05e87f3d4cb8b4/tgf-b-inhibitor-pipeline-expands-with-25-companies-developing-novel-therapies-for-cancer-and-fibrosis 2025-09-23T21:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/2372795ba41286d4/ncardia-launches-first-commercial-ipsc-derived-non-human-primate-cardiomyocytes-for-cardiac-safety-testing 2025-09-23T21:22:18+00:00 hourly 0.9 https://trial.medpath.com/news/04d1add620348384/amneal-pharmaceuticals-receives-fda-approval-for-generic-bimatoprost-eye-drops-to-treat-glaucoma 2025-09-23T21:21:39+00:00 hourly 0.9 https://trial.medpath.com/news/9119e915e116348e/anova-launches-global-clinical-registry-to-accelerate-drug-development-and-patient-access 2025-09-23T21:21:09+00:00 hourly 0.9 https://trial.medpath.com/news/e790446d1579d166/federal-circuit-upholds-generic-challenge-to-bayer-s-xarelto-patent-protection 2025-09-23T17:33:59+00:00 hourly 0.9 https://trial.medpath.com/news/09fb5d3a0d1433f5/mrna-lipid-nanoparticle-vaccine-shows-promise-against-severe-allergic-reactions-in-preclinical-study 2025-09-23T17:32:29+00:00 hourly 0.9 https://trial.medpath.com/news/44df0197ef5b3ab6/bristol-myers-squibb-s-iberdomide-combination-achieves-primary-endpoint-in-phase-3-multiple-myeloma-trial 2025-09-23T17:32:23+00:00 hourly 0.9 https://trial.medpath.com/news/54c133fb4da15bbc/federal-circuit-rules-clinically-proven-effective-claims-cannot-rescue-anticipated-drug-methods-from-prior-art 2025-09-23T17:31:19+00:00 hourly 0.9 https://trial.medpath.com/news/58a9a8af1cbaeec8/opdivo-subcutaneous-formulation-receives-positive-reimbursement-recommendation-in-quebec 2025-09-23T17:30:46+00:00 hourly 0.9 https://trial.medpath.com/news/ca86f673972853b0/onconetix-subsidiary-proteomedix-licenses-manufacturing-ip-to-immunovia-for-pancreasure-pancreatic-cancer-test 2025-09-23T17:30:03+00:00 hourly 0.9 https://trial.medpath.com/news/a8ae1d3557fc1bba/kinea-bio-secures-1-1m-investment-and-aav-slb101-license-to-advance-dysferlinopathy-gene-therapy 2025-09-23T17:29:10+00:00 hourly 0.9 https://trial.medpath.com/news/ff9cc68141e963fd/exmoor-pharma-and-siam-bioscience-partner-to-establish-southeast-asia-s-leading-cell-and-gene-therapy-manufacturing-hub 2025-09-23T17:29:03+00:00 hourly 0.9 https://trial.medpath.com/news/10916d86f3904dfb/fda-issues-complete-response-letter-for-scholar-rock-s-apitegromab-due-to-manufacturing-issues 2025-09-23T17:27:09+00:00 hourly 0.9 https://trial.medpath.com/news/f3bebafcbe82df89/prellis-biologics-partners-with-eli-lilly-to-accelerate-antibody-discovery-using-novel-biological-ai-platform 2025-09-23T17:26:11+00:00 hourly 0.9 https://trial.medpath.com/news/820d8d6d4147019f/triveni-bio-initiates-phase-2-trial-of-novel-anti-klk5-7-antibody-triv-509-for-atopic-dermatitis 2025-09-23T17:25:55+00:00 hourly 0.9 https://trial.medpath.com/news/abbe0c4ec7592e8e/heartflow-receives-fda-clearance-for-next-generation-ai-plaque-analysis-platform-with-enhanced-detection-capabilities 2025-09-23T17:24:36+00:00 hourly 0.9 https://trial.medpath.com/news/0f7b66928aa448dd/myriad-genetics-and-sophia-genetics-partner-to-develop-global-liquid-biopsy-companion-diagnostic-platform 2025-09-23T17:24:01+00:00 hourly 0.9 https://trial.medpath.com/news/355c0fa206e7f521/santhera-secures-chf-20-million-growth-funding-to-accelerate-global-agamree-rollout-for-duchenne-muscular-dystrophy 2025-09-23T17:23:52+00:00 hourly 0.9 https://trial.medpath.com/news/0c915a5df8dae428/digital-outreach-study-reveals-major-diagnostic-gap-in-dysmenorrhea-affecting-thousands-of-european-women 2025-09-23T17:22:51+00:00 hourly 0.9 https://trial.medpath.com/news/0078c753df619c6b/allergan-aesthetics-expands-skinvive-injectable-treatment-to-35-new-global-markets 2025-09-23T17:22:22+00:00 hourly 0.9 https://trial.medpath.com/news/80604829c1987f65/cms-secures-exclusive-rights-to-two-breakthrough-antibody-therapies-for-tetanus-and-rabies-prevention 2025-09-23T13:26:01+00:00 hourly 0.9 https://trial.medpath.com/news/9fc3fbbbb4fd9cbf/aptahem-secures-chinese-patent-protection-for-rna-based-anti-inflammatory-therapy-through-2038 2025-09-23T13:23:41+00:00 hourly 0.9 https://trial.medpath.com/news/0fef97df54d295c0/icr-and-enamine-launch-fragment-based-drug-discovery-collaboration-to-accelerate-cancer-drug-development 2025-09-23T13:21:06+00:00 hourly 0.9 https://trial.medpath.com/news/796a3dd4ef09ef93/daltontx-emerges-from-stealth-with-ps4m-seed-funding-to-transform-drug-discovery-with-adaptive-ai-platform 2025-09-23T13:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/6bd4aff45eb1ba6c/softox-solutions-advances-cystic-fibrosis-treatment-with-phase-2a-trial-application-and-stability-breakthrough 2025-09-23T13:19:27+00:00 hourly 0.9 https://trial.medpath.com/news/45eab9c4d19cf55a/virtuoso-surgical-robotic-system-receives-fda-breakthrough-device-designation-for-bladder-cancer-surgery 2025-09-23T13:19:25+00:00 hourly 0.9 https://trial.medpath.com/news/0d6b64b2057629d8/healx-partners-with-vuja-de-sciences-to-advance-ai-driven-therapy-for-metastatic-osteosarcoma-recurrence 2025-09-23T09:24:44+00:00 hourly 0.9 https://trial.medpath.com/news/e119d12f6012c51f/percheron-therapeutics-appoints-cmo-and-cto-to-advance-hmbd-002-cancer-immunotherapy-toward-phase-ii-trial 2025-09-23T09:22:09+00:00 hourly 0.9 https://trial.medpath.com/news/71241ff7219fdf20/merck-and-siemens-expand-partnership-to-accelerate-ai-driven-drug-discovery-and-manufacturing 2025-09-23T09:21:25+00:00 hourly 0.9 https://trial.medpath.com/news/e80991d4e9847bb3/aurobindo-pharma-advances-denosumab-biosimilar-following-phase-3-success-eyes-7-billion-market-entry 2025-09-23T09:21:06+00:00 hourly 0.9 https://trial.medpath.com/news/5061b036af09dcd7/altria-partners-with-kt-g-to-expand-global-nicotine-pouch-and-wellness-product-portfolio 2025-09-23T08:15:00+00:00 hourly 0.9 https://trial.medpath.com/news/a6dfe83947a708e6/stanford-researchers-unveil-crispr-gpt-ai-powered-system-accelerates-gene-editing-experiments 2025-09-23T05:17:20+00:00 hourly 0.9 https://trial.medpath.com/news/1c1e7407aae29e0c/kelun-biotech-s-next-generation-ret-inhibitor-a400-ep0031-receives-nda-acceptance-in-china-for-nsclc-treatment 2025-09-23T05:15:39+00:00 hourly 0.9 https://trial.medpath.com/news/ce062a78e2d20dd1/algorae-pharmaceuticals-expands-commercial-portfolio-through-strategic-partnerships-in-australia-and-new-zealand 2025-09-23T05:14:49+00:00 hourly 0.9 https://trial.medpath.com/news/5df0124a55589948/catalym-initiates-phase-2b-trial-of-visugromab-in-first-line-metastatic-nsclc 2025-09-23T01:18:10+00:00 hourly 0.9 https://trial.medpath.com/news/ff8e2dc7855d8d49/trump-administration-links-acetaminophen-to-autism-risk-triggering-sharp-decline-in-kenvue-stock 2025-09-23T01:17:50+00:00 hourly 0.9 https://trial.medpath.com/news/71d9feed13098cbb/arrivent-biopharma-appoints-brent-rice-as-chief-commercial-officer-to-lead-firmonertinib-commercialization 2025-09-23T01:17:41+00:00 hourly 0.9 https://trial.medpath.com/news/aaf803f0893ccaa7/crispr-therapeutics-and-sirius-therapeutics-dose-first-patient-in-phase-2-trial-of-srsd107-for-venous-thromboembolism-prevention 2025-09-23T01:14:25+00:00 hourly 0.9 https://trial.medpath.com/news/5603752c77bd3a6f/eupraxia-pharmaceuticals-announces-public-offering-to-advance-extended-release-drug-pipeline 2025-09-23T01:14:23+00:00 hourly 0.9 https://trial.medpath.com/news/5bce69004cd91f5c/salt-ai-secures-10-million-to-advance-contextual-ai-platform-for-life-sciences 2025-09-23T01:14:02+00:00 hourly 0.9 https://trial.medpath.com/news/7df438eb3ca07279/gsk-to-submit-label-update-for-leucovorin-following-fda-request-for-cerebral-folate-deficiency-treatment 2025-09-23T01:12:57+00:00 hourly 0.9 https://trial.medpath.com/news/ac522aac17f3e0fe/cps-technologies-secures-1-15m-army-contract-for-advanced-tungsten-warhead-development 2025-09-23T01:11:40+00:00 hourly 0.9 https://trial.medpath.com/news/6389c52899cb64cd/shilpa-medicare-receives-ema-approval-for-generic-rivaroxaban-orodispersible-films 2025-09-23T01:10:50+00:00 hourly 0.9 https://trial.medpath.com/news/f5083b36fc6af7b7/myocardial-infarction-pipeline-shows-promise-with-40-therapies-in-development-across-multiple-clinical-phases 2025-09-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/62a299ea2474ada5/kt-g-signs-comprehensive-mou-with-altria-for-nicotine-pouch-and-health-functional-foods-collaboration 2025-09-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/873021879d2dd1c8/tegmine-therapeutics-partners-with-boehringer-ingelheim-to-develop-next-generation-adcs-using-novel-2-factor-antibody-system 2025-09-23T00:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/ec09ff271da30c9f/cellares-strengthens-leadership-team-with-key-commercial-and-advisory-appointments-to-drive-cell-therapy-manufacturing-expansion 2025-09-22T21:19:39+00:00 hourly 0.9 https://trial.medpath.com/news/b4a6b909f820dad0/mindwalk-unveils-ai-designed-dual-pathway-glp-1-regimen-targeting-60b-longevity-market 2025-09-22T21:19:36+00:00 hourly 0.9 https://trial.medpath.com/news/7db6377e485a578a/fda-authorizes-cytocell-kmt2a-companion-diagnostic-for-revumenib-in-acute-leukemia 2025-09-22T21:18:42+00:00 hourly 0.9 https://trial.medpath.com/news/a52db160714c7619/patient-square-capital-acquires-healthcare-technology-firm-premier-for-2-6-billion 2025-09-22T21:17:25+00:00 hourly 0.9 https://trial.medpath.com/news/9b8f68c721cfce10/enzene-launches-commercial-supply-of-pertuzumab-biosimilar-using-continuous-manufacturing-technology 2025-09-22T21:16:37+00:00 hourly 0.9 https://trial.medpath.com/news/6dd9d01012a5ea5d/moderna-s-melbourne-mrna-facility-could-save-australia-4-8-billion-in-future-pandemic-costs 2025-09-22T21:15:48+00:00 hourly 0.9 https://trial.medpath.com/news/24f627ec71ce8150/engineered-salmonella-bacteria-show-promise-in-colorectal-cancer-treatment-through-immune-system-activation 2025-09-22T21:15:38+00:00 hourly 0.9 https://trial.medpath.com/news/b1e84f43f30560c7/median-technologies-secures-eur61-4m-financing-extends-cash-runway-through-2026-as-ai-cancer-diagnostic-tool-awaits-fda-clearance 2025-09-22T21:15:21+00:00 hourly 0.9 https://trial.medpath.com/news/d54629fd188edf2c/supreme-court-may-reshape-generic-drug-labeling-practices-in-landmark-patent-infringement-case 2025-09-22T21:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/ee539ef21e9461fb/alcon-staar-surgical-merger-advances-as-hart-scott-rodino-waiting-period-expires 2025-09-22T18:10:00+00:00 hourly 0.9 https://trial.medpath.com/news/eb4788c64d046fca/tubulis-reports-promising-phase-i-iia-data-for-tub-040-adc-in-platinum-resistant-ovarian-cancer 2025-09-22T17:24:59+00:00 hourly 0.9 https://trial.medpath.com/news/8b10337b37310dae/cerevance-reports-positive-phase-2-results-for-novel-non-dopaminergic-parkinson-s-treatment-solengepras 2025-09-22T17:24:47+00:00 hourly 0.9 https://trial.medpath.com/news/f0cca06297ac8380/fda-approves-first-subcutaneous-pd-1-inhibitor-as-msd-launches-keytruda-qlex 2025-09-22T17:24:39+00:00 hourly 0.9 https://trial.medpath.com/news/07cfb594d5a976e2/pfizer-acquires-obesity-drug-developer-metsera-in-strategic-move-to-enter-weight-management-market 2025-09-22T17:23:56+00:00 hourly 0.9 https://trial.medpath.com/news/90963ed815efc4e4/lynk-labs-challenges-federal-circuit-s-patent-prior-art-interpretation-in-supreme-court-petition 2025-09-22T17:22:20+00:00 hourly 0.9 https://trial.medpath.com/news/0e2bebbd85d68ccd/aim-immunotech-s-ampligen-shows-synergistic-effect-with-interferon-alpha-in-overcoming-pd-1-resistance-in-cold-tumors 2025-09-22T17:22:18+00:00 hourly 0.9 https://trial.medpath.com/news/ee8a3d3832a4a55c/cdi-therapeutics-market-shows-promise-with-48-molecule-pipeline-and-over-2-million-annual-cases 2025-09-22T17:21:58+00:00 hourly 0.9 https://trial.medpath.com/news/eb6a80a7d5cf11b1/trump-administration-promotes-leucovorin-as-potential-autism-treatment-despite-limited-clinical-evidence 2025-09-22T17:21:41+00:00 hourly 0.9 https://trial.medpath.com/news/91cf57f410324597/netramark-partners-with-academic-medical-center-to-apply-ai-platform-for-glioblastoma-trial-optimization 2025-09-22T17:18:53+00:00 hourly 0.9 https://trial.medpath.com/news/7a6e765ae4d5429a/avenzo-therapeutics-secures-60-million-series-b-to-advance-next-generation-oncology-pipeline 2025-09-22T17:17:09+00:00 hourly 0.9 https://trial.medpath.com/news/91a1c502e27413da/angelini-pharma-secures-exclusive-option-for-sovargen-s-novel-brain-health-asset-svg105 2025-09-22T17:17:07+00:00 hourly 0.9 https://trial.medpath.com/news/4bf22f7eaf88ba1f/zealand-pharma-explores-direct-to-consumer-sales-for-novel-amylin-based-obesity-drug-petrelintide 2025-09-22T17:16:22+00:00 hourly 0.9 https://trial.medpath.com/news/be4feca3ee1029e0/alkem-laboratories-launches-affordable-pertuzumab-biosimilar-for-her2-positive-breast-cancer-in-india 2025-09-22T17:15:51+00:00 hourly 0.9 https://trial.medpath.com/news/03ac685b3c78c3b8/immutep-partners-with-george-washington-university-for-phase-ii-neoadjuvant-breast-cancer-trial 2025-09-22T17:14:54+00:00 hourly 0.9 https://trial.medpath.com/news/9b241aa6ce063ed3/fda-grants-fast-track-designation-to-mavrix-bio-s-mvx-220-gene-therapy-for-angelman-syndrome 2025-09-22T17:14:01+00:00 hourly 0.9 https://trial.medpath.com/news/042496a77244681f/european-commission-publishes-new-variations-guidelines-to-streamline-drug-lifecycle-management 2025-09-22T17:12:32+00:00 hourly 0.9 https://trial.medpath.com/news/83e89649fdcc2ff6/tempus-ai-receives-fda-510-k-clearance-for-rna-based-cancer-diagnostic-device 2025-09-22T17:12:26+00:00 hourly 0.9 https://trial.medpath.com/news/3b001913dc09f577/techsomed-expands-ai-powered-biotraceio360-platform-to-kidney-ablation-following-fda-510-k-clearance 2025-09-22T17:12:24+00:00 hourly 0.9 https://trial.medpath.com/news/40c5cbba3e42db8a/usc-scientists-create-most-advanced-lab-grown-kidney-structures-with-real-function-for-disease-modeling 2025-09-22T17:12:22+00:00 hourly 0.9 https://trial.medpath.com/news/963abdf2f93c9226/biontech-and-bristol-myers-squibb-report-promising-phase-2-results-for-pumitamig-in-triple-negative-breast-cancer 2025-09-22T17:11:48+00:00 hourly 0.9 https://trial.medpath.com/news/580d06933aa11c80/sharp-services-announces-100-million-global-investment-to-expand-injectable-drug-manufacturing-capacity 2025-09-22T13:16:34+00:00 hourly 0.9 https://trial.medpath.com/news/6a06ae6145f7adba/nuclide-therapeutics-secures-ps5m-to-advance-aldh1a1-targeted-radiotheranostics-for-therapy-resistant-cancers 2025-09-22T13:15:12+00:00 hourly 0.9 https://trial.medpath.com/news/cf8b0e8b69a86397/hetero-healthcare-and-enzene-launch-perzea-india-s-most-affordable-pertuzumab-biosimilar-for-her2-positive-breast-cancer 2025-09-22T13:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/b351eb129e7167c2/european-medicines-agency-recommends-approval-of-alvotech-s-gobivaz-biosimilar-to-johnson-johnson-s-simponi 2025-09-22T13:13:53+00:00 hourly 0.9 https://trial.medpath.com/news/03fbb5c909cae1fc/johnson-johnson-secures-multiple-fda-approvals-boosting-pharmaceutical-portfolio-and-market-outlook 2025-09-22T13:12:36+00:00 hourly 0.9 https://trial.medpath.com/news/0d010d0023a3987e/tolvaptan-shows-promise-as-universal-pharmacological-chaperone-for-rare-disease-treatment 2025-09-22T13:12:30+00:00 hourly 0.9 https://trial.medpath.com/news/5cdea5c7759bf14b/n4-pharma-s-nuvec-delivery-system-achieves-targeted-rna-delivery-to-lung-cancer-cells 2025-09-22T13:12:07+00:00 hourly 0.9 https://trial.medpath.com/news/db1af13b26872e10/ensoma-secures-53-million-to-advance-first-in-class-gene-therapy-for-x-linked-chronic-granulomatous-disease 2025-09-22T13:10:49+00:00 hourly 0.9 https://trial.medpath.com/news/af7d4a37b0f08a1f/debra-research-and-nonsense-therapeutics-form-readon-therapeutics-to-advance-epidermolysis-bullosa-treatments 2025-09-22T13:10:47+00:00 hourly 0.9 https://trial.medpath.com/news/4bfc81d3b396b221/phase-scientific-launches-world-s-largest-urine-based-hpv-screening-study-with-17000-participants 2025-09-22T13:09:43+00:00 hourly 0.9 https://trial.medpath.com/news/63ac44bb849a7de4/bristol-myers-squibb-plans-2026-uk-launch-of-breakthrough-schizophrenia-drug-cobenfy-at-22500-annual-price 2025-09-22T13:09:19+00:00 hourly 0.9 https://trial.medpath.com/news/3422ba9ce1a16fed/c4x-discovery-selects-once-daily-oral-a4b7-inhibitor-candidate-for-inflammatory-bowel-disease-treatment 2025-09-22T09:21:51+00:00 hourly 0.9 https://trial.medpath.com/news/2e2a6ca1ff746901/gc-green-cross-submits-phase-1-clinical-trial-application-for-covid-19-mrna-vaccine-in-south-korea 2025-09-22T09:18:59+00:00 hourly 0.9 https://trial.medpath.com/news/9b285148070022da/pfizer-pursues-7-3-billion-acquisition-of-metsera-to-enter-rapidly-expanding-anti-obesity-drug-market 2025-09-22T09:16:50+00:00 hourly 0.9 https://trial.medpath.com/news/a8a05bc6cddc4845/astrazeneca-s-tezspire-receives-eu-regulatory-recommendation-for-chronic-rhinosinusitis-with-nasal-polyps 2025-09-22T09:16:28+00:00 hourly 0.9 https://trial.medpath.com/news/43526537f693a81d/myricx-bio-appoints-new-ceo-as-company-advances-novel-adc-platform-toward-clinical-trials 2025-09-22T09:15:40+00:00 hourly 0.9 https://trial.medpath.com/news/7ad9690254bdf532/idorsia-s-quviviq-launches-in-china-through-simcere-partnership-expanding-global-reach-of-novel-insomnia-treatment 2025-09-22T09:14:25+00:00 hourly 0.9 https://trial.medpath.com/news/eb0a373cd768b959/ipsen-s-ipn10200-shows-superior-long-term-efficacy-in-phase-ii-glabellar-lines-trial 2025-09-22T09:13:47+00:00 hourly 0.9 https://trial.medpath.com/news/d0ec45005293c393/roche-s-giredestrant-combination-meets-phase-iii-endpoints-in-advanced-breast-cancer 2025-09-22T09:13:41+00:00 hourly 0.9 https://trial.medpath.com/news/4d3f8d0d6a16e13e/proteomics-international-achieves-iso-15189-certification-accelerates-commercial-launch-of-precision-diagnostic-tests 2025-09-22T09:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/f21917d93ae74c68/fda-clears-first-in-human-trial-for-lbl-047-novel-bispecific-protein-targeting-autoimmune-diseases 2025-09-22T09:12:07+00:00 hourly 0.9 https://trial.medpath.com/news/9998a4013b3e5cb9/crossject-receives-additional-11-3m-barda-funding-for-zepizure-needle-free-epilepsy-treatment 2025-09-22T09:12:04+00:00 hourly 0.9 https://trial.medpath.com/news/103ea52c5510bb57/novartis-ianalumab-combination-shows-45-improvement-in-itp-disease-control-in-phase-iii-trial 2025-09-22T07:12:00+00:00 hourly 0.9 https://trial.medpath.com/news/8c76820ed05fb425/yangtze-river-pharmaceutical-unveils-phase-iii-results-for-novel-insomnia-drug-fazamorexant-at-world-sleep-congress 2025-09-22T05:17:48+00:00 hourly 0.9 https://trial.medpath.com/news/19235eb8d9a9ed0b/gemvax-seeks-fda-breakthrough-therapy-designation-for-gv1001-in-progressive-supranuclear-palsy 2025-09-22T05:17:44+00:00 hourly 0.9 https://trial.medpath.com/news/8914263bc6ce7d6e/ceretas-secures-2-4-million-government-grant-to-advance-non-invasive-ultrasound-therapy-for-alzheimer-s-disease 2025-09-22T05:17:28+00:00 hourly 0.9 https://trial.medpath.com/news/66d487e85e8a7932/ltr-pharma-increases-stake-in-levomega-to-43-with-1m-investment-for-sustainable-omega-3-development 2025-09-22T01:10:02+00:00 hourly 0.9 https://trial.medpath.com/news/d651519bead6a1a7/positive-trial-shows-tildrakizumab-delivers-comprehensive-quality-of-life-benefits-in-psoriatic-disease 2025-09-21T21:12:03+00:00 hourly 0.9 https://trial.medpath.com/news/3606783339e1b458/medtronic-secures-fda-approval-for-altaviva-tibial-neuromodulation-device-becomes-sole-provider-of-complete-bladder-control-portfolio 2025-09-21T21:11:28+00:00 hourly 0.9 https://trial.medpath.com/news/3e8bee935ed047f0/magnesium-supplements-show-promise-for-colorectal-cancer-prevention-through-gut-microbiome-modulation 2025-09-21T17:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/545c7c3699deda07/phase-1-helios-trial-shows-promise-for-otx-tki-in-diabetic-retinopathy-treatment 2025-09-21T17:09:07+00:00 hourly 0.9 https://trial.medpath.com/news/7926325951b91194/tumor-infiltrating-lymphocytes-and-macrophages-drive-cancer-immunoediting-through-three-critical-phases 2025-09-21T16:00:00+00:00 hourly 0.9 https://trial.medpath.com/news/a93bdcc975c5c41e/henagliflozin-shows-promise-as-anti-aging-therapy-in-type-2-diabetes-patients 2025-09-21T13:13:31+00:00 hourly 0.9 https://trial.medpath.com/news/0933be91a8e0e5e8/our-lady-of-the-lake-cancer-institute-launches-louisiana-s-first-allogeneic-car-t-cell-therapy-clinical-trial 2025-09-21T13:12:56+00:00 hourly 0.9 https://trial.medpath.com/news/938b1eaf30aa2557/iranian-researchers-develop-ai-powered-personalized-mrna-vaccine-for-lung-cancer 2025-09-21T13:12:12+00:00 hourly 0.9 https://trial.medpath.com/news/bcccb51854f10904/avidity-biosciences-advances-rna-therapeutics-with-clinical-trials-for-rare-diseases 2025-09-21T12:03:00+00:00 hourly 0.9 https://trial.medpath.com/news/3554e57101897e04/real-world-data-show-austedo-xr-delivers-high-patient-satisfaction-and-movement-improvement-in-tardive-dyskinesia 2025-09-21T09:11:26+00:00 hourly 0.9 https://trial.medpath.com/news/1c555563de18653d/teva-s-olanzapine-lai-shows-no-pdss-events-in-56-week-phase-3-trial-paving-way-for-first-long-acting-olanzapine-treatment 2025-09-21T05:09:58+00:00 hourly 0.9 https://trial.medpath.com/news/8618ee33f87bf7dd/pegasus-laboratories-expands-florida-manufacturing-facility-to-meet-growing-veterinary-drug-demand 2025-09-21T01:25:09+00:00 hourly 0.9 https://trial.medpath.com/news/ba066cee3e607e97/mmrf-presents-breakthrough-multiple-myeloma-research-at-international-conference-revealing-immune-system-changes-during-treatment 2025-09-21T01:21:19+00:00 hourly 0.9 https://trial.medpath.com/news/19499f38c8a3a163/genfit-discontinues-vs-01-development-in-liver-failure-following-safety-concerns-refocuses-on-rare-disease 2025-09-20T21:13:30+00:00 hourly 0.9 https://trial.medpath.com/news/a4210408e093c370/lupin-receives-four-fda-observations-at-pune-biotech-facility-following-pre-approval-inspection 2025-09-20T21:11:58+00:00 hourly 0.9 https://trial.medpath.com/news/ec9c16cf553b3012/faers-analysis-reveals-lower-infection-risk-with-ide-cel-compared-to-other-bcma-targeted-therapies-in-multiple-myeloma 2025-09-20T21:10:52+00:00 hourly 0.9 https://trial.medpath.com/news/1a6f9539cd72836f/elutia-s-biologic-envelope-shows-43-reduction-in-cied-reoperation-difficulty-in-heal-study 2025-09-20T21:08:46+00:00 hourly 0.9 https://trial.medpath.com/news/15922b4c13858aad/savara-receives-fda-alignment-on-molbreevi-bla-resubmission-stock-surges-15-76-following-strategic-financing 2025-09-20T17:10:16+00:00 hourly 0.9 https://trial.medpath.com/news/22c890d1cac507ad/faraday-future-invests-41-million-in-qualigen-therapeutics-for-strategic-pivot-to-cryptocurrency-and-web3-business 2025-09-20T17:09:57+00:00 hourly 0.9 https://trial.medpath.com/news/0ca50cc7a1863264/large-australian-trial-finds-pneumococcal-vaccine-ineffective-for-cardiovascular-protection 2025-09-20T10:49:00+00:00 hourly 0.9 https://trial.medpath.com/news/be6020b0cd5a4a83/two-major-nih-grants-totaling-7-3-million-fund-groundbreaking-adhd-medication-research 2025-09-20T09:10:15+00:00 hourly 0.9 https://trial.medpath.com/news/101c0d529d647f1b/cdc-advisory-committee-delays-vote-on-proposed-changes-to-newborn-hepatitis-b-vaccination-schedule 2025-09-20T09:10:13+00:00 hourly 0.9 https://trial.medpath.com/news/cf0ab734ac425982/johnson-johnson-reports-positive-phase-3-results-for-darzalex-faspro-combination-in-newly-diagnosed-multiple-myeloma 2025-09-20T05:10:31+00:00 hourly 0.9 https://trial.medpath.com/news/cfd8c2f21a210f3b/fda-approves-injectable-keytruda-marking-new-era-in-cancer-treatment-convenience 2025-09-20T01:15:41+00:00 hourly 0.9 https://trial.medpath.com/news/9bfe1ba2ecd9c840/advanced-biomed-launches-a-perfusctm-3d-cell-culture-platform-for-enhanced-drug-discovery-and-precision-medicine 2025-09-20T01:12:48+00:00 hourly 0.9 https://trial.medpath.com/news/f5b308657930b93a/fda-clears-hdt-bio-s-first-in-class-hdt-321-for-crimean-congo-hemorrhagic-fever-prevention 2025-09-19T21:14:17+00:00 hourly 0.9 https://trial.medpath.com/news/f982efd25d6f810b/six-year-upadacitinib-safety-data-shows-comparable-cardiovascular-risk-in-atopic-dermatitis-patients 2025-09-19T21:13:56+00:00 hourly 0.9 https://trial.medpath.com/news/10318ecf1732a520/alvotech-challenges-regeneron-s-high-dose-aflibercept-patent-in-post-grant-review 2025-09-19T21:13:03+00:00 hourly 0.9 https://trial.medpath.com/news/7b8144605efa63c0/ema-recommends-amgen-s-uplizna-for-rare-autoimmune-disease-igg4-rd 2025-09-19T21:11:31+00:00 hourly 0.9 https://trial.medpath.com/news/474f3ba6474a0898/fda-approves-subcutaneous-pembrolizumab-formulation-for-solid-tumors-reducing-treatment-time-by-nearly-50 2025-09-19T21:10:29+00:00 hourly 0.9 https://trial.medpath.com/news/344c5fb8d2e9b982/r-pharm-presents-long-term-olokizumab-data-showing-sustained-improvement-in-rheumatoid-arthritis-patients 2025-09-19T17:20:38+00:00 hourly 0.9 https://trial.medpath.com/news/08875edef7b371a2/curateq-biologics-completes-successful-phase-3-trial-for-denosumab-biosimilar-in-postmenopausal-osteoporosis 2025-09-19T17:20:06+00:00 hourly 0.9 https://trial.medpath.com/news/5ccb6895fc8bb3aa/elicera-therapeutics-faces-u-s-patent-setback-for-itank-car-t-enhancement-platform 2025-09-19T17:19:22+00:00 hourly 0.9 https://trial.medpath.com/news/d334e77479aefcba/otsuka-receives-japanese-approval-for-nexletol-as-novel-non-statin-cholesterol-treatment 2025-09-19T17:19:17+00:00 hourly 0.9 https://trial.medpath.com/news/6abcec6d4186cd69/bluebird-bio-rebrands-as-genetix-biotherapeutics-following-private-buyout-refocuses-on-gene-therapy-access 2025-09-19T17:18:37+00:00 hourly 0.9 https://trial.medpath.com/news/c2460bdffaf71ebb/eckert-ziegler-receives-japanese-approval-for-galliapharm-r-generator-expanding-gallium-68-diagnostics-for-prostate-cancer 2025-09-19T17:18:20+00:00 hourly 0.9 https://trial.medpath.com/news/fa65042219056833/tecvayli-and-darzalex-faspro-combination-achieves-100-mrd-negativity-in-newly-diagnosed-multiple-myeloma-patients 2025-09-19T17:17:33+00:00 hourly 0.9 https://trial.medpath.com/news/a77ea7442644459b/precision-biologics-reports-promising-efficacy-data-for-novel-ovarian-cancer-adc-pb-vcmmae-5 2025-09-19T17:16:21+00:00 hourly 0.9 https://trial.medpath.com/news/0564f8c88063a35f/lexaria-s-dehydratech-technology-enhances-semaglutide-brain-delivery-in-preclinical-study 2025-09-19T17:15:18+00:00 hourly 0.9 https://trial.medpath.com/news/5447ac960b3bee9a/indoco-remedies-achieves-zero-fda-observations-at-mumbai-api-manufacturing-facility 2025-09-19T17:15:13+00:00 hourly 0.9 https://trial.medpath.com/news/f40bdc44e6e32555/alvotech-secures-japanese-approval-for-three-biosimilars-including-first-global-golimumab-biosimilar 2025-09-19T17:14:35+00:00 hourly 0.9 https://trial.medpath.com/news/809fc9f351415964/kindeva-opens-150000-sq-ft-uk-facility-to-develop-environmentally-friendly-inhaler-propellants 2025-09-19T17:14:10+00:00 hourly 0.9 https://trial.medpath.com/news/d3d38f3166f90a98/european-regulators-recommend-approval-for-novo-nordisk-s-weekly-diabetes-combination-therapy-kyinsu 2025-09-19T17:12:39+00:00 hourly 0.9 https://trial.medpath.com/news/bca3cffc854dea42/fda-approves-medtronic-s-altaviva-implantable-device-for-urge-urinary-incontinence 2025-09-19T17:11:50+00:00 hourly 0.9 https://trial.medpath.com/news/13c892a2b3981cb9/ipsen-s-bylvay-receives-japanese-approval-for-rare-liver-disease-pfic-offering-first-non-surgical-treatment-option 2025-09-19T17:11:02+00:00 hourly 0.9 https://trial.medpath.com/news/354c4e69f3d84dd6/landmark-clinical-trials-demonstrate-efficacy-of-il-13-and-il-4-il-13-inhibitors-in-patients-with-darker-skin-tones 2025-09-19T17:10:38+00:00 hourly 0.9 https://trial.medpath.com/news/479bc251f8fbc200/datavant-and-indegene-partner-to-accelerate-clinical-trial-recruitment-for-rare-diseases 2025-09-19T17:10:26+00:00 hourly 0.9 https://trial.medpath.com/news/a4a531bfdd7aa077/fda-issues-early-alert-for-abbott-s-tactiflex-ablation-catheter-following-tip-detachment-reports 2025-09-19T13:13:02+00:00 hourly 0.9 https://trial.medpath.com/news/62ba0d2249b3f19a/genflow-biosciences-files-patent-examination-request-in-china-for-sirt6-based-nash-therapy 2025-09-19T13:12:21+00:00 hourly 0.9 https://trial.medpath.com/news/53c77168992b284a/ema-approves-first-treatment-for-non-cystic-fibrosis-bronchiectasis-as-16-new-medicines-receive-marketing-authorization 2025-09-19T13:11:27+00:00 hourly 0.9 https://trial.medpath.com/news/04990a38ef5a89f1/ql-biopharm-s-zovaglutide-achieves-13-8-weight-loss-with-monthly-dosing-in-phase-2-trial 2025-09-19T13:11:04+00:00 hourly 0.9 https://trial.medpath.com/news/b89771e63d54e7dc/chugai-receives-japanese-approval-for-tecentriq-in-rare-lymphoma-marking-first-checkpoint-inhibitor-for-enkl 2025-09-19T13:10:22+00:00 hourly 0.9 https://trial.medpath.com/news/6f30ea3c0eea1bb4/vitamin-b3-derivative-shows-54-reduction-in-skin-cancer-risk-in-large-veterans-study 2025-09-19T09:15:02+00:00 hourly 0.9 https://trial.medpath.com/news/320d1867d388f0f9/iaso-biotherapeutics-reports-sustained-36-month-efficacy-data-for-fucaso-car-t-therapy-in-multiple-myeloma 2025-09-19T09:14:41+00:00 hourly 0.9 https://trial.medpath.com/news/6a740593dd7366bd/advanced-liver-cancer-pipeline-shows-robust-growth-with-50-companies-developing-novel-therapies 2025-09-19T09:12:30+00:00 hourly 0.9 https://trial.medpath.com/news/b5b1a7f880fc9362/biocon-biologics-targets-7-billion-global-biosimilar-market-with-fda-approved-denosumab-products 2025-09-19T09:11:29+00:00 hourly 0.9 https://trial.medpath.com/news/b5219442d21c7e37/cdc-advisory-panel-votes-to-limit-combined-mmrv-vaccine-use-in-young-children-due-to-seizure-risk 2025-09-19T09:10:33+00:00 hourly 0.9 https://trial.medpath.com/news/fb934e3515773e02/kane-biotech-submits-fda-510-k-application-for-third-revyve-wound-care-product 2025-09-19T05:14:59+00:00 hourly 0.9 https://trial.medpath.com/news/9fc5231144022eeb/sight-sciences-omni-system-gains-unitedhealthcare-coverage-as-meta-analysis-confirms-long-term-efficacy-in-glaucoma-treatment 2025-09-19T05:14:31+00:00 hourly 0.9 https://trial.medpath.com/news/c5713f1fdc0bda11/cdc-advisory-committee-narrows-mmrv-vaccine-recommendations-signals-potential-changes-to-covid-19-and-hepatitis-b-guidelines 2025-09-19T05:14:28+00:00 hourly 0.9 https://trial.medpath.com/news/70da2203d5179f3e/exsight-ventures-backs-revopsis-therapeutics-novel-tri-specific-antibody-platform-for-retinal-diseases 2025-09-19T05:11:56+00:00 hourly 0.9 https://trial.medpath.com/news/d93f8605419b6a8f/genedx-strengthens-leadership-team-with-key-appointments-to-advance-ai-powered-precision-medicine 2025-09-19T05:09:41+00:00 hourly 0.9 https://trial.medpath.com/news/3ce7bb04a2dc5fee/aurora-spine-launches-world-s-first-bone-density-matched-spinal-implant-for-lumbar-fusion 2025-09-19T05:09:23+00:00 hourly 0.9